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ABSTRACT OF DISSERTATION 
 
 
 
 
EXPRESSION OF BORDERLINE PERSONALITY DISORDER SYMPTOMS 
ACROSS THE OVULATORY CYCLE: A MULTILEVEL INVESTIGATION 
 
 
 
Borderline Personality Disorder (BPD) is a disabling condition characterized by chronic 
emotion dysregulation and behavioral impulsivity.  Prospective studies that test proposed 
mechanisms of within-person change in BPD hold the key to improving symptom 
predictability and control in this disorder. A small body of evidence suggests that 
fluctuations in estradiol such as those occurring naturally at ovulation during the monthly 
female reproductive cycle may increase symptoms in women with BPD (DeSoto et al., 
2003).  Furthermore, there is preliminary evidence that both self-esteem and feelings of 
social rejection are highest at ovulation, when estradiol peaks (Durante and Hill, 2009; 
Eisenlohr-Moul et al., under review). Such feelings have been reliably linked to increases 
in BPD-related behavior in all individuals (e.g., Twenge et al., 2002). The purpose of this 
dissertation was to test a cyclical vulnerability model for women with BPD in which 
ovulatory estradiol shifts are associated with reductions in felt social acceptance, which 
in turn are associated with increased BPD symptom expression. 40 women, sampled to 
achieve a flat distribution of BPD symptoms, completed 28 daily diaries online, as well 
as four 1-hour weekly visits to the laboratory to complete longer assessments and provide 
saliva samples, which were assayed for estradiol.  In addition, participants underwent the 
Structured Clinical Interview for the Diagnosis of BPD at the end of the study.  
Results of multilevel models revealed the opposite of the predicted effects of within-
person changes in estradiol and their interaction with trait BPD. The data suggest a 
pattern in which women high in trait BPD show increases in felt acceptance and 
reductions in BPD symptom expression at higher levels of conception probability and 
higher-than-usual levels of estradiol. Women low in trait BPD show the opposite pattern 
in some cases. Several alternative moderators were tested, and results suggest that some 
risk factors for BPD (e.g., Neuroticism, Sexual Abuse) interact with high trait levels of 
estradiol to predict greater symptoms. Both average levels of estradiol and monthly 
fluctuations in estradiol may have relevance for women with BPD. It is recommended 
that future studies utilize clinical samples and additional physiological measures to 
	  
further elucidate the mechanisms through which estradiol exerts clinically-relevant 
change.  
 
KEY WORDS: Borderline Personality Disorder, 17-Beta Estradiol, Menstrual Cycle, 
Ovulation 
     Tory Anne Eisenlohr-Moul 
 
April 24, 2013 
  
	  
 
 
 
 
 
 
 
 
EXPRESSION OF BORDERLINE PERSONALITY DISORDER SYMPTOMS 
ACROSS THE OVULATORY CYCLE: A MULTILEVEL INVESTIGATION 
 
By 
Tory Anne Eisenlohr-Moul 
 
 
 
 
 
    C. Nathan DeWall, Ph.D. 
 Co-Director of Dissertation 
 
Suzanne C. Segerstrom, Ph.D. 
           Co-Director of Dissertation 
 
David T. Berry, Ph.D. 
Director of Graduate Studies 
 
April 24, 2013 
Date 
 
 
  
	  iii	  
ACKNOWLEDGMENTS 
 
 I’d like to thank a few people by name for their roles in my completion of this 
dissertation.  Mother and Father: You instilled in me an appreciation for education at a 
very early age, and a great deal of my success can be traced back to your love and 
encouragement. Dr. Erin Walsh: The tenderness you feel toward strangers continues to 
inspire me, but thanks for loving me best.  Jessica Peters: It’s been so important for me to 
have a friend like you who really understands me.  Thanks for every little thing you’ve 
done for me—but especially for your assistance on this project. Kaitlyn Chamberlain: 
Thank you for your dedication and hard work in helping me to run participants through 
this protocol.  I’d also like to acknowledge funding received through a petit grant from 
the Center for Drug and Alcohol Research, without which this work would not have been 
possible, and resources from the Center for Drug Abuse Research Translation. Thank you 
to my patients with Borderline Personality Disorder, whose passion and intensity delights 
me. Last but not least, I’d like to thank the three people who have had the strongest 
influence on my development as a clinical scientist.  Dr. Ruth Baer: Thank you for 
modeling equanimity, demonstrating kindness, and teaching me how to be effective in 
helping those who suffer. Dr. Nathan DeWall: You have been so supportive of me. Thank 
you for your kindness and for mentoring me in efficiency and self-assuredness.  You 
helped me to become a much more productive scientist. Dr. Suzanne Segerstrom: Thank 
you for modeling genuine curiosity, methodological rigor, and passion for the field. You 
never settled for anything less than my best, and I’m deeply grateful to you for that. 
  
	  iv	  
TABLE OF CONTENTS 
ACKNOWLEDGMENTS ................................................................................................. iii 
LIST OF TABLES ............................................................................................................. vi 
LIST OF FIGURES ........................................................................................................... ix 
Chapter One: Introduction .................................................................................................. 1 
Borderline Personality Disorder ..................................................................................... 1 
The Reproductive Cycle and BPD Symptoms: Could Hormones Play a Role? ............. 2 
A New Cyclical Vulnerability Theory of BPD in Women ............................................. 5 
FFM Personality Abnormalities: Alternative Moderators of Cyclical Vulnerability ..... 6 
A Special Case of Linehan’s Biosocial Model of BPD: Aspects of Childhood ............. 7 
Maltreatment as Alternative Moderators of Cyclical Vulnerability ............................... 7 
Alternative Mechanisms of Cycle-Related Change in BPD Symptoms ......................... 8 
Global Self-Control as an Alternative Mediator ......................................................... 9 
Aspects of Impulsivity as Alternative Mediators ........................................................ 9 
The Present Study: Aims and Hypotheses .................................................................... 10 
Chapter Two: Method ....................................................................................................... 12 
Overview and Study Design ......................................................................................... 12 
Participants .................................................................................................................... 12 
Procedure ...................................................................................................................... 13 
Screening and Recruitment ....................................................................................... 13 
Weekly Laboratory Protocol ..................................................................................... 13 
Follow-Up Risk Assessment Protocol ...................................................................... 16 
Daily Diary Protocol ................................................................................................. 16 
Weekly Measures .......................................................................................................... 17 
17β-Estradiol ............................................................................................................. 17 
Weekly BPD Symptoms ........................................................................................... 18 
Weekly Feelings of Social Acceptance ..................................................................... 20 
Weekly Self-Control ................................................................................................. 20 
Weekly Impulsivity ................................................................................................... 21 
Daily Measures ............................................................................................................. 22 
Conception Probability ............................................................................................. 22 
Daily BPD Symptoms ............................................................................................... 22 
Daily Felt Acceptance ............................................................................................... 23 
Between-Person Measures ............................................................................................ 23 
Five Factor Model (FFM) Personality ...................................................................... 23 
Childhood Maltreatment ........................................................................................... 24 
DSM-IV Diagnosis of BPD ...................................................................................... 24 
Data Analytic Plan ........................................................................................................ 25 
Power Analysis ......................................................................................................... 25 
Multilevel Models ..................................................................................................... 25 
Model Fitting and Random Effects ........................................................................... 26 
Specific Hypothesis Tests ......................................................................................... 27 
Observations at the Daily and Weekly Level ............................................................... 30 
Descriptive and Correlational Analyses ........................................................................ 30 
	  v	  
Testing Hypothesis 1: Ovulation, Estradiol, and BPD Symptom Expression .............. 33 
Testing Hypothesis 2: Moderation of Cycle Effects by Trait BPD .............................. 39 
Testing Hypothesis 3a: Mediation by Felt Social Acceptance ..................................... 56 
Testing Hypothesis 3b and 3c: Mediation by Impulsivity and Self-Control ................ 74 
Testing Alternative Moderators: Dismantling Trait BPD Moderation Effects Using 
FFM Personality and Childhood Maltreatment .......................................................... 125 
Chapter Four: Discussion ................................................................................................ 180 
Do Ovulation or Increases in Estradiol Predict Greater BPD Symptoms? ................. 181 
Do Ovulation or Increases in Estradiol Predict Lower Felt Acceptance? .................. 184 
Alternative, Proximal Mediators: Are Changes in Self-Control or Impulsivity 
Responsible for Cycle Effects? ................................................................................... 185 
Investigating Alternative Moderators of Cyclical and Hormonal Effects: Roles of FFM 
Personality and Childhood Maltreatment ................................................................... 187 
Contextualizing the Present Findings in the Extant Literature on the Cycle and BPD
 ..................................................................................................................................... 191 
Using Biosocial and Evolutionary Theories to Understand the Effects of the Cycle on 
BPD Symptoms ........................................................................................................... 193 
Using FFM and Biosocial Theories of BPD to Understand the Effects of Average 
Levels of Estradiol on BPD Symptoms ...................................................................... 195 
Limitations and General Recommendations for Future Work in this Area ................ 201 
Clinical Implications and Directions for Future Clinical Research ............................ 203 
Conclusions ................................................................................................................. 205 
References ....................................................................................................................... 206 
CURRICULUM VITAE ................................................................................................. 217 
 
 
  
	  vi	  
LIST OF TABLES 
 
Table 1. Demographic Sample Characteristics………………………………………..…14 
Table 2. Zero-order correlations among between-person measures, average estradiol, and 
average daily and weekly measures of BPD……………………………………………..31 
Table 3. Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from 
Daily Conception Probability Values……………………………………………………34 
Table 4. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from 
Average Levels of Estradiol and Weekly Deviations in Estradiol……………………....36 
Table 5. Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from 
the Interaction of Daily Conception Probability Values and Average of Weekly PAI-BOR 
Assessments (Trait BPD) ……………………………………………………………….40 
Table 6. Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from 
the Interaction of Daily Conception Probability Values and Number of SCID-II BPD 
Criteria Met (Trait BPD) ………………………………………………………………..44 
Table 7. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from 
the Interaction of Average of Weekly PAI-BOR Assessments (Trait BPD) with Average 
Estradiol and Weekly Deviations in Estradiol…………………………………………..47 
Table 8. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from 
the Interaction of Number of SCID-II Criteria Met (Trait BPD) with Average Estradiol 
and Weekly Deviations in Estradiol……………………………………………………..57 
Table 9. Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from 
Daily Conception Probability Values……………………………………………………60 
Table 10. Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from 
the Interaction of Daily Conception Probability Values and Average of Weekly PAI-BOR 
Assessments (Trait BPD) ………………………………………………………………..62 
Table 11. Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from 
the Interaction of Daily Conception Probability Values and Number of SCID-II BPD 
Criteria Met (Trait BPD) ………………………………………………………………...63 
Table 12. Multilevel Regression Models Predicting Weekly Felt Acceptance from 
Average Estradiol and Weekly Deviations in Estradiol…………………………………66 
Table 13. Multilevel Regression Models Predicting Weekly Felt Acceptance from the 
Interaction of Average Weekly PAI-BOR Total Score with Average Estradiol and 
Weekly Deviations in Estradiol………………………………………………………….67 
Table 14. Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from 
Average Levels of Daily Felt Acceptance and Daily Deviations in Felt Acceptance…...68 
Table 15. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from Average Levels of Weekly Felt Acceptance and Weekly Deviations in Felt 
Acceptance……………………………………………………………………………….72 
Table 16. Multilevel Regression Models Predicting Weekly Self-Control and Impulsivity 
from Average Estradiol and Weekly Deviations in Estradiol……………………………80 
Table 17. Multilevel Regression Models Predicting Weekly Self-Control and Impulsivity 
from the Interaction of Average Weekly PAI-BOR Total Score with Average Estradiol 
and Weekly Deviations in Estradiol……………………………………………………..82 
	  vii	  
Table 18. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from Average Levels of Weekly Self-Control and Weekly Deviations in Self-
Control...............................................................................................................................95 
Table 19. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from Average Levels of Weekly UPPS-P Negative Urgency and Weekly Deviations in 
UPPS-P Negative Urgency………………………………………………………………97 
Table 20. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from Average Levels of Weekly UPPS-P Positive Urgency and Weekly Deviations in 
UPPS-P Positive Urgency………………………………………………………………..99 
Table 21. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from Average Levels of Weekly UPPS-P Lack of Premeditation and Weekly Deviations 
in UPPS-P Lack of Premeditation………………………………………………………101 
Table 22. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from Average Levels of Weekly UPPS-P Lack of Perseverance and Weekly Deviations in 
UPPS-P Lack of Perseverance………………………………………………………….103 
Table 23. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from Average Levels of Weekly UPPS-P Sensation Seeking and Weekly Deviations in 
UPPS-P Sensation Seeking……………………………………………………………..105 
Table 24. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of Neuroticism with Average Estradiol and Weekly Deviations in 
Estradiol………………………………………………………………………………...131 
Table 25. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of Extraversion with Average Estradiol and Weekly Deviations in 
Estradiol………………………………………………………………………………...134 
Table 26. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of Openness to Experience with Average Estradiol and Weekly 
Deviations in Estradiol………………………………………………………………….137 
Table 27. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of Agreeableness with Average Estradiol and Weekly Deviations in 
Estradiol………………………………………………………………………………...140 
Table 28. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of Conscientiousness with Average Estradiol and Weekly Deviations 
in Estradiol……………………………………………………………………………...143 
Table 29. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of the Emotional Abuse scale of the CTQ with Average Estradiol 
and Weekly Deviations in Estradiol……………………………………………………156 
Table 30. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of the Emotional Neglect scale of the CTQ with Average Estradiol 
and Weekly Deviations in Estradiol……………………………………………………159 
Table 31. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of the Physical Abuse scale of the CTQ with Average Estradiol and 
Weekly Deviations in Estradiol……………………………………………………...…162 
Table 32. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of the Physical Neglect scale of the CTQ with Average Estradiol and 
Weekly Deviations in Estradiol………………………………………………………...165 
	  viii	  
Table 33. Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms 
from the Interaction of the Sexual Abuse scale of the CTQ with Average Estradiol and 
Weekly Deviations in Estradiol………………………………………………………...168 
  
	  ix	  
LIST OF FIGURES 
 
Figure 1. A graph of the interaction between trait BPD symptoms and daily conception 
probability predicting daily PAI-BOR total score. ……………………………………...43 
Figure 2. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly PAI-BOR total score.………………………………………50 
Figure 3. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly PAI-BOR Identity Disturbance subscale score…………….51 
Figure 4. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly PAI-BOR Affective Instability subscale score……………..52 
Figure 5. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly BSL-23 score…….…………………………………………53 
Figure 6. A graph of the interaction between trait BPD symptoms and average estradiol 
predicting weekly PAI-BOR Self-Harm subscale score.………………………………...55 
Figure 7. A graph of the interaction between trait BPD symptoms and daily conception 
probability predicting daily felt acceptance.……………………………………………..64 
Figure 8. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly felt acceptance.……………………………………………..70   
Figure 9. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly felt 
acceptance………………………………………………………………………………..75 
Figure 10. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability scores via weekly 
felt acceptance. ………………………………………………………………………….76 
Figure 11. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance scores via 
weekly felt acceptance.…………………………………………………………………..77 
Figure 12. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 scores via weekly felt acceptance……78  
Figure 13. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly self-control.…………………………………………………85 
Figure 14. A graph of the interaction between trait BPD symptoms and Average estradiol 
predicting weekly self-control…………………………………………………………...86   
Figure 15. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P negative urgency………………………………….87  
Figure 16. A graph of the interaction between trait BPD symptoms and average estradiol 
predicting weekly UPPS-P negative urgency……………………………………………89   
Figure 17. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P positive urgency…………………………………..90   
Figure 18. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P lack of perseverance………………………………91   
Figure 19. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P lack of premeditation…………………………...…93   
Figure 20. A graph of the interaction between trait BPD symptoms and average estradiol 
predicting weekly UPPS-P lack of premeditation……………………………………….94   
	  x	  
Figure 21. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly self-
control…………………………………………………………………………………..110  
Figure 22. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
self-control.……………………………………………………………………………..111  
Figure 23. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
self-control…………………………………………………………………………..….112 
Figure 24. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly self-control……….113 
Figure 25. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P 
Negative Urgency………………………………………………………………………115  
Figure 26. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
UPPS-P Negative Urgency…………………………………………………………..…116 
Figure 27. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
UPPS-P Negative Urgency……………………………………………………………..117 
Figure 28. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Negative 
Urgency…………………………………………………………………………………118 
Figure 29. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Positive 
Urgency…………………………………………………………………………………119 
Figure 30. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P Lack 
of Perseverance…………………………………………………………………………121  
Figure 31. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
UPPS-P Lack of Perseverance…………………………………………………………122 
Figure 32. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
UPPS-P Lack of Perseverance…………………………………………………………123 
Figure 33. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Lack of 
Perseverance……………………………………………………………………………124 
Figure 34. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P Lack 
of Premeditation……………………………………………………………………….. 126 
Figure 35. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
UPPS-P Lack of Premeditation…………………………………………………………127  
	  xi	  
Figure 36. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
UPPS-P Lack of Premeditation…………………………………………………………128 
Figure 37. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Lack of 
Premeditation…………………………………………………………………………...129 
Figure 38. A graph of the interaction between Neuroticism and average estradiol 
predicting weekly PAI-BOR Affective Instability subscale score……………………..147   
Figure 39. A graph of the interaction between Neuroticism and average estradiol 
predicting weekly PAI-BOR Identity Disturbance subscale score.…………………….148   
Figure 40. A graph of the interaction between Neuroticism and average estradiol 
predicting weekly BSL-23 score.……………………………………………………….149 
Figure 41. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR total score.……………………………………..150  
Figure 42. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR Affective Instability subscale score……………151 
Figure 43. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR Identity Disturbance subscale score…………...152 
Figure 44. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR Affective Instability subscale score……………154   
Figure 45. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly number of items endorsed on the MSI-BPD……………...155   
Figure 46. A graph of the interaction between self-reported levels of childhood sexual 
abuse and average estradiol predicting weekly PAI-BOR Self-Harm subscale score….172   
Figure 47. A graph of the interaction between self-reported levels of childhood sexual 
abuse and average estradiol predicting weekly BSL-23 score………………………….173 
Figure 48. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly PAI-BOR total score……………...175   
Figure 49. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly PAI-BOR Affective Instability 
subscale score…………………………………………………………………………...176   
Figure 50. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly PAI-BOR Identity Disturbance 
subscale score.…………………………………………………………………………..177 
Figure 51. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly BSL-23 score……………………..179  
Figure 52. Descriptive scatterplot of the (nonsignificant) association between average 
levels of estradiol and weekly PAI-BOR scores in the full sample…………………….198   
Figure 53. Descriptive scatterplot of the association between average estradiol and 
weekly PAI-BOR scores graphed by quartiles of average PAI-BOR total score………199   
  
 1 
Chapter One: Introduction 
Borderline Personality Disorder 
Individuals with Borderline Personality Disorder (BPD) suffer from a distinctive 
combination of particularly disabling psychological and behavioral symptoms (Skodol et 
al., 2002). Extreme emotion dysregulation, harmful impulsive behaviors, identity 
disturbance, chronic feelings of emptiness, repeated parasuicidal and suicidal behaviors, 
and chaotic interpersonal relationships are all common features of BPD. Roughly 10% of 
outpatients and 20% of inpatients meet criteria for BPD, and epidemiological studies 
suggest that roughly 6% of the U.S. population will meet criteria for BPD at some point 
in their lives (DSM-IV-TR, 2000; Swartz et al., 1990; Widiger & Weissman, 1991; Grant 
et al., 2008). Though the disorder is equally prevalent in men and women, more women 
than men receive the diagnosis, and BPD is associated with greater distress and 
functional impairment in women (Grant et al., 2008). 
For many years, BPD was considered untreatable by psychiatrists and 
psychologists alike. Historically, individuals with BPD have been perceived by clinicians 
as manipulative, hostile, and unable to benefit from treatment due to their erratically 
shifting emotions, behavior, and attitudes—especially toward clinicians and therapy. 
However, the recent development of cognitive and behavioral interventions such as 
Dialectical Behavior Therapy (DBT; Linehan, 1993), which have shown promise in the 
treatment of BPD, has led clinical scientists to rethink the assumption that individuals 
with BPD either do not wish to change or are unable to change. This has led to an 
increased interest in the study of potential mechanisms of treatment-related improvement 
among those who suffer from this condition.   
 2 
Though BPD and its response to treatment are better understood today than when 
treatments such as DBT were initially developed, the nature and causes of natural day-to-
day variability in BPD symptom expression remain poorly understood, especially on a 
physiological level. A clearer understanding of the physiological underpinnings of 
emotional, cognitive, and behavioral variability in BPD would be of great use to those 
interested in improving and streamlining both psychosocial and physiological treatments 
for the disorder. Existing treatments for BPD focus on the development of skills aimed at 
understanding, acknowledging, and responding to emotions, thoughts, and physical 
sensations in more helpful ways. Such cognitive behavioral treatments are effective for 
reducing dysfunctional, harmful behavior patterns; they are also costly and more time 
consuming than normal outpatient psychotherapy. A better understanding of the 
physiological causes of symptom variability in BPD could aid in the development of 
synergistic approaches that utilize both psychosocial and biological treatments. Therefore, 
the present project sought to address this gap in the scientific literature by exploring 
whether the female monthly reproductive cycle is a reliable source of variability in day-
to-day and week-to-week expression of BPD symptoms.   
The Reproductive Cycle and BPD Symptoms: Could Hormones Play a Role? 
Given the higher rates of diagnosis and diagnosis-related distress and impairment 
among women with BPD, it has been suggested that monthly fluctuations in reproductive 
hormones associated with the reproductive (or ovulatory) cycle may play a role in 
symptom expression. A small literature, reviewed below, specifically examines the links 
between estradiol and BPD symptoms. Although progesterone and other hormones may 
play important roles in predicting these outcomes, the present project focuses primarily 
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on the association of ovulation and associated changes in estradiol on symptom 
expression.   
Cyclical and Hormonal Effects on BPD Symptoms. A small body of research 
links shifts in estradiol, a steroid reproductive hormone that rises before and falls after 
ovulation, to increased expression of BPD symptoms. Across the female lifespan, BPD 
symptoms are greatest during adolescence and perimenopause—developmental 
transitions characterized by rapid changes in estradiol (Bardenstein & McGlashen, 1988; 
Stone, 1992). Additionally, differential prevalence of BPD in men and women has been 
identified during these same developmental transitions, suggesting that shifts in estradiol 
may be associated with changes in BPD symptom expression (Bardenstein & McGlashen, 
1988).  
The most convincing evidence for a causal link between estradiol and BPD 
symptoms comes from a series of three studies conducted by DeSoto, Geary, Hoard, 
Sheldon, and Cooper (2003). In the first study, 226 undergraduate women completed the 
Borderline subscale of the Personality Assessment Inventory (PAI-BOR; Morey, 1991) 
and reported the number of days since the beginning of their most recent menstrual 
period. Individuals assessed on days 5 through 10 of their cycle, when estradiol is rising, 
reported higher levels of BPD symptoms. In the second study, 57 women provided four 
weekly saliva samples and PAI-BOR assessments. Greater overall variability in estradiol 
across the cycle was associated with higher overall PAI-BOR scores. In the third study, 
24 women about to begin estrogen-containing hormonal contraceptives and 29 control 
participants completed eight weekly PAI-BOR measurements (four measurements prior 
to starting birth control and four measurements after starting birth control). Women with 
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above average levels of BPD symptoms prior to starting the pill evidenced a significant 
increase in symptoms after starting the pill, whereas BPD symptoms did not change 
significantly in women with low pre-existing symptoms or in women not starting the pill. 
Additionally, results of a laboratory study of 52 women suggest that even short-term 
changes in estradiol occurring during a laboratory session are associated with higher 
scores on the PAI-BOR (Evardone, Alexander, & Morey, 2008). Taken together, these 
results provide a groundwork of evidence that changes in estradiol at ovulation may have 
implications for the expression of BPD symptoms. Furthermore, the finding that shifts in 
estradiol may be problematic specifically for women with high trait levels of BPD 
symptoms is consistent with recent evidence that women may differ in their emotional 
and behavioral responses to hormones across the reproductive cycle (Kiesner, 2011). 
Finally, no study has examined the effects of both average levels of estradiol (between-
person effects on trait BPD symptoms) and fluctuations in estradiol (within-person 
effects on state BPD symptoms).  
Cyclical Effects on Felt Social Acceptance. Evidence from the social and 
evolutionary psychological literature also indicates that ovulation—and, by extension, 
fluctuations in estradiol—is associated with decreased self-esteem (Hill & Durante, 2009), 
decreased felt acceptance (Eisenlohr-Moul et al., under review), and increased implicit 
motivation to affiliate closely with others (Schultheiss, Dargel, & Rohde, 2003). Such 
changes may indicate a downward shift in feelings of social acceptance at ovulation 
(Leary, Haupt, Strausser, & Chokel, 1998). While such patterns may be benign or even 
adaptive in normal women, fluctuations in levels of self-esteem, felt acceptance, and 
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motivations to pursue relationships may play a role in within-person changes in BPD 
symptoms across the reproductive cycle. 
A New Cyclical Vulnerability Theory of BPD in Women 
Sociometer theory (Leary et al., 1998) argues that self-esteem serves as an 
indicator of social acceptance (i.e., a “sociometer”). Leary (2004) points out that the 
“sociometer” can sometimes be miscalibrated; one type of miscalibration occurs when 
the sociometer is “set low.” Individuals with a sociometer that is set low tend to perceive 
less social acceptance than others are objectively communicating, thereby experiencing 
chronically low self-esteem. If, in some women, ovulatory estradiol release leads to 
exaggerated reductions in self-esteem (i.e., decreased felt acceptance), this may create 
strong monthly patterns of change in attitudes towards oneself and others. This appears to 
describe BPD symptoms quite well; individuals with BPD suffer from excessive 
variability in attitudes toward themselves (self-esteem; Tolpin, Gunthert, Cohen, & 
O’Neill, 2004) and others (Russell, Moskowitz, Zuroff, Sookman, & Paris, 2007) that 
may be expected to arise when a sociometer is recalibrated drastically twice each month 
(i.e., prior to and after ovulation). 
I propose a new cyclical vulnerability theory of within-woman change in BPD 
that predicts exaggerated downward shifts in sociometric calibration and increased 
symptoms as a function of ovulatory increases in estradiol in women with high trait levels 
of BPD symptoms. As stated before, some evidence suggests that feelings of self-esteem 
and social acceptance decrease at ovulation in all women (Durante & Hill, 2009; 
Eisenlohr-Moul et al., under review). Such feelings of low social acceptance are 1) 
inherent in many of the symptoms of BPD and 2) a reliable risk factor for behavioral 
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dysregulation of the kind typically seen in BPD (impulsivity and risk-taking: Twenge, 
Catanese, & Baumeister, 2002; anger and aggression: Sampson & Laub, 1990; Twenge et 
al., 2007; identity disturbance: Richman et al., under review; chronic feelings of 
emptiness: Twenge, Catanese, & Baumeister, 2003). Also critically, no study has 
simultaneously examined the impact of both trait levels of felt acceptance (e.g., rejection 
sensitivity) and within-person changes in felt acceptance on expression of BPD 
symptoms. The present study will seek to comprehensively test this full cyclical 
vulnerability theory on multiple levels using multiple methods.  
FFM Personality Abnormalities: Alternative Moderators of Cyclical Vulnerability 
BPD is an extremely heterogeneous disorder; there are 256 ways to meet criteria 
for BPD using the DSM-IV-TR diagnostic criteria (Ellis, Abrams, & Abrams, 2008). 
Furthermore, BPD symptoms overlap strongly with a wide variety of other psychological 
disorders such as anxiety disorders, other personality disorders, mood disorders, and 
substance use disorders (Lenzenweger, Lane, Loranger, & Kessler, 2007). In an attempt 
to more clearly capture the underlying personality extremity that characterizes BPD and 
other personality disorders, recent models of personality disorders posit a dimensional 
model of personality disorders based on the Five Factor Model (FFM) of Personality 
(Widiger & Mullins-Sweatt, 2009). Of relevance for the present study, individuals with 
BPD are characterized by extremely high levels of all aspects of Neuroticism, low levels 
of some aspects of Agreeableness and Conscientiousness, and high levels of some aspects 
of Openness to Experience.  Such traits may be the “active ingredients” in moderating the 
effect of cycle variables on BPD symptoms. If “trait” levels of BPD do indeed modulate 
the impact of ovulatory estradiol shifts on BPD symptom expression, it would be 
 7 
theoretically important to determine which aspect(s) of extreme FFM personality 
functioning are responsible for this reactivity to the cycle.  
A Special Case of Linehan’s Biosocial Model of BPD: Aspects of Childhood  
Maltreatment as Alternative Moderators of Cyclical Vulnerability 
Linehan’s biosocial model of BPD (Linehan, 1993) is “a biological theory of 
emotion regulation” positing that symptoms of BPD emerge as a result of a complex 
interaction between (1) a physiological predisposition toward emotion dysregulation, and 
(2) an invalidating childhood environment. The physiological predisposition is 
conceptualized as whichever physiological conditions produce a pattern of extreme 
emotional reactions, sensitivity to such emotional reactions, and abnormally prolonged 
emotional reactions (i.e., slow return to baseline). The cyclical vulnerability model 
proposed above assumes that, at least for some women, higher-than-usual estradiol may 
temporarily increase one’s physiological predisposition toward emotion dysregulation. In 
this way, the cyclical vulnerability model is a kind of special case of the biosocial theory 
in which state levels of physiological variables (i.e., fertility, estradiol) are thought to 
boost a physiological predisposition to emotion dysregulation, creating a greater 
sensitivity to internal and external social rejection cues.  
The second part of the biosocial model has to do with childhood environments 
that invalidate and devalue the child’s desires and emotions rather than instructing the 
child in or modeling useful skills for managing emotions, thoughts, and behavior.  
Linehan argues that such invalidating environments teach the child to respond to their 
own emotional responses in unhelpful ways (e.g., chronic emotional suppression) that 
tend to have the paradoxical effects of further dysregulating emotions and behavior 
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among these individuals. In discussing the myriad forms that such invalidating 
environments can take, Linehan emphasizes both the subjectivity of the experience of 
emotional invalidation and the idea that overt childhood emotional, physical, and sexual 
abuse exemplify invalidating environments. It is possible that some aspects of childhood 
maltreatment that interact with trait physiological vulnerability to emotion dysregulation 
could also act as potent moderators of the transient ovulatory changes in physiologically-
based emotional vulnerability hypothesized here.  In the present study, therefore, if “trait” 
levels of BPD do indeed modulate responses to estradiol and other ovulatory processes, I 
will explore the possibility that various aspects of childhood maltreatment serve as a 
central predisposing factors that interact with ovulatory physiological changes to 
produce changes in BPD symptoms.  
Alternative Mechanisms of Cycle-Related Change in BPD Symptoms 
The cyclical vulnerability theory presented here predicts that ovulatory effects on 
the emotional and behavioral symptoms of BPD across the cycle occur due to decreases 
in felt acceptance.  More proximally, however, these changes may also be due to 
ovulatory changes in various aspects of impulsivity or global self-control. In the context 
of this theory, it may be helpful to determine whether cycle-related changes in BPD 
symptoms are also mediated by ovulatory effects on one of these interrelated variables 
with relevance for BPD: global self-regulatory ability, emotion-related urges, problems 
with thinking ahead (or premeditation), problems persisting in the face of difficulty, or 
desire to seek out new, potentially dangerous sensations.  Therefore, in addition to testing 
felt acceptance as the primary mediator in the cyclical vulnerability model, I will also 
test these more proximal mediators of cyclical effects on BPD symptoms.  
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Global Self-Control as an Alternative Mediator  
 
Self-control refers to the application of executive cognitive functions in the 
service of long-term goals. Although some evidence suggests that self-control and the 
executive functions that underlie self-control may be heterogeneous (Duckworth & Kern, 
2011), questionnaires measuring a unitary construct of self-control perform quite well in 
predicting a wide variety of BPD-related distress and functional outcomes (de Ridder, 
Lensvelt-Mulders, Finkenauer, Stok, & Baumeister, 2012).  Therefore, the present study 
operationalizes self-control as successful application of executive functions that produce 
adaptive behavioral responses consistent with long-term goals in a wide variety of 
situations (Tangney, Baumeister, and Boone, 2004). This will also be the first study to 
simultaneously examine both between-person and within-person effects of global self-
control on the expression of BPD symptoms.  
Aspects of Impulsivity as Alternative Mediators 
 
The UPPS-P model of impulsivity describes five aspects of impulsivity 
(Whiteside and Lynam, 2001): Negative Urgency, or the tendency to experience 
increased urges and to engage in related rash action under conditions of negative 
emotion; Positive Urgency, or the tendency to experience increased urges and to engage 
in related rash action under conditions of positive emotion; Lack of Premeditation, or the 
tendency to fail to think over the consequences of an action before engaging in that 
action; Lack of Perseverance, or difficulty persisting on tasks that may be difficult or 
boring; and Sensation Seeking, or the tendency to seek out and be open to engaging in 
stimulating, novel experiences that may or may not be dangerous. Previous evidence 
links trait levels of BPD symptoms as measured using the Personality Assessment 
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Inventory Borderline subscale (PAI-BOR; Morey, 1991) to higher trait levels of Negative 
Urgency, Positive Urgency, and Lack of Premeditation (Tragesser & Robinson, 2009). 
However, as with self-control, no study has examined the potentially unique roles of 
between-person differences and within-person changes in the UPPS-P facets on BPD 
symptoms. 
The Present Study: Aims and Hypotheses 
Since the establishment of tentative links between ovulatory estradiol shifts and 
BPD symptoms a decade ago (DeSoto et al, 2003), little or no work has examined the 
psychological mechanisms through which estradiol influences BPD symptoms. 
Prospective studies that test proposed mechanisms of within-person change in BPD hold 
the key to improving symptom predictability and control in this disorder. The present 
study aimed to test a proposed cyclical vulnerability model of BPD: women, and 
especially those with higher trait levels of BPD, respond to ovulatory estradiol shifts with 
exaggerated downward shifts in the calibration of the sociometer (decreased feelings of 
acceptance), which in turn leads to increases in BPD symptom expression. The present 
study tested this model using a 2-pronged repeated measures design.   
It was hypothesized that; 
1. In all participants, ovulation (as measured by both deviations in estradiol at the 
weekly level and conception probability at the daily level) would be associated with 
greater expression of BPD symptoms as measured by daily and weekly measures of BPD 
symptoms.  
2. Trait levels of BPD symptoms (as measured by the average of weekly scores on 
a measure of BPD symptoms and number of SCID-II items endorsed in a diagnostic 
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interview) would moderate the effect of ovulation (as measured using weekly deviations 
in estradiol and daily conception probability) on expression of BPD symptoms. If these 
results are significant, further models will replace the Trait BPD variable with each of the 
five domains of the FFM and with aspects of childhood maltreatment in order to elucidate 
the underlying factor(s) conferring risk for ovulatory changes in BPD.  
3. All significant effects of both deviations in estradiol and conception probability 
on symptoms of BPD would be mediated by decreases in felt acceptance at the same 
measurement level. Specifically, on days or weeks when estradiol or conception 
probability is high, felt social acceptance will be low and will mediate the association 
between estradiol deviations or conception probability and symptoms of BPD. Decreased 
feelings of social acceptance were also expected to mediate the interactive effect of 
estradiol and trait BPD on daily BPD symptoms.  
Further, weekly changes in aspects of impulsivity and self-control were expected 
to mediate the association between weekly estradiol deviations and increased BPD 
symptoms, and also to mediate the interactive effect of estradiol deviations and trait BPD 
on weekly symptoms. 
 
 
 
 
 
 
Copyright © Tory Eisenlohr-Moul 2013  
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Chapter Two: Method 
Overview and Study Design 
The present study consisted of a two-pronged repeated measures approach to 
understanding within-woman change in BPD across the reproductive cycle. 40 women, 
sampled to achieve a flat distribution of trait BPD scores, were invited and incentivized 
to provide up to 28 days of online daily dairy reports of ovulatory cycle status, felt 
acceptance, and BPD symptoms. Self-harm and suicidality items were omitted from daily 
diary assessments in order to reduce the risk of participant distress. In addition, they 
attended 4 weekly laboratory sessions at which they completed more comprehensive 
repeated assessments of felt acceptance, BPD symptoms, impulsivity, and self-control. 
During a fifth and final visit, participants underwent a structured clinical interview for 
diagnosis of BPD and completed trait measures of FFM personality traits and aspects of 
childhood maltreatment.  
Participants 
Participants were 40 naturally-cycling undergraduate women between the ages of 
18 and 30 who were fulfilling research participation requirements for an introductory 
undergraduate psychology course. Participants were recruited so as to achieve a “flat” 
distribution; 10 participants had low average PAI-BOR scores (T<50), 10 had high 
average scores (50<T<60), 10 had above average scores (60<T<70), and 10 will have 
high scores (T>70). Participants were not allowed to participate if they reported 1) 
currently using hormonal birth control, 2) currently using any “as needed” psychiatric 
medication (e.g., benzodiazepines), 3) not speaking English fluently, 3) having 
reproductive cycles typically lasting fewer than 25 days or greater than 35 days, or 4) 
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having a history of psychosis other than brief periods of dissociation. Final demographic 
characteristics of the sample can be found in Table 1.  
Procedure 
Screening and Recruitment 
 
Initial screening was completed in introductory psychology classes. During a 
department-wide screening session, women completed the PAI-BOR and a measure of 
inclusion criteria. 10 eligible women were recruited via telephone from each of the four 
symptom ranges. Interested participants were asked to schedule 4 repeating weekly 
timeslots at the same day and time each week.  
Because individuals with high levels of trait BPD symptoms were expected to 
have greater-than-average difficulty complying with laboratory attendance expectations 
and daily diary protocols, monetary incentives were offered to increase the rate of daily 
diary and weekly session compliance. In addition to course credit for the completion of 
laboratory visits, individuals were paid $25 if they completed at least 75% of the 28 daily 
diaries. In addition, in order to improve retention, weekly laboratory visits lasted only 50 
minutes, and daily diaries were pre-tested to ensure that the average time to complete the 
diaries was roughly 5 minutes. 
Weekly Laboratory Protocol 
 
Participants came to the lab once a week for 5 weeks at the same day and time (4 
assessments and 1 interview/debriefing session). Reminder emails were sent two days in 
advance of each session, reminding the participant of the location, date, and time of their 
next session as well as requesting that participants refrain from chewing gum, drinking 
caffeine or alcohol, or taking nonprescription medications for 12 hours prior to sessions   
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Table 1  
Demographic Sample Characteristics (N = 40) 
Variable Mean SD % 
Age 18.66 1.38  
Body Mass Index (BMI) 23.20 3.62  
Race    
   Caucasian   73.2 
   African American   9.8 
   Hispanic   9.8 
   Asian American   14.6 
   Other   2.4 
Religion    
   Christian - Protestant   39 
   Christian - Catholic   34.1 
   Islam   2.4 
   Judaism   2.4 
   Other   2.4 
   None/Atheist/Agnostic   19.7 
Note. SD = standard deviation.  
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on visit days (instructions related to saliva sample; see Estradiol section below). Nearly 
all missed sessions were rescheduled and completed within 3 days of the missed 
appointments; in the few cases where this was not possible (n = 6 sessions), the 
participant returned to the lab for the next scheduled session and added an additional 
week to their participation to compensate for the missed session.  
Upon arrival in the laboratory for weekly sessions, the participant was met by 
either the principal investigator or an undergraduate research assistant and taken to a 
private room. At the first session, participants completed an informed consent form, were 
reminded of the exclusion criteria, and were oriented to the online diary system. Next, at 
each session, participants were reminded of the free mental health services available to 
them as students at the university and reminded that they could always call emergency 
services if they felt that they were not safe due to parasuicidal or suicidal symptoms. 
Participants were then asked to turn off their cell phones. Next, they were instructed in 
the provision of the saliva sample and entered information about any relevant control 
information into the computer (e.g., use of caffeine, medication, etc.). After that, 
participants were given 8 minutes to provide the saliva sample. Finally, after the 
experimenter assured the individual that all answers were confidential, participants 
completed all weekly measures on a computer in a randomized order. At the fifth session, 
the principal investigator administered the SCID-II for BPD diagnosis and debriefed the 
participant. Following the fifth session, participants were sent a check in the mail for $25 
if they had completed at least 75% of the online diaries that they received.  
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Follow-Up Risk Assessment Protocol 
 
Weekly measurements included self-harm and suicidality items.  Responses to 
these items were screened daily by the principal investigator, and follow-up telephone 
risk assessments were conducted where endorsement level indicated significant risk of 
harm to the participant.  Follow-up telephone risk assessments consisted of a call to the 
participant in which the principal investigator briefly screened the participant for current 
risk of life-threatening self-harm or suicidal behavior (n = 23). In each case, risk 
assessments were carried out to ensure that the participant was not actively suicidal. 
Though in some cases participants endorsed suicidal planning (n = 3), no participants 
endorsed current intent to engage in self-injury or suicidal behavior.  Each call consisted 
of a brief screening followed by encouraging the client to (1) seek out the free mental 
health care available to them as students at the university, and (2) go to the local 
emergency room if necessary. Though some participants reported thoughts about suicidal 
planning (n = 6; e.g., “I think about the fact that if I cut myself in the right way, I could 
die), no participants reported current suicidal intent (e.g., “I think about how I could do it, 
but I never would and I have no intent to die”). Therefore, these telephone risk 
assessments did not result in any emergency hospitalization of clients. No clients reported 
seeking out psychological or psychiatric services during the study; however, several 
participants noted their intention to do so after completion of the study.  
Daily Diary Protocol 
 
As described above, participants were oriented to the online diary system during 
the first laboratory session.  They provided their email address, which was then added to 
the mailing list to receive the daily diaries for 28 days.  Participants received a daily 
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email with a link to the URL for that day’s online diary for the completion of de-
identified daily assessments. During the first session, participants were instructed to fill 
out the daily diary between 5pm-2am, and that diaries completed outside of this time 
frame would not be accepted.  
Weekly Measures 
Items administered repeatedly at each of the four weekly sessions are discussed 
below. Means, standard deviations, and aggregated internal consistencies for estradiol 
and measures of BPD are discussed and compared in the descriptive analysis section of 
the Results. Means, standard deviations, and aggregated internal consistencies for weekly 
mediators are presented in the text below.  
17β-Estradiol 
 
Participants were instructed to salivate by passive drool into a polypropylene vial 
(Salimetrics; State College, PA). During each session, participants recorded use of the 
following in the past 24 hours: nicotine, caffeine, over-the-counter drugs, prescription 
drugs, and illicit drugs. No participants reported prescription or illicit drug use. At some 
assessment points, participants reported having smoked cigarettes (13 assessment points), 
having more than 1 caffeinated beverage (2 assessment points), or having used over-the-
counter drugs (7 assessment points) in the past 12 hours.1 Participants passively drooled 
into a prolyprolyene vial through a straw until 1.8 mL of saliva had been collected.  
Samples were immediately frozen at -20° C in a locked room. Later, they were 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 All hypotheses concerning estradiol were originally tested controlling for the use of 
these substances; however, use of these substances did not significantly impact estradiol 
or any outcome, and inclusion of these controls in models did not change model 
outcomes in any substantive way. Therefore, they were not included in models presented 
in the results section.  
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transferred to the University of Kentucky General Clinical Research Center for 17ß-
Estradiol assay using ELISA kits (Salimetrics). Intra-assay coefficient of variation for 
estradiol was 1.6%; inter-assay coefficient of variation was 2.2%.  The standard curves 
were of expected shape and slope for 17ß-Estradiol.  
Weekly BPD Symptoms 
 
Personality Assessment Inventory - Borderline Subscale (PAI-BOR; Morey, 1991). 
The PAI-BOR is a 24-item measure of BPD symptoms, including 4 subscales measuring 
affective instability (example item: “my mood could shift quite suddenly”), identity 
problems (example item: “my attitude about myself changed a lot”), negative 
relationships (example item: “my relationships have been stormy”), and self-harm 
(example item: “I was a reckless person).  Notably, the self-harm subscale actually 
measures tendency toward impulsive behaviors rather than physical self-harm. The PAI-
BOR is the most well-studied measure of borderline personality disorder symptoms, and 
has been used widely in both research and clinical settings to predict BPD diagnosis 
(Morey, 1991; Stein, Pinsker-Aspen, & Hilsenroth, 2007). Participants were asked to rate 
the extent to which each statement described them in the past week on a scale from 0 
(False, Not True at All) to 4 (Very True).  
Borderline Symptom List - 23 (BSL-23; Bohus et al., 2007). The BSL-23 is a 23-
item shortened version of a 95-item measure of BPD symptoms based on the SCID-II 
DSM-IV diagnosis of BPD. In the initial validation sample, scores on the full and 
shortened versions of the BSL were significantly greater among individuals with a SCID-
II diagnosis of BPD than among those with Axis I diagnosis (e.g., mood or anxiety 
disorders) and among healthy controls. In another validation sample of individuals with a 
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diagnosis of BPD, scores the BSL reduced significantly in response to Dialectical 
Behavior Therapy; this evidence that BSL scores change with treatment makes it a 
particularly appropriate measure of change for the present study. Example items include 
“I felt helpless”, “my mood rapidly cycled in terms of anxiety, anger, and depression”, “I 
was afraid of losing control”, and “I didn’t believe in my right to live.”  Participants were 
asked to rate the extent to which each statement described them in the past week on a 
scale from 0 (Not at all) to 4 (Very much). A simple comparison of the face validity of 
the items on this scale to items on the PAI-BOR led to the conclusion that the items on 
this scale may be more appropriate for measuring the upper, more extreme range of BPD 
symptoms.  Distributions of the two scales confirmed this; scores on the BSL-23 
appeared more positively skewed than scores on the PAI-BOR, suggesting that the BSL-
23 may be capturing rarer, more extreme symptoms of BPD. In further support of this 
hypothesis, the correlations of number of SCID-II criteria met in the present study with 
the PAI-BOR and the BSL-23 revealed a significantly stronger correlation of SCID-II 
number of criteria with the BSL-23 than with the PAI-BOR or the MSI-BPD (see 
descriptive section of the Results).  
McLean Screening Instrument for BPD (MSI-BPD; Zanarini et al., 2003). The 
MSI-BPD uses 10 dichotomous (yes or no) items to measure the nine DSM-IV BPD 
criteria. Example items include, “Have you been distrustful of other people?”, “Have you 
been extremely moody?”, and “Have you deliberately hurt yourself physically (e.g., 
punched yourself, cut yourself, burned yourself)? How about made a suicide attempt?” In 
several studies, scores on the MSI-BPD were positively associated with other measures 
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of BPD symptoms (Gardner & Qualter, 2009), and predicted actual SCID-II diagnosis of 
BPD (Zanarini et al., 2003).  
Weekly Feelings of Social Acceptance 
 
Weekly feelings of social acceptance were measured using the Social Evaluation 
scale of the State Self-Esteem Scale (SSES; Heatherton & Polivy, 1991). The Social 
Evaluation subscale uses 7 items to measure the degree to which an individual feels that 
they a valued highly by the members of their social group. Social stress tasks and social 
shame inductions reliably produce temporary reductions in scores on this subscale of the 
SSES, suggesting that it taps into relatively temporary levels of felt acceptance 
(Gruenewald, Kemeny, Aziz, & Fahey, 2004).  Example items include, “I feel inferior to 
others at this moment” (reverse scored) and “I feel that others respect and admire me.” 
Participants rated the extent to which they felt each item described their thoughts in the 
past week on a scale from 1 (Not at all) to 5 (Extremely). In the present study, individuals’ 
average scores on this scale functioned adequately with a mean of 5.37, a standard 
deviation of .88, and an internal consistency of α = .87.  
Weekly Self-Control 
 
Self-control was measured using the Brief Self-Control Scale (BSCS; Tangney, 
Baumeister, & Boone, 2004). The BSCS is a 13-item questionnaire designed to measure 
one’s trait capacity for self-control. Example items include, “I am good at resisting 
temptation”, “I am lazy” (reverse-scored), and “People would say that I have iron self-
discipline.” Participants were asked to rate the extent to which each item had been true of 
them in the past week on a scale from 1 (“Not at All”) to 5 (“Very Much).  Higher scores 
on the self-control scale are associated with higher grade point average and positive 
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psychological adjustment (Tagney, Baumeister, & Boone, 2004). In the present study, 
individuals’ average scores on the SCS functioned adequately, with a mean of 3.42, a 
standard deviation of .05, and an internal consistency of α = .87. 
Weekly Impulsivity 
 
Weekly impulsivity was measured using the UPPS-P Impulsivity Scale 
(Whiteside and Lynam, 2001). The UPPS-P impulsivity scale measures five distinct 
pathways to impulsive behavior: negative urgency, or the tendency to act rashly in the 
face of negative emotion, positive urgency, or the tendency to act rashly in the presence 
of positive emotion, lack of perseverance, or the lack of ability to persist in the face of 
boredom, lack of premeditation, or the tendency not to think through actions, and 
sensation seeking, or the tendency to engage in novel, high-sensation behaviors. Example 
items include, “This week, it was hard for me to resist acting on my feelings” (Negative 
Urgency), “This week when I was happy, I tended to do things that could cause problems 
in my life” (Positive Urgency), “This week, my thinking was careful and purposeful” 
(Lack of Premeditation), “This week, I finished what I started” (Lack of Perseverance, 
and “This week, I sought out new experiences and sensations” (Sensation Seeking).  
Participants were asked to rate the extent to which each item had been true for them in 
the past week on a scale from 1 (Not at All) to 4 (Very much).  In a variety of studies, 
facets of the UPPS-P have predicted a variety of impulsivity-related outcomes such as 
substance use and abuse (Verdejo-Garcia, Bechara, Recknor, & Perez-Garcia, 2007), 
problem gambling (Cyders & Smith, 2008), eating disorder symptoms (Fischer, 
Anderson, & Smith, 2004), and aggression (Derefinko, DeWall, Metze, Walsh, & Lynam, 
2011).  In the present study, individuals’ average scores on the UPPS-P functioned 
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adequately, including Negative Urgency (Mean: 3.30, SD: .05, α = .83), Positive Urgency 
(Mean: 3.15, SD: .04, α = .73), Lack of Premeditation (Mean: 3.15, SD: .06, α = .85), 
Lack of Perseverance (Mean: 3.13, SD: .05, α = .84), and Sensation Seeking (Mean: 2.76, 
SD: .06, α = .78).  
Daily Measures 
Conception Probability 
 
Daily, participants reported the start date of their most recent menstrual period. 
This allowed for the calculation of cycle day and associated conception probabilities 
(Wilcox et al., 2001) for estimating fertility/ovulation.  
Daily BPD Symptoms 
 
Daily symptoms of BPD were measured using a modified version of the 
Personality Assessment Inventory - Borderline Subscale (see weekly measures above; 
PAI-BOR; Morey, 1991) in which the one item referencing physical self-harm (“When I 
was upset, I typically did something to hurt myself”) was omitted. This item was omitted 
to reduce the risk of daily priming and distress. Participants were asked to rate the extent 
to which each statement described them in the past 24 hours on a scale from 0 (False, not 
true at all) to 4 (Very true).  Descriptive statistics and internal consistencies on the PAI-
BOR at the daily level were as follows: Affective Instability (Mean: .59, SD: .02, α = .84), 
Identity Instability (Mean: .65, SD: .02, α = .70), Negative Relationships (Mean: .73, 
SD: .02, α = .74), and Self-Harm (Mean: .38, SD: .01, α = .73).  
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Daily Felt Acceptance 
 
Daily levels of felt acceptance were measured using a scale created for this study. 
Participants were asked to rate the following items indicating the extent to which she had 
experienced each item in the past 24 hours: “Accepted”, “Included”, “Rejected”, 
“Excluded”, “Lonely”, and “Abandoned” (last four items reverse-scored).  Response 
options ranged from 1 (“Very Slightly or Not at All”) to 5 (“Extremely”). Descriptive 
statistics and internal consistency for the average of daily felt acceptance are as follows: 
Mean = 4.05, SD = 1.10, α = .91.  In addition, person averages of this composite variable 
were negatively associated with person averages of weekly measures of Social 
Evaluation subscale of the State Self-Esteem Scale (r = .84, p < .0001).  
Between-Person Measures 
Five Factor Model (FFM) Personality 
 
The Five Factor Model Rating Form (FFMRF) is a 30-item instrument that asks 
participants to rate themselves on the 30 facets of the Five Factor Model of personality 
(FFM; Mullins-Sweatt, Jamerson, Samuel, Olson, & Widiger, 2006). Each item is rated 
on a scale from 1 (“Extremely Low”) and 5 (“Extremely High”). Individual facets were 
combined to construct the FFM domains: Neuroticism, Extraversion, Openness to 
Experience, Agreeableness, and Conscientiousness. This short measure of the five factor 
model of personality has been validated for use in student samples, and correlates well 
with longer measures of FFM personality such as the NEO-PI-R (Costa & McCrae, 1992; 
Mullins-Sweatt et al., 2006).  
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Childhood Maltreatment 
 
The Childhood Trauma Questionnaire (CTQ) is a 28-item retrospective measure 
of various types of maltreatment in childhood, and includes subscales measuring 
Emotional Abuse (example item: “Someone in my family yelled and screamed at me”, 
Emotional Neglect “I felt like there was someone in my family who wanted me to be a 
success”—reverse-scored), Physical Abuse (“Someone in my family hit me so hard that it 
left me with bruises or marks”), Physical Neglect (“I had to wear dirty clothes”), and 
Sexual Abuse (“Someone threatened to hurt me or tell lies about me unless I did 
something sexual with them”) (Bernstein et al., 2003). Each item begins with the phrase, 
“When I was growing up,” and is rated on a scale from 1 (“Never True”) to 5 (“Rarely 
True”). The CTQ also includes a 3-item validity scale designed to detect underreporting 
of maltreatment; subscale scores from individuals scoring above the cutoff on this 
validity scale are invalid and not included in analyses (n = 0 in the present study).  In 
diverse samples, the CTQ correlates well with therapist and peer reports of an 
individual’s childhood maltreatment, as well as independent evidence of childhood 
maltreatment in the domain specified (Bernstein et al., 2003).  
DSM-IV Diagnosis of BPD 
 
The BPD module of the Structured Clinical Interview for Diagnosis—II (SCID-II; 
First, 1997) was administered to determine diagnostic status and the number of DSM-IV 
BPD criteria met.  During the final session, the principal investigator (n = 30) and another 
master’s level clinician with experience completing the SCID-II (n = 10) led each 
participant through the BPD module of the SCID-II. After completion of the study, 
transcripts of participant responses to interview prompts were independently scored 
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(without knowledge of the original clinician’s ratings) by the clinician who did not 
complete the interview. Agreement was perfect for all items.  
Data Analytic Plan 
Power Analysis 
 
The current study is powered on the results of the post-hoc moderation analyses 
from a preliminary study (Eisenlohr-Moul et al., under review). Power was estimated by 
(1) using formulae provided by Snijders and Bosker (1999) to determine design effects 
due to the intraclass correlation (ICC) and the resulting effective N, and (2) calculating 
smallest detectable effect size based upon the effective N, 80% power, and an alpha level 
of .05. Results indicated that the current study would have 80% power to detect small 
effects (r = .10) with 711 lower-level units, yielding an effective N of 515 after 
accounting for average ICCs for daily felt acceptance and BPD-related outcomes found in 
the original study. In order to obtain an effective N of this size in the current study, I 
would need only 25 women (i.e., 25 multiplied by 28 is equal to 728 daily measurements). 
However, in order to allow for missed diaries and to ensure that the sample size will be 
large enough to detect week-level effects, data will be collected from 40 women (i.e., 40 
multiplied by 4 weekly visits is equal to 160 weekly measurements; effective N estimated 
to be 115). This results in 80% power to detect medium (r = .25) effects of estradiol at 
the weekly level, and small effects (r = .12) of conception probability (ovulation) at the 
daily level.  
Multilevel Models 
 
Data were analyzed using multilevel models in SAS PROC MIXED and SAS 
PROC GLIMMIX with daily diaries or laboratory visits at Level 1 and people at Level 2. 
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Multilevel models utilize all available data with no listwise deletion. In daily and weekly 
models, level 1 predictors were centered to isolate the within-person component. For 
example, each person at each laboratory visit had two estradiol variables: (1) the person’s 
mean levels of estradiol across all visits (the same across all visits within an individual), and 
(2) the person’s deviation from their own mean score at the current laboratory visit. The latter 
deviation reflects fluctuations in estradiol relative to the person’s own mean level and was 
the relevant, visit-level predictor. Prior to conducting analyses, all variables were screened 
for distributional normality; in most cases, the distribution was positively skewed to such an 
extent that linear transformations were not successful in approximating normality. Given the 
relatively low base rate of BPD in the general population, such distributional characteristics 
are unsurprising. Preliminary inspection of the properties of these distributions suggested that 
most followed a Poisson or zero-inflated Poisson distribution. Furthermore, comparisons of 
the model fit for various alternative multilevel models (zero-inflated Poisson, negative 
binomial, and Poisson) suggested that a Poisson distribution resulted in the best fit. In these 
cases, therefore, multilevel Poisson models were utilized. All continuous between-person 
predictors were standardized.  
Model Fitting and Random Effects 
 
For each model, I tested the significance of changes in -2 log likelihood (or, in the 
case of Poisson models, -2 restricted log pseudo-likelihood) in a stepwise manner, 
comparing: (1) a model with no predictors and a random intercept, (2) a model adding all 
relevant predictors for testing hypotheses as fixed effects, and (3) a model adding random 
effects for the relevant within-person predictor (e.g., deviations in estradiol). Significant 
differences between each model and the best-fitting previous model are clearly labeled in 
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each table. Random effects were only retained in further (e.g., mediation/moderation) 
models where the improvement in model fit was significant with their inclusion. When 
moderation hypotheses were tested, results of best-fitting models up to that point were 
transposed to new tables for ease of model comparison.  
Specific Hypothesis Tests 
 
The primary hypothesis was that increases in conception probability and estradiol 
would be associated with increased expression of BPD symptoms. At the daily level, this 
hypothesis was tested in multilevel Poisson regression models with daily assessments at 
level one and women at level two; daily scores on the PAI-BOR were regressed on 
conception probability. At the weekly level, the hypothesis was tested in multilevel 
Poisson regression models with weekly assessments at level one and women at level two; 
weekly scores on the PAI-BOR, the BSL-23, and the MSI-BPD were regressed on 
average estradiol and weekly deviation in estradiol.  
Moderation by Trait BPD Symptoms. The second hypothesis concerned the 
moderation of these effects by trait levels of BPD symptoms as measured by (1) the 
average of weekly PAI-BOR total score and (2) the number of SCID-II criteria met in the 
diagnostic interview. At the daily level, I tested this hypothesis in two multilevel Poisson 
regression models: (1) regressing daily PAI-BOR scores on conception probability, 
average weekly PAI-BOR total score, and their interaction, and (2) regressing daily PAI-
BOR scores on conception probability, number of SCID-II criteria met during the 
diagnostic interview, and their interaction. At the weekly level, I tested this hypothesis in 
two multilevel Poisson regression models for each of the three measures of BPD 
symptoms (PAI-BOR, BSL-23, and MSI-BPD): (1) regressing weekly symptoms on 
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average estradiol and weekly deviation in estradiol, average weekly PAI-BOR total score, 
and the interactions of average weekly PAI-BOR total score with both average estradiol 
and weekly deviation in estradiol, and (2) regressing weekly symptoms on average 
estradiol and weekly deviation in estradiol, number of SCID-II criteria met during the 
diagnostic interview, and the interactions of number of SCID-II criteria with both average 
estradiol and weekly deviation in estradiol. Because trait BPD as defined here is a 
heterogeneous construct, further moderation analyses were also conducted in which 
aspects of FFM personality and different types of childhood maltreatment were 
substituted as moderators of the effects of estradiol.  
Mediation by Felt Acceptance, Impulsivity, and Self-Control. The third hypothesis 
concerned the mediation of conception probability and estradiol effects on symptoms by 
felt acceptance, multiple facets of impulsivity, and self-control. A primary step in testing 
mediation is to test for effects of the focal predictors on outcomes of interest; this was 
accomplished during tests of hypothesis 1 and 2. A second step is to test the effects of 
these focal predictors on the mediators. A third step is to test the impact of the mediator 
on the outcomes of interest. Finally, given significant findings in these three tests, a final 
test used estimates and standard errors for the A and B paths to generate a 95% 
confidence interval for the indirect effect of the focal predictor (e.g., weekly deviations in 
estradiol) on the outcome of interest (e.g., BPD symptoms) via the mediator (e.g., felt 
acceptance) using the RMediation program (Tofighi & MacKinnon, 2011). Where 
moderation hypotheses were supported, mediational analyses were also conducted to 
determine whether felt acceptance, UPPS impulsivity, or self-control mediated these 
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moderation effects. Models included in testing the second and third steps discussed above 
will now be described in detail for each of the three proposed mediators.  
The first proposed mediator was felt acceptance. At the daily level, this was tested 
in two models: (1) regressing daily felt acceptance on conception probability, and (2) 
regressing daily PAI-BOR scores on average levels of felt acceptance and daily 
deviations in felt acceptance. At the weekly level, this was tested in similar models: (1) 
regressing weekly scores on the Social Evaluation subscale of the SSE scale on average 
estradiol and weekly deviations in estradiol, and (2) regressing weekly BPD symptoms 
(on the PAI-BOR, the BSL-23, and the MSI) on average scores on the Social Evaluation 
subscale of the SSE scale and weekly deviations in scores on the Social Evaluation 
subscale of the SSE scale. Where moderation models were significant, tests of mediated 
moderation were also carried out. The second proposed mediator was impulsivity. At the 
weekly level, this was tested in the following models: (1) regressing weekly scores on 
each subscale of the UPPS-P on average estradiol and weekly deviations in estradiol, and 
(2) regressing weekly BPD symptoms (on the PAI-BOR, the BSL-23, and the MSI-BPD) 
on average scores on each subscale of the UPPS-P and weekly deviations in scores on 
each subscale of the UPPS-P. The third proposed mediator was self-control. At the 
weekly level, this was tested in the following models: (1) regressing weekly scores on the 
BSCS on average estradiol and weekly deviations in estradiol, and (2) regressing weekly 
BPD symptoms (on the PAI-BOR, the BSL-23, and the MSI) on average of all weekly 
scores on the BSCS and weekly deviations in scores on the BSCS. 
 
Copyright © Tory Eisenlohr-Moul 2013 
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Chapter Three: Results 
Observations at the Daily and Weekly Level 
At the daily level, there were 729 observations, indicating an average of 18.22 
diaries completed per participant. At the weekly level, there were no missed lab sessions 
that were unable to be rescheduled; therefore, the maximum number of 160 data points 
were collected. This means that all 40 participants provided data at exactly four lab visits.  
Descriptive and Correlational Analyses 
 
Before carrying out hypothesis tests, I examined the zero-order correlations 
between a woman’s average levels of estradiol, a woman’s average scores on daily and 
weekly BPD measures, and between-person variables (e.g., SCID criteria met, FFM 
personality domains, and types of childhood maltreatment). Zero-order correlations, 
means, standard deviations, and internal consistencies for these variables can be found in 
Table 2. Unexpectedly, higher average levels of estradiol were significantly negatively 
correlated with Extraversion. Additional post-hoc correlations of average estradiol with 
the five facet items for Extraversion on the FFM-RF revealed that this significant 
association was accounted for by significant negative correlations between average 
estradiol and the warmth (r = -.36, p = .01) and positive emotions (r = -.32, p = .02) 
facets. In addition, average levels of estradiol were associated with higher levels of both 
physical and emotional abuse; these correlations were also not anticipated, and the 
reasons for these associations are unclear. Average levels of estradiol were uncorrelated 
with any measure of BPD.  
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Table 2 
Zero-order correlations among between-person measures, average estradiol, and average daily and weekly measures of BPD  
 
Variable 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 Average Estradiol -                
2 Neuroticism .12 -               
3 Agreeableness -.02 -.24 -              
4 Conscientiousness .11 -.19 .07 -             
5 Extraversion -.30* -.23 .21 .21 -            
6 Openness .03 .12 .33* -.05 .27* -           
7 Emotional Abuse  .25* .27* -.14 .05 -.02 .14 -          
8 Emotional Neglect .02 .32* -.21 -.13 -.07 .15 .83* -         
9 Physical Abuse .26* .22 -.17 .10 -.14 .09 .81* .70* -        
10 Physical Neglect .13 .34* -.09 -.10 -.04 .28* .70* .78* .78* -       
11 Sexual Abuse .04 .18 -.26* .11 .0001 .01 .52* .39* .55* .61* -      
12 SCID-II Criteria Met -.13 .41* -.10 -.18 .06 .15 .38* .42* .18 .26* .13 -     
13 Avg PAI-BOR (D) -.08 .59* -.29* -.29* -.04 .21 .21 .34* .06 .19 .006 .64* -    
14 Avg PAI-BOR (W) -.002 .59* -.31* -.26* -.08 .17 .33* .38* .17 .26* .25* .66* .95* -   
15 Avg BSL-23 (W) .07 .59* -.34* -.10 -.09 .13 .54* .62* .42* .47* .26* .78* .82* .88* -  
16 Avg MSI (W) -.10 .49* -.31* -.19 -.03 .23 .22 .40* .15 .25* .03 .67* .88* .87* .87* - 
Mean  
(SD) 
3.39 
(.08) 
2.40 
(.12) 
3.55 
(.11) 
3.57 
(.09) 
3.71 
(.12) 
3.90 
(.10) 
.13 
(.37) 
1.55 
(.15) 
1.26 
(.11) 
1.22 
(.09) 
1.28 
(.14) 
1.32 
(.33) 
.59 
(.06) 
.70 
(.04) 
.48 
(.47) 
2.08 
(2.26) 
Cronbach’s α - .75 .75 .71 .77 .81 .85 .93 .86 .81 .95 - .89 .91 .93 .77 
Note. *p < .05. Estradiol units are pg/mL.   
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Consistent with dimensional FFM personality models of BPD (Widiger & 
Mullins-Sweatt, 2009), Neuroticism was positively correlated with all measures of BPD. 
Agreeableness was negatively correlated with all measures of BPD except the SCID-II 
interview, and Conscientiousness was negatively associated with two of the five 
measures of BPD; however, Openness was not associated with any measure of BPD. 
Neuroticism was also positively correlated with higher scores on some facets of the CTQ 
(Emotional Abuse, Emotional Neglect, and Physical Neglect). Consistent with Linehan’s 
biosocial theory of BPD, subscales of the CTQ were generally but inconsistently 
associated with higher BPD features; Emotional Abuse, Emotional Neglect, Physical 
Neglect, and Sexual Abuse showed the most consistent positive associations with BPD 
scores. Notably, scores on the Sexual Abuse subscale were both positively associated 
with higher average scores on the weekly PAI-BOR and BSL-23 and negatively 
correlated with Agreeableness. Intercorrelations among average daily, average weekly, 
and number of SCID-II criteria met were all significant in expected directions, suggesting 
good convergent validity among these various ways of measuring BPD (all r’s 
between .69 and .95). All subscales of the CTQ were also highly intercorrelated in 
expected directions. Internal consistencies were all acceptable to excellent. 
Examination of the SCID-II criteria met variable revealed that, on average, 
individuals endorsed a low number (1.33) of BPD criteria during the interview. Notably, 
though all of the other measures of BPD were significantly correlated with number of 
SCID-II criteria met, significance testing for the differences between correlations 
revealed that the correlation between the BSL-23 and number of SCID-II criteria met (r 
= .78) was significantly greater than the correlations between number of SCID-II criteria 
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met and average weekly PAI-BOR (t(37) = -2.38, p = .002), average daily PAI-BOR 
(t(37) = -2.25, p =.03), and the MSI-BPD (t(37) = -2.09, p =.04). Therefore, although all 
of the self-report measures were highly positively correlated with BPD symptoms as 
measured using the SCID-II diagnostic interview, the BSL-23 may be considered a 
stronger indicator of interview-confirmed BPD symptoms in the present sample.  
Testing Hypothesis 1: Ovulation, Estradiol, and BPD Symptom Expression 
Daily Analyses. It was predicted that higher levels of conception probability 
would predict greater expression of BPD symptoms at the daily level. Results of 
multilevel Poisson regression models predicting each of the four PAI-BOR subscales and 
the PAI-BOR total scale from conception probability are presented in Table 3.  
Results of these models do not support Hypothesis 1; conception probability did 
not significantly predict any PAI-BOR subscale or the total scale. However, comparing 
Model 2 (a model with a fixed effect of conception probability) to Model 3 (a model with 
a random effect specified for conception probability) revealed significant improvement in 
model fit when predicting each of the PAI-BOR subscales and the total. This indicates 
that the influence of conception probability (ovulation) on BPD symptoms differs 
between individuals (i.e., there is a moderator).    
Weekly Analyses. It was also predicted that increases in estradiol (which are 
typically associated with ovulation) would predict greater expression of BPD symptoms 
at the weekly level. Results of models predicting each of the four PAI-BOR subscales 
and total score, the MSI-BPD, and BSL-23 from average estradiol and weekly deviations 
in estradiol are presented in Table 4.  
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Table 3 
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from Daily 
Conception Probability Values 
 
Parameter Model 1  
(null) 
Model 2  
(fixed CP slope) 
Model 3  
(random CP slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.62* (.10) -.62* (.10) -.62* (.10) 
Conception Probability  .17 (.59) .20 (.98) 
 Random Parameters 
Intercept .38* (.09) .37* (.09) .39* (.09) 
Conception Probability   18.25* (7.30) 
Residual .13* (.006) .13* (.007) .12* (.006) 
    
-2 Restricted Log Pseudo-
likelihood 
1348.35 1224.61† 1185.02† 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.68* (.12) -.68* (.13) -.67* (.13) 
Conception Probability  .13 (.93) -.24 (1.29) 
 Random Parameters 
Intercept .59* (.15) .60* (.15) .60* (.15) 
Conception Probability   20.71* (12.12) 
Residual .33* (.01) .13* (.93) .31* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
2117.42 1915.66† 1903.81† 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.55* (.10) -.53* (.10) -.53* (.11) 
Conception Probability  -.56 (.65) -.71 (.99) 
 Random Parameters 
Intercept .42* (.10) .43* (.10) .45* (.11) 
Conception Probability   15.48* (7.39) 
Residual .17* (.009) .17* (.009) .16* (.009) 
    
-2 Restricted Log Pseudo-
likelihood 
1521.40 1376.87† 1357.97† 
Table Continued on Next Page 
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Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
  
Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.48* (.10) -.49* (.11) -.50* (.11) 
Conception Probability  .60 (.68) .73 (1.04) 
 Random Parameters 
Intercept .44* (.10) .44* (.11) .45* (.11) 
Conception Probability   16.59* (8.81) 
Residual .22* (.01) .23* (.01) .21* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
1622.09 1487.02† 1472.61† 
Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.13* (.15) -1.11* (.15) -1.10* (.15) 
Conception Probability  .70 (1.17) .36 (.83) 
 Random Parameters 
Intercept .87* (.24) .77* (.22) .77* (.23) 
Conception Probability   48.07* (23.80) 
Residual .34* (.01) .34* (.01) .31* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
2551.02 2264.19† 2242.93† 
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Table 4 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random deviation 
slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50* (.10) -.50* (.10) -.50* (.10) 
Average Weekly Estradiol  -.02 (.10) -.02 (.09) 
Deviations in Estradiol  .001 (.04) .001 (.05) 
 Random Parameters 
Intercept .39* (.09) .40* (.10) .40* (.10) 
Deviations in Estradiol   .03 (.06) 
Residual .08* (.01) .08* (.01) .08* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
240.55 239.27 240.27 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60* (.15) -.61* (.15) -.61* (.15) 
Average Weekly Estradiol  -.10 (.15) -.10 (.14) 
Deviations in Estradiol  -.05 (.06) -.05 (.06) 
 Random Parameters 
Intercept .83* (.23) .85* (.23) .85* (.23) 
Deviations in Estradiol   .04 (.03) 
Residual .16* (.02) .16* (.02) .16* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
370.17 370.09 369.89 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30* (.11) -.30* (.11) -.30* (.11) 
Average Weekly Estradiol  -.03 (.11) -.04 (.11) 
Deviations in Estradiol  -.00069 (.05) .01 (.06) 
 Random Parameters 
Intercept .45* (.11) .46* (.11) .47* (.11) 
Deviations in Estradiol   .02 (.04) 
Residual .12* (.01) .12* (.01) .11* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
274.93 273.58 273.18 
Table Continued on Next Page 
	   	  
	  
 37 
Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.42 (.12) -.42 (.12) 
Average Weekly Estradiol  -.01 (.10) -.01 (.10) 
Deviations in Estradiol  .03 (.15) .03 (.15) 
 Random Parameters 
Intercept .53* (.14) .55* (.16) .55* (.16) 
Deviations in Estradiol   .01 (.07) 
Residual .16* (.02) .17* (.02) .17* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
332.16 332.10 330.77 
Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03* (.11) -1.03* (.11) -1.04* (.11) 
Average Weekly Estradiol  .01 (.11) .01 (.11) 
Deviations in Estradiol  .02 (.09) .02 (.09) 
 Random Parameters 
Intercept .35* (.12) .37* (.12) .37* (.12) 
Deviations in Estradiol   .002 (.05) 
Residual .18* (.02) .18* (.02) .18* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
407.23 411.88 411.86 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05* (.16) 2.04* (.17) 2.04* (.18) 
Average Weekly Estradiol  .003 (.17) .003 (.16) 
Deviations in Estradiol  -.11* (.03) -.11* (.02) 
 Random Parameters 
Intercept 1.06* (.29) 1.11* (.30) 1.11* (.30) 
Deviations in Estradiol   .004 (.06) 
Residual 2.34* (.31) 2.26* (.30) 2.26* (.30) 
    
-2 Restricted Log Pseudo-
likelihood 
379.72 371.22 378.22 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .17 (.22) .17 (.22) 
Average Weekly Estradiol  -.03 (.22) -.03 (.22) 
Deviations in Estradiol  -.08 (.07) -.08 (.07) 
 Random Parameters 
Intercept 1.80* (.54) 1.86* (.56) 1.87* (.56) 
Deviations in Estradiol   -.03 (.22) 
Residual .68* (.09) .69* (.09) -.08 (.07) 
    
-2 Restricted Log Pseudo-
likelihood 
481.04 480.91 480.02 
Note. Standard errors are in parentheses. A dashed line indicates that the model did not converge, likely due 
to nonsignificance of random effects included.  
*p < .05.   
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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For each of the models except the one predicting the BSL-23, were no significant 
fixed or random effects of either average levels of estradiol or weekly deviations in 
estradiol.  There was a significant fixed effect of deviations in estradiol such that higher-
than-usual levels of estradiol were associated with lower scores on the BSL-23.  
Testing Hypothesis 2: Moderation of Cycle Effects by Trait BPD 
Daily Analyses. It was predicted that the effect of daily conception probability 
values on expression of BPD symptoms as measured by the PAI-BOR would be 
moderated by (1) average weekly values of the total PAI-BOR scale and (2) number of 
BPD criteria met during the SCID-II diagnostic interview. Specifically, it was 
hypothesized that women with generally higher levels of BPD symptoms (as measured by 
average of the four extended weekly assessments or number of BPD criteria met during 
the SCID-II interview) would show a stronger positive association between daily 
conception probability values and BPD symptoms. Results of models predicting each of 
the four PAI-BOR subscales and total scale from conception probability, average of 
weekly PAI-BOR total score assessments, and their interaction are presented in Table 5. 
In each case, Model 3 information was transplanted from Table 3 for ease of comparing 
Model 3 (in which a random effect of conception probability was identified) to Model 4, 
in which the moderator is included.  
Though models including the moderator provided significantly better model fit 
than a model including only a random effect of conception probability, only one of these 
models provided evidence that trait BPD moderates the impact of daily conception 
probability values on daily BPD symptoms. There was a significant interactive effect of 
average daily total PAI-BOR scores and conception probability in the opposite of the  
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Table 5 
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from the 
Interaction of Daily Conception Probability Values and Average of Weekly PAI-BOR 
Assessments (Trait BPD) 
 
Parameter Model 3 
(random CP slope) 
Model 4 
(with moderator) 
Dependent Variable: Daily PAI-BOR Total Score  
 Fixed Effects 
Intercept -.62* (.10) -.65* (.04) 
Conception Probability .20 (.98) .49 (.64) 
Avg of Weekly PAI-BOR  .56* (.03) 
Avg of Weekly PAI-BOR*CP   -.89* (.07) 
 Random Parameters 
Intercept .39* (.09) .03* (.01) 
Conception Probability 18.25* (7.30) 16.48* (6.67) 
Residual .12* (.006) .13* (.007) 
   
-2 Restricted Log Pseudo-likelihood 1185.02 1146.20† 
Dependent Variable: Daily PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.67* (.13) -.70* (.07) 
Conception Probability -.24* (1.29) -.43 (1.33) 
Avg of Weekly PAI-BOR  .62* (.18) 
Avg of Weekly PAI-BOR*CP   -.17 (.88) 
 Random Parameters 
Intercept .60* (.15) .15* (.05) 
Conception Probability 20.71* (12.12) 19.12* (11.02) 
Residual .31* (.01) .31* (.01) 
   
-2 Restricted Log Pseudo-likelihood 1903.81 1849.49† 
Dependent Variable: Daily PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.53* (.11) -.56* (.06) 
Conception Probability -.71 (.99) -.54 (.99) 
Avg of Weekly PAI-BOR  .57* (.05) 
Avg of Weekly PAI-BOR*CP   -1.11 (.89) 
 Random Parameters 
Intercept .45* (.11) .10* (.03) 
Conception Probability 15.48* (7.39) 13.93* (6.82) 
Residual .16* (.009) .16* (.009) 
   
-2 Restricted Log Pseudo-likelihood 1357.97 1307.95† 
Table Continued on Next Page 
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Dependent Variable: Daily PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.50* (.11) -.52* (.06) 
Conception Probability .73 (1.04) .97 (1.00) 
Avg of Weekly PAI-BOR  .57* (.06) 
Avg of Weekly PAI-BOR*CP   -1.16 (.91) 
 Random Parameters 
Intercept .45* (.11) .11* (.03) 
Conception Probability 16.59* (8.81) 12.79* (7.38) 
Residual .21* (.01) .21* (.01) 
   
-2 Restricted Log Pseudo-likelihood 1472.61 1424.62† 
Dependent Variable: Daily PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -.62* (.10) -1.12* (.12) 
Conception Probability .20 (.98) .14 (1.77) 
Avg of Weekly PAI-BOR  .55* (.11) 
Avg of Weekly PAI-BOR*CP   -.25 (.87) 
 Random Parameters 
Intercept .77* (.23) .43* (.13) 
Conception Probability 48.07* (23.80) 46.84* (23.18) 
Residual .31* (.01) .31* (.01) 
   
-2 Restricted Log Pseudo-likelihood 2242.93 2216.45† 
Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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predicted direction: women with lower (-1 standard deviation) trait BPD symptoms 
showed increased daily BPD symptoms on days when conception probability was higher 
(γLOWTRAITBPD*CP = .58, SE = .44, t(697) = 3.53, p = .0004), whereas there was no effect 
of conception probability in women with higher (+1 standard deviation) trait levels of 
BPD (γHIGHTRAITBPD*CP = -.05, SE = .26, t(697) = -.19, p = .84). A graph depicting the 
interaction can be found in Figure 1.  
Next, models were executed in which number of SCID-II criteria met was 
substituted for Average Weekly PAI-BOR scores as an alternative measure of trait BPD 
symptoms.  Results of these models are presented in Table 6. The results from the 
random slope models (Model 3) were again transplanted from Table 3 for ease of model 
comparison. As with the majority of the PAI-BOR moderation models, the SCID-II 
criteria moderation models provided significantly better model fit than a model including 
only a random effect of conception probability; however, these models provided no 
evidence that trait BPD influences the impact of daily conception probability values on 
daily BPD symptoms.  
Weekly Analyses. It was also predicted that the effect of weekly deviations in 
estradiol on BPD symptoms as measured by the PAI-BOR, the BSL-23, and the MSI-
BPD would be moderated by (1) average weekly values of the total PAI-BOR scale and 
(2) number of criteria met on the SCID-II BPD module. Again, it was hypothesized that 
women with generally higher levels of BPD symptoms (as measured by average of the 
four extended weekly assessments and number of BPD criteria met during the SCID-II 
interview) would show stronger positive associations between weekly fluctuations in 
estradiol and BPD symptoms. Results of models predicting each of the four PAI-BOR  
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Figure 1. A graph of the interaction between trait BPD symptoms and daily conception 
probability predicting daily PAI-BOR total score.   
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Table 6 
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from the 
Interaction of Daily Conception Probability Values and Number of SCID-II BPD Criteria 
Met (Trait BPD) 
 
Parameter Model 3 
(random CP slope) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.62* (.10) -.65*(.08) 
Conception Probability .20 (.98) .24 (99) 
SCID-II BPD Criteria Met  .39* (.08) 
SCID-II BPD Criteria Met*CP   -.56 (.89) 
 Random Parameters 
Intercept .39* (.09) .24* (.06) 
Conception Probability 18.25* (7.30) 18.23* (.7.22) 
Residual .12* (.006) .12* (.006) 
   
-2 Restricted Log Pseudo-likelihood 1185.02 1164.11† 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.67* (.13) -.70* (.11) 
Conception Probability -.24 (1.29) -.47 (1.34) 
SCID-II BPD Criteria Met  .46* (.10) 
SCID-II BPD Criteria Met*CP   .10 (1.17) 
 Random Parameters 
Intercept .60* (.15) .38* (.10) 
Conception Probability 20.71* (12.12) 21.46* (12.34) 
Residual .31* (.01) .31* (.01) 
   
-2 Restricted Log Pseudo-likelihood 1903.81 1883.70† 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.53* (.11) -.56* (.09) 
Conception Probability -.71 (.99) -.54 (1.01) 
SCID-II BPD Criteria Met  .40* (.09) 
SCID-II BPD Criteria Met*CP   -.51 (.91) 
 Random Parameters 
Intercept .45* (.11) .30* (.07) 
Conception Probability 15.48* (7.39) 15.86* (7.34) 
Residual .16* (.009) .16* (.009) 
   
-2 Restricted Log Pseudo-likelihood 1357.97 1336.18† 
Table Continued on Next Page 
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Dependent Variable: Negative Relationships Subscale 
 Fixed Effects 
Intercept -.50* (.11) -.52* (.09) 
Conception Probability .73 (1.04) .77 (1.06) 
SCID-II BPD Criteria Met  .39* (.09) 
SCID-II BPD Criteria Met*CP   -.53 (.95) 
 Random Parameters 
Intercept .45* (.11) .31* (.08) 
Conception Probability 16.59* (8.81) 16.88* (8.85) 
Residual .21* (.01) .21* (.01) 
   
-2 Restricted Log Pseudo-likelihood 1472.61 1457.30† 
Dependent Variable: Self-Harm Subscale  
 Fixed Effects 
Intercept -.62* (.10) -1.14* (.14) 
Conception Probability .20 (.98) .40 (1.75) 
SCID-II BPD Criteria Met  .33* (.14) 
SCID-II BPD Criteria Met*CP   -1.32 (1.60) 
 Random Parameters 
Intercept .77* (.23) .71* (.21) 
Conception Probability 48.07* (23.80) 47.84* (23.67) 
Residual .31* (.01) .31* (.01) 
   
-2 Restricted Log Pseudo-likelihood 2242.93 2234.05† 
Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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subscales and the PAI-BOR total scale, the BSL-23, and the MSI-BPD from average 
estradiol, deviations in estradiol, average of weekly PAI-BOR total score assessments, 
and the interactions of trait BPD and each estradiol variable are presented in Table 7. In 
each case, the null model (Model 1) was transplanted from Table 4 for ease of 
comparison with Model 4, in which the trait BPD moderator is included.  
For each outcome, model fit was significantly improved with the inclusion of the 
fixed effects. Results presented in Table 7 reveal several significant interactive effects of 
trait BPD and fluctuations in estradiol, though the interactive effects are in the opposite 
of the predicted direction.  In the model predicting the total score of the PAI-BOR, 
women with lower levels of trait BPD showed a positive association between higher-
than-usual levels of estradiol and BPD symptoms (γLOWTRAITBPD*ESTRADIOLDEVIATION = .14, 
SE = .08, t(117) = 2.70, p = .007), while higher-than-usual levels in estradiol were 
associated with lower BPD symptoms among women with higher levels of trait BPD 
(γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.13, SE = .03, t(117) = 4.33, p < .0001). A graph of 
the interaction can be found in Figure 2.  
Results for several of the other scales tended to follow a similar pattern of results 
in which BPD symptoms tended to be reduced at higher-than-usual estradiol among those 
with high trait levels of BPD but tended to be increased with higher-than-usual estradiol 
among those with low trait levels of BPD symptoms (see Figure 3-5 for graphs depicting 
significant interactions). In the model predicting Identity Disturbance, there was a 
significant association between higher-than-usual estradiol and decreased symptoms 
among women high in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.18, SE = .06, 
t(117) = 1.99, p = .04), but there was not a significant association between fluctuations in   
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Table 7 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the 
Interaction of Average of Weekly PAI-BOR Assessments (Trait BPD) with Average 
Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.51* (.03) 
Avg Estradiol  -.01 (.03) 
Weekly Deviation in Estradiol   .03 (.05) 
Avg of Weekly PAI-BOR  .53* (.02) 
Avg of Weekly PAI-BOR*Avg Estradiol  .003 (.02) 
Avg of Weekly PAI-BOR*Estradiol Deviation  -.10* (.05) 
 Random Parameters 
Intercept .39* (.09) .001 (.007) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 161.70† 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.62* (.08) 
Avg Estradiol  -.09 (.08) 
Weekly Deviation in Estradiol   .001 (.07) 
Avg of Weekly PAI-BOR  .69* (.07) 
Avg of Weekly PAI-BOR*Avg Estradiol  .02 (.07) 
Avg of Weekly PAI-BOR*Estradiol Deviation  -.13* (.03) 
 Random Parameters 
Intercept .83* (.23) .16* (.06) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 328.42† 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30* (.11) -.33* (.05) 
Avg Estradiol  -.03 (.05) 
Weekly Deviation in Estradiol   .04 (.05) 
Avg of Weekly PAI-BOR  .58* (.04) 
Avg of Weekly PAI-BOR*Avg Estradiol  .01 (.04) 
Avg of Weekly PAI-BOR*Estradiol Deviation  -.13* (.05) 
 Random Parameters 
Intercept .45* (.11) .05* (.02) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 223.86† 
Dependent Variable: PAI-BOR Negative Relationships Subscale  
 Fixed Effects 
Intercept -.41* (.12) -.42* (.06) 
Avg Estradiol  -.01 (.06) 
Weekly Deviation in Estradiol   .06 (.06) 
Avg of Weekly PAI-BOR  .57* (.05) 
Avg of Weekly PAI-BOR*Avg Estradiol  .04 (.05) 
Avg of Weekly PAI-BOR*Estradiol Deviation  -.07 (.07) 
 Random Parameters 
Intercept .53* (.14) .07* (.03) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 288.91† 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.05* (.09) 
Avg Estradiol  .06 (.09) 
Weekly Deviation in Estradiol   .04 (.09) 
Avg of Weekly PAI-BOR  .39* (.08) 
Avg of Weekly PAI-BOR*Avg Estradiol  -.15* (.06) 
Avg of Weekly PAI-BOR*Estradiol Deviation  -.10 (.10) 
 Random Parameters 
Intercept .35* (.12) .17* (.08) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .19* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 402.96† 
Table Continued on Next Page 
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Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05* (.16) 2.02* (.10) 
Avg Estradiol  .03 (.10) 
Weekly Deviation in Estradiol   -.07 (.06) 
Avg of Weekly PAI-BOR  .77* (.09) 
Avg of Weekly PAI-BOR*Avg Estradiol  -.03 (.09) 
Avg of Weekly PAI-BOR*Estradiol Deviation  -.13* (.05) 
 Random Parameters 
Intercept 1.06* (.29) .32* (.10) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.24* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 342.77† 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)  
 Fixed Effects 
Intercept .17 (.22) .17 (.14) 
Avg Estradiol  -.02 (.14) 
Weekly Deviation in Estradiol   -.05 (.09) 
Avg of Weekly PAI-BOR  .96* (.13) 
Avg of Weekly PAI-BOR*Avg Estradiol  -.11 (.12) 
Avg of Weekly PAI-BOR*Estradiol Deviation  -.06 (.10) 
 Random Parameters 
Intercept 1.80* (.54) .56* (.20) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .72* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 450.59† 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Figure 2. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly PAI-BOR total score.   
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Figure 3. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly PAI-BOR Identity Disturbance subscale score.   
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Figure 4. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly PAI-BOR Affective Instability subscale score.   
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Figure 5. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly BSL-23 score.   
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estradiol and symptom expression among women low in trait BPD symptoms 
(γLOWTRAITBPD*ESTRADIOLDEVIATION = .08, SE = .06, t(117) = 1.39, p = .16). In the model 
predicting the Affective Instability subscale, there was a significant effect of higher-than-
usual estradiol predicting lower Affective Instability among women higher in trait BPD 
(γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.13, SE = .04, t(117) = -3.25, p = .0007), but there 
was no significant effect of higher-than-usual estradiol on Affective Instability among 
women with lower trait BPD (γLOWTRAITBPD*ESTRADIOLDEVIATION = .13, SE = .11, t(117) = 
1.18, p = .29). There was also a significant interaction between average scores on the 
PAI-BOR total and fluctuations in estradiol predicting scores on the BSL-23. Among 
women higher in trait BPD, higher-than-usual levels of estradiol were associated with 
decreased BPD symptoms (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.21, SE = .07, t(117) = -
2.72, p = .003). However, among women lower in trait BPD, higher-than-usual estradiol 
was not associated with BPD symptom expression (γLOWTRAITBPD*ESTRADIOLDEVIATION = .06, 
SE = .11, t(117) = .54, p = .58). Finally, in the model predicting the Self-Harm subscale, 
there was no significant interaction between trait BPD and fluctuations in estradiol; 
however, there was a significant interaction between trait BPD and average levels of 
estradiol such that higher average levels of estradiol were associated with greater 
symptoms among women with lower trait BPD (γLOWTRAITBPD*HIGHAVGESTRADIOL = .21, SE 
= .10, t(117) = 2.10, p = .01), but was not significant among women with higher trait 
BPD (γHIGHTRAITBPD*HIGHAVGESTRADIOL = -.09, SE = .11, t(117) = -.81, p = .40). A graph of 
the interaction predicting Self-Harm can be found in Figure 6.  
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Figure 6. A graph of the interaction between trait BPD symptoms and average estradiol 
predicting weekly PAI-BOR Self-Harm subscale score.   
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Results of models substituting number of SCID-II criteria met for average weekly 
scores on the PAI-BOR total scale are presented in Table 8. None of the interactions of 
trait BPD with average estradiol or fluctuations in estradiol were statistically significant.  
Testing Hypothesis 3a: Mediation by Felt Social Acceptance 
It was predicted that increases in daily conception probability would be associated 
with lower daily felt acceptance, and that these effects would be stronger among women 
high in trait BPD features. Previous analyses suggest that conception probability and 
estradiol may not exert robust main effects on BPD features (i.e., the C path of the 
mediation model may not be significant); however, tests of whether increases in 
conception probability and estradiol are associated with decreased felt acceptance (Path 
A in the mediation model) and whether changes in felt acceptance were associated with 
daily BPD symptom expression (Path B in the mediation model) were nevertheless 
carried out.  In addition, because the interactive effect of weekly deviations in estradiol 
and trait levels of BPD features on weekly BPD features were in some cases significant, 
similar models predicting felt acceptance (in addition to full mediation testing) were be 
carried out as well using averages of weekly PAI-BOR as the moderator.   
Path A at the Daily Level: Does daily conception probability exert a main or 
moderated effect on daily felt acceptance? Results of multilevel models regressing daily 
felt acceptance on conception probability are presented in Table 9. Because the 
distribution of daily felt rejection followed the inverse of a Poisson distribution (i.e., most 
people reported feeling high levels of acceptance on most days) and could not be 
transformed to normality using a linear transformation, Poisson models predicting 
reverse-scored acceptance (i.e., rejection), were utilized; however, the signs (i.e., -/+)   
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Table 8 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the 
Interaction of Number of SCID-II Criteria Met (Trait BPD) with Average Estradiol and 
Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.52* (.07) 
Avg Estradiol  -.02 (.08) 
Weekly Deviation in Estradiol   .001 (.04) 
Number of SCID-II Criteria Met  .42* (.07) 
Number of SCID-II Criteria Met*Avg Estradiol  .09 (.06) 
Number of SCID-II Criteria Met*Estradiol 
Deviation 
 .03 (.05) 
 Random Parameters 
Intercept .39* (.09) .20* (.05) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 232.89† 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.61* (.12) 
Avg Estradiol  -.11 (.12) 
Weekly Deviation in Estradiol   -.05 (.06) 
Number of SCID-II Criteria Met  .55* (.12) 
Number of SCID-II Criteria Met*Avg Estradiol  .16 (.12) 
Number of SCID-II Criteria Met*Estradiol 
Deviation 
 .03 (.07) 
 Random Parameters 
Intercept .83* (.23) .49* (.15) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 361.50† 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30* (.11) -.32 (.08) 
Avg Estradiol  -.03 (.08) 
Weekly Deviation in Estradiol   .001 (.05) 
Number of SCID-II Criteria Met  .48 (.08) 
Number of SCID-II Criteria Met*Avg Estradiol  .08 (.06) 
Number of SCID-II Criteria Met*Estradiol 
Deviation 
 -.01 (.05) 
 Random Parameters 
Intercept .45* (.11) .20* (.06) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 261.14† 
Dependent Variable: PAI-BOR Negative Relationships Subscale  
 Fixed Effects 
Intercept -.41* (.12) -.29* (.09) 
Avg Estradiol  -.03 (.10) 
Weekly Deviation in Estradiol   .04 (.15) 
Number of SCID-II Criteria Met  .33* (.08) 
Number of SCID-II Criteria Met*Avg Estradiol  .11 (.08) 
Number of SCID-II Criteria Met*Estradiol 
Deviation 
 .005 (.18) 
 Random Parameters 
Intercept .53* (.14) .37* (.11) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 329.44† 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.04* (.11) 
Avg Estradiol  .05 (.11) 
Weekly Deviation in Estradiol   .04 (.11) 
Number of SCID-II Criteria Met  .22* (.11) 
Number of SCID-II Criteria Met*Avg Estradiol  .02 (.09) 
Number of SCID-II Criteria Met*Estradiol 
Deviation 
 .11 (.10) 
 Random Parameters 
Intercept .35* (.12) .35* (.12) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 406.88 
Table Continued on Next Page 
 
 
 
 
 
 
 
	  
 59 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05* (.16) 2.02* (.14) 
Avg Estradiol  .03 (.14) 
Weekly Deviation in Estradiol   -.11* (.05) 
Number of SCID-II Criteria Met  .62* (.14) 
Number of SCID-II Criteria Met*Avg Estradiol  .09 (.11) 
Number of SCID-II Criteria Met*Estradiol 
Deviation 
 -.05 (.07) 
 Random Parameters 
Intercept 1.06* (.29) .68* (.20) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.26* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 366.35† 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)  
 Fixed Effects 
Intercept .17 (.22) .13 (.19) 
Avg Estradiol  .007 (.20) 
Weekly Deviation in Estradiol   -.08 (.07) 
Number of SCID-II Criteria Met  .76* (.19) 
Number of SCID-II Criteria Met*Avg Estradiol  .02 (.15) 
Number of SCID-II Criteria Met*Estradiol 
Deviation 
 .04 (.08) 
 Random Parameters 
Intercept 1.80* (.54) 1.26* (.41) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .70* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 473.71† 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 9 
Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from Daily 
Conception Probability Values 
 
Parameter Model 1  
(null) 
Model 2  
(fixed CP slope) 
Model 3  
(random CP slope) 
Dependent Variable: Daily Felt Acceptance 
 Fixed Effects 
Intercept -.13* (.05) -.53* (.06) -.54* (.06) 
Conception Probability  .27 (.40) .65 (.73) 
 Random Parameters 
Intercept -.13* (.03) -.13* (.03) -.14* (.03 
Conception Probability   -11.98* (4.33) 
Residual -.17* (.009) -.18* (.09) -.16* (.008) 
    
-2 Restricted Log Pseudo-
likelihood 
652.33 603.67† 548.99† 
Note. Standard errors are in parentheses. CP = Daily Conception Probability.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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were reversed so that the estimates presented in Table 9 reflect the prediction of daily felt 
acceptance rather than felt rejection.  
Results presented in Table 9 indicate that, though the fixed effect of conception 
probability was not significant for daily felt acceptance, there was a significant random 
effect of conception probability on daily felt acceptance. This indicates that the influence 
of conception probability values on daily felt acceptance differed between individuals.  
Therefore, I next carried out moderation analyses to determine whether the average of 
weekly PAI-BOR total score assessments or (2) the number of SCID-II BPD criteria met 
moderated the effect of conception probability.  Results of those models are presented in 
Table 10 and Table 11. As before, estimates from previous best-fitting models were 
transposed into these tables for ease of model comparison. 
Results revealed a significant interactive effect of trait BPD and conception 
probability predicting daily felt acceptance in the opposite of the direction predicted. 
Women with higher levels of trait BPD showed increases in daily felt acceptance when 
conception probability was higher (γHIGHTRAITBPD*CP = .70, SE = .20, t(686) = 3.50, p 
= .0006), while women with lower levels of trait BPD showed no association between 
conception probability and felt acceptance (γLOWTRAITBPD*CP = .41, SE = .63, t(686) = .65, 
p = .51).  A graph depicting the interaction can be found in Figure 7. In contrast, number 
of SCID-II BPD criteria met was not a significant moderator of the effect of conception 
probability.  
Path A at the Weekly Level: Do changes in weekly felt acceptance impact 
weekly BPD symptom expression? Next, I tested the same hypothesis at the weekly level. 
Results of models regressing weekly scores on the Social Evaluation subscale of the State  
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Table 10 
Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from the 
Interaction of Daily Conception Probability Values and Average of Weekly PAI-BOR 
Assessments (Trait BPD) 
 
Parameter Model 3 
(random CP slope) 
Model 4 
(with moderator) 
Dependent Variable: Daily Felt Acceptance 
 Fixed Effects 
Intercept -.54* (.06) -.52* (.04) 
Conception Probability .65 (.73) .61 (.73) 
Avg of Weekly PAI-BOR  -.29* (.04) 
Avg of Weekly PAI-BOR*CP   1.02* (.10) 
 Random Parameters 
Intercept -.14* (.03 -.05* (.01) 
Conception Probability -11.98* (4.33) -12.21* (.4.47) 
Residual -.16* (.008) -.15* (.008) 
   
-2 Restricted Log Pseudo-likelihood 548.99 517.22† 
Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 11 
Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from the 
Interaction of Daily Conception Probability Values and Number of SCID-II BPD Criteria 
Met (Trait BPD) 
 
Parameter Model 3 
(random CP slope) 
Model 4 
(with moderator) 
Dependent Variable: Daily Felt Acceptance 
 Fixed Effects 
Intercept .54* (.06) -.52* (.05) 
Conception Probability -.65 (.73) .52 (.74) 
SCID-II BPD Criteria Met  -.20* (.05) 
SCID-II BPD Criteria Met*CP   .61 (.70) 
 Random Parameters 
Intercept .14* (.03 .10* (.02) 
Conception Probability 11.98* (4.33) 12.40* (4.42) 
Residual .16* (.008) .15* (.008) 
   
-2 Restricted Log Pseudo-likelihood 548.99 531.54† 
Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Figure 7. A graph of the interaction between trait BPD symptoms and daily conception 
probability predicting daily felt acceptance.   
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Self-Esteem Scale on average estradiol and weekly deviations in estradiol are presented 
in Table 12. There were no significant effects of deviations in estradiol on felt acceptance.  
However, there was a significant improvement in model fit with the inclusion of a 
random effect of deviations in estradiol, indicating that the effect of deviations in 
estradiol on felt social acceptance differed between individuals.  
Therefore, I next examined whether the effect of deviations in estradiol on weekly 
felt acceptance was moderated by trait BPD symptoms as measured using the average of 
weekly PAI-BOR total assessments.  Results of this model can be found in Table 13. 
Inclusion of the moderator significantly improved model fit, and the interaction was 
significant in the opposite of the predicted direction. Among women higher in trait BPD, 
higher-than-usual levels of estradiol were associated with higher felt acceptance 
(γHIGHTRAITBPD*ESTRADIOLDEVIATION = .21, SE = .08, t(117) = 2.71, p = .007). Among 
women lower in trait BPD, higher-than-usual levels of estradiol were associated with 
lower felt acceptance (γLOWTRAITBPD*ESTRADIOLDEVIATION = -.17, SE = .08, t(117) = -2.12, p 
= .03). A graph depicting this interaction can be found in Figure 8.  
Path B at the Daily Level: Do changes in daily felt acceptance impact daily 
BPD symptom expression? Next, I tested whether average levels of and daily changes in 
felt acceptance impact expression of BPD symptoms. Results of models regressing 
average levels of daily felt acceptance and daily deviations from one’s own average 
levels of felt acceptance on each subscale and the total score of the daily PAI-BOR are 
presented in Table 14.  
For each subscale and the PAI-BOR total score, model fit was significantly 
improved with the addition of the felt acceptance predictors as fixed effects.  Model fit   
	  
 66 
Table 12 
Multilevel Regression Models Predicting Weekly Felt Acceptance from Average Estradiol 
and Weekly Deviations in Estradiol 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: Weekly Felt Acceptance (Social Evaluation subscale of the SSES) 
 Fixed Effects 
Intercept 5.37* (.12) 5.37* (.12) 5.37* (.12) 
Average Estradiol  .06 (.13) .09 (.13) 
Weekly Deviations in Estradiol  .02 (.05) .0002 (.05) 
 Random Parameters 
Intercept .58* (.14) .58* (.13) .58* (.14) 
Weekly Deviations in Estradiol   .001 (.09) 
Residual .18* (.02) .18* (.02) .18* (.02) 
    
-2 log likelihood 292.9 292.1 289.4† 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 log likelihood over the previous model is significant at p < .05. 
  
	  
 67 
Table 13 
Multilevel Regression Models Predicting Weekly Felt Acceptance from the Interaction of 
Average Weekly PAI-BOR Total Score with Average Estradiol and Deviations in 
Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: Weekly Felt Acceptance (Social Evaluation subscale of the SSES) 
 Fixed Effects 
Intercept 5.37* (.12) 5.39* (.10) 
Average Estradiol  .04 (.11) 
Weekly Deviations in Estradiol  .03 (.05) 
Avg Weekly PAI-BOR Total  -.40* (.09) 
Avg PAI-BOR*Avg Estradiol  .15 (.10) 
Avg PAI-BOR*Estradiol Deviation  .16* (.05) 
 Random Parameters 
Intercept .58* (.14) .40* (.09) 
Weekly Deviations in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 log likelihood 292.9 272.3† 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 log likelihood over the previous model is significant at p < .05. 
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Table 14 
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from Average 
Levels of Daily Felt Acceptance and Daily Deviations in Felt Acceptance 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.62* (.10) .70* (.06) .70* (.06) 
Average Daily Felt Acceptance  -.45* (.06) -.45* (.06) 
Deviations in Felt Acceptance  -.34* (.01) -.36* (.03) 
 Random Parameters 
Intercept .38* (.09) .15* (.03) .15* (.03) 
Deviations in Felt Acceptance   .01 (.01) 
Residual .13* (.006) .08* (.004) .08* (.004) 
    
-2 Restricted Log Pseudo-
likelihood 
1348.35 1015.14† 1009.87† 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.68* (.12) .70* (.09) .78* (.09) 
Average Daily Felt Acceptance  -.49* (.06) -.50* (.08) 
Deviations in Felt Acceptance  -.41* (.04) -.45* (.04) 
 Random Parameters 
Intercept .59* (.15) .31* (.08) .31* (.08) 
Deviations in Felt Acceptance   .01 (.01) 
Residual .33* (.01) .01* (.01) .25* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
2117.42 2048.48† 1938.95† 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.55* (.10) .62* (.07) .62* (.06) 
Average Daily Felt Acceptance  -.47* (.06) -.47* (.06) 
Deviations in Felt Acceptance  -.30* (.02) -.34* (.03) 
 Random Parameters 
Intercept .42* (.10) .17* (.04) .17* (.04) 
Deviations in Felt Acceptance   .01 (.02) 
Residual .17* (.009) .13* (.007) .13* (.007) 
    
-2 Restricted Log Pseudo-
likelihood 
1521.40 1322.46† 1324.32 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.48* (.10) .55* (.07) .55* (.07) 
Average Daily Felt Acceptance  -.47* (.07) -.47* (.07) 
Deviations in Felt Acceptance  -.31* (.02) -.35* (.05) 
 Random Parameters 
Intercept .44* (.10) .19* (.04) .19* (.04) 
Deviations in Felt Acceptance   .04 (.03) 
Residual .22* (.01) .18* (.009) .17* (.009) 
    
-2 Restricted Log Pseudo-
likelihood 
1622.09 1450.27† 1447.83† 
Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.13* (.15) 1.21* (.14) 1.20* (.14) 
Average Daily Felt Acceptance  -.38* (.13) -.38* (.13) 
Deviations in Felt Acceptance  -.31* (.04) -.29* (.05) 
 Random Parameters 
Intercept .87* (.24) .74* (.21) .74* (.21) 
Deviations in Felt Acceptance   .01 (.01) 
Residual .34* (.01) .32* (.01) .32* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
2551.02 2521.59† 2520.04 
Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Figure 8. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly felt acceptance.   
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improved significantly with the addition of random effects of daily deviations in felt 
acceptance in all cases except the Self-Harm subscale and the Identity Disturbance 
subscale; however, the random effect of deviations in felt acceptance was not significant 
for any of the subscales or the total, suggesting that the effects of changes in felt 
acceptance may be relatively similar across women. Results indicate that, for each daily 
PAI-BOR subscale and the total score, both average levels of daily felt acceptance and 
higher-than-usual daily levels of felt acceptance were associated with lower expression of 
BPD symptoms.  
Path B at the Weekly Level: Do changes in weekly felt acceptance impact 
weekly BPD symptom expression? Next, I tested whether average levels of and daily 
changes in felt acceptance impact expression of BPD symptoms at the weekly level. 
Results of models regressing average levels of weekly felt acceptance (measured using 
the Social Evaluation subscale of the State Self-Esteem Scale) and weekly deviations in 
felt acceptance on each subscale and the total score of the daily PAI-BOR, the BSL-23, 
and the MSI-BPD are presented in Table 15. For each dependent variable, model fit was 
significantly improved with the inclusion of fixed effects of average weekly levels of felt 
acceptance and weekly fluctuations in felt acceptance; however, model fit was not 
improved significantly with the inclusion of random effect of weekly fluctuations in felt 
acceptance, suggesting once again that the impact of felt acceptance on BPD symptoms is 
similar across individuals. In every case, both higher average levels of felt acceptance 
and higher-than-usual weekly felt acceptance were associated with lower levels of BPD 
symptoms.  
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Table 15 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Weekly Felt Acceptance and Weekly Deviations in Felt Acceptance 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50 (.10) -.51* (.08) -.51* (.08) 
Average Weekly Felt Acceptance  -.36* (.08) -.36* (.08) 
Deviations in Felt Acceptance  -.27* (.06) -.26* (.08) 
 Random Parameters 
Intercept .39* (.09) .27* (.07) .27* (.07) 
Deviations in Felt Acceptance   .04 (.04) 
Residual .08* (.01) .07* (.009) .06* (.009) 
    
-2 Restricted Log Pseudo-
likelihood 
240.55 220.48† 218.38 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60 (.15) -.63* (.14) -.64* (.14) 
Average Weekly Felt Acceptance  -.42* (.14) -.42* (.14) 
Deviations in Felt Acceptance  -.38* (.08) -.39* (.11) 
 Random Parameters 
Intercept .83* (.23) .70* (.20) .72* (.20) 
Deviations in Felt Acceptance   .07 (.07) 
Residual .16* (.02) .14* (.01) .13* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
370.17 358.78† 358.85 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30 (.11) -.31* (.09) -.31* (.09) 
Average Weekly Felt Acceptance  -.42* (.09) -.42* (.09) 
Deviations in Felt Acceptance  -.24* (.06) -.23* (.07) 
 Random Parameters 
Intercept .45* (.11) .29* (.07) .29* (.07) 
Deviations in Felt Acceptance   .02 (.03) 
Residual .12* (.01) .11* (.01) .11* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
274.93 258.58† 256.62 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.42* (.10) -.42* (.10) 
Average Weekly Felt Acceptance  -.42* (.10) -.42* (.12) 
Deviations in Felt Acceptance  -.22* (.08) -.23* (.08) 
 Random Parameters 
Intercept .53* (.14) .36* (.10) .36* (.11) 
Deviations in Felt Acceptance   .001 (.10) 
Residual .16* (.02) .16* (.02) .16* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
332.16 320.31† 322.34 
Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03 (.11) -1.04* (.10) -1.06* (.10) 
Average Weekly Felt Acceptance  -.19* (.06) -.18* (.06) 
Deviations in Felt Acceptance  -.23* (.13) -.23* (.13) 
 Random Parameters 
Intercept .35* (.12) .33* (.11) .35* (.12) 
Deviations in Felt Acceptance   .24* (.23) 
Residual .18* (.02) .18* (.02) .16* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
407.23 405.74† 406.88 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .15 (.18) .12 (.19) 
Average Weekly Felt Acceptance  -.85* (.19) -.87* (.20) 
Deviations in Felt Acceptance  -.30* (.10) -.27* (.14) 
 Random Parameters 
Intercept 1.80* (.54) 1.16* (.36) 1.22* (.38) 
Deviations in Felt Acceptance   .12 (.11) 
Residual .68* (.09) .67* (.09) .61* (.08) 
    
-2 Restricted Log Pseudo-
likelihood 
481.04 470.40† 471.91 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05 (.16) 1.97* 1.97* 
Average Weekly Felt Acceptance  -.85* (.13) -.85* (.13) 
Deviations in Felt Acceptance  -.48* (.11) -.48* (.11) 
 Random Parameters 
Intercept 1.06* (.29) .54* (.14) .56* (.15) 
Deviations in Felt Acceptance  .15* (.08) .15* (.08) 
Residual 2.34* (.31) 1.36* (.19) 1.35* (.19) 
    
-2 Restricted Log Pseudo-
likelihood 
379.72 322.00† 336.62 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Tests of Indirect Effects. Figures 9-12 depict mediation models with felt 
acceptance as the mediator. First, I used the RMediation program (Tofighi & MacKinnon, 
2011) to estimate 95% confidence intervals for the indirect effects of the interaction of 
trait BPD and deviations in estradiol on weekly BPD symptoms through weekly felt 
acceptance. The 95% confidence intervals did not include zero for the indirect effects of 
Trait BPD x Deviations in Estradiol on the total score of the PAI-BOR (95% CI: -.01 to -
.08), the Affective Instability subscale of the PAI-BOR (95% CI: -.03 to -.12), the 
Identity Disturbance subscale of the PAI-BOR (95% CI: -.02 to -.07), or the BSL-23 
(95% CI: -.03 to -.14) via weekly felt acceptance. Furthermore, when average and weekly 
deviations in felt acceptance were included in the models predicting BPD symptoms from 
the interaction of Trait BPD with deviations in estradiol, none of the interactive effects of 
Trait BPD X Deviations in Estradiol remained significant (Predicting the PAI-BOR total 
score: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .05, t(117) = -1.05, p = .29; Predicting 
the PAI-BOR Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .07, 
t(117) = -.70, p = .48; Predicting the PAI-BOR Identity Disturbance subscale: 
γTRAITBPD*ESTRADIOLDEVIATION = -.08, SE = .05, t(117) = -1.49, p = .13; Predicting the BSL-
23: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE = .05, t(117) = -.59, p = .55). These results 
indicate that the interactive effects of Trait BPD and deviations in estradiol on BPD 
symptom expression are partially attributable to changes in felt acceptance.  
Testing Hypothesis 3b and 3c: Mediation by Impulsivity and Self-Control 
It was hypothesized that increases in estradiol would be associated with greater 
impulsivity and poorer self-control, that these effects would be stronger among women 
high in trait BPD features, and that such effects would mediate the main or moderated   
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Figure 9. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly felt acceptance.  
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Figure 10. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability scores via weekly 
felt acceptance. 
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Figure 11. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance scores via 
weekly felt acceptance.   
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Figure 12. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 scores via weekly felt acceptance.   
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effects of deviations in estradiol on weekly BPD features. Previous analyses suggest that 
weekly deviations in estradiol do not exert a main effect on BPD features (i.e., there is 
not a significant C path in the mediation model); however, tests of whether increases in 
estradiol are associated with poorer self-control and greater impulsivity (Path A in the 
mediation model) and whether changes in self-control and impulsivity are associated with 
weekly BPD symptom expression (Path B in the mediation model) were nevertheless 
carried out.  In addition, because the interactive effect of weekly deviations in estradiol 
and trait levels of BPD features on weekly BPD features were in some cases significant, 
similar models predicting impulsivity and self-control (in addition to full mediation 
testing) will be carried out as well using averages of weekly PAI-BOR as the moderator.  
Because self-control and impulsivity were measured only at the weekly level, this 
hypothesis was tested only at that level. 
Path A at the Weekly Level: Do changes in weekly self-control impact weekly 
BPD symptom expression? First, I regressed weekly scores on self-control and 
impulsivity on average estradiol and weekly deviations in estradiol are presented in Table 
16. Higher-than-usual levels of estradiol were associated with higher Self-Control, lower 
Negative Urgency, lower Positive Urgency, and lower Lack of Perseverance. In each case, 
model fit was significantly improved with the inclusion of a random effect of deviations 
in estradiol, indicating the presence of a moderator. Therefore, I next examined models 
predicting self-control and aspects of impulsivity from the interaction of the average of 
weekly PAI-BOR total scores and deviations in estradiol. Results of these models can be 
found in Table 17. The results of Model 3 (including a random effect of deviations in 
estradiol) were transferred into the table for ease of model comparison. 
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Table 16 
 
Multilevel Regression Models Predicting Weekly Self-Control and Impulsivity from 
Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: Weekly Self-Control 
 Fixed Effects 
Intercept 3.42* (.10) 3.41* (.09) 3.41* (.09) 
Average Estradiol  .07 (.09) .06 (.09) 
Weekly Deviations in Estradiol  .09+ (.06) .09* (.03) 
 Random Parameters 
Intercept .37* (.09) .36* (.09) .37* (.09) 
Weekly Deviations in Estradiol   .02+ (.01) 
Residual .14* (.01) .14* (.01) .13* (.01) 
    
-2 log likelihood 246.7 242.6† 238.8† 
Dependent Variable: Weekly UPPS-P Negative Urgency (Poisson model) 
 Fixed Effects 
Intercept .48* (.05) .48* (.05) .48* (.05) 
Average Estradiol  -.05 (.05) -.05 (.05) 
Weekly Deviations in Estradiol  -.05* (.01) -.05* (.01) 
 Random Parameters 
Intercept .10* (.02) .10* (.02) .10* (.02) 
Weekly Deviations in Estradiol   .002* (.001) 
Residual .07* (.009) .07* (.009) .07* (.01) 
    
-2 log likelihood 57.05 55.34† 50.24† 
Dependent Variable: Weekly UPPS-P Positive Urgency 
 Fixed Effects 
Intercept 1.84* (.07) 1.84* (.07) 1.84* (.07) 
Average Estradiol  -.15* (.06) -.14* (.06) 
Weekly Deviations in Estradiol  -.10* (.02) -.11* (.03) 
 Random Parameters 
Intercept .20* (.05) .17* (.04) .17* (.04) 
Weekly Deviations in Estradiol   .01 (.02) 
Residual .13* (.01) .12* (.01) .12* (.01) 
    
-2 log likelihood 210.1 201.70† 191.23† 
Dependent Variable: Weekly UPPS-P Lack of Premeditation 
 Fixed Effects 
Intercept 1.84* (.08) 1.84* (.08) 1.84* (.08) 
Average Estradiol  -.08 (.08) -.06 (.07) 
Weekly Deviations in Estradiol  -.02 (.03) -.02 (.03) 
 Random Parameters 
Intercept .26* (.06) .26* (.06) .28* (.07) 
Weekly Deviations in Estradiol   .001 (.10) 
Residual .14* (.01) .14* (.01) .14* (.01) 
    
-2 log likelihood 231.20 227.3† 220.4† 
Table Continued on Next Page 
 
 
	  
 81 
Dependent Variable: Weekly UPPS-P Lack of Perseverance 
 Fixed Effects 
Intercept 1.85* (.08) 1.85* (.08) 1.85* (.08) 
Average Estradiol  -.03 (.08) -.04 (.07) 
Weekly Deviations in Estradiol  -.14* (.06) -.15* (.06) 
 Random Parameters 
Intercept .23* (.06) .23* (.06) .23* (.06) 
Weekly Deviations in Estradiol   .03 (.03) 
Residual .17* (.02) .16* (.02) .14* (.02) 
    
-2 log likelihood 250 242.4† 235.10† 
Dependent Variable: Weekly Sensation Seeking 
 Fixed Effects 
Intercept 2.24* (.10) 2.24* (.10) 2.24* (.10) 
Average Estradiol  -.03 (.10) -.05 (.10) 
Weekly Deviations in Estradiol  -.07 (.07) -.07 (.06) 
 Random Parameters 
Intercept .36* (.09) .36* (.09) .36* (.09) 
Weekly Deviations in Estradiol   .03+ (.03) 
Residual .17* (.02) .17* (.02) .15* (.02) 
    
-2 log likelihood 269 266.1† 262.1† 
Note. Standard errors are in parentheses.  
*p < .05.  
+p < .15. 
†Change in -2 log likelihood over the previous model is significant at p < .05. 
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Table 17 
Multilevel Regression Models Predicting Weekly Self-Control and Impulsivity from the 
Interaction of Average Weekly PAI-BOR Total Score with Average Estradiol and Weekly 
Deviations in Estradiol 
 
Parameter Model 3 
(random deviation slope) 
Model 4 
(with moderator) 
Dependent Variable: Weekly Self-Control 
 Fixed Effects 
Intercept 3.41* (.09) 3.43* (.06) 
Average Estradiol .06 (.09) .06 (.05) 
Weekly Deviations in Estradiol .09+ (.05) .09+ (.05) 
Avg Weekly PAI-BOR Total  -.44* (.05) 
Avg PAI-BOR* Avg Estradiol  .13* (.04) 
Avg PAI-BOR* Estradiol Deviation  .18* (.06) 
 Random Parameters 
Intercept .37* (.09) .16* (.04) 
Weekly Deviations in Estradiol .02+ (.01) .01 (.02) 
Residual .13* (.01) .13* (.01) 
   
-2 log likelihood 239.8 202.9† 
Dependent Variable: Weekly UPPS-P Negative Urgency 
 Fixed Effects 
Intercept .48* (.05) .47* (.02) 
Average Estradiol -.05 (.05) -.04+ (.02) 
Weekly Deviations in Estradiol -.05* (.02) -.05* (.02) 
Avg Weekly PAI-BOR Total  .27* (.02) 
Avg PAI-BOR* Avg Estradiol  -.03* (.01) 
Avg PAI-BOR* Estradiol Deviation  -.06* (.03) 
 Random Parameters 
Intercept .10* (.02) .02* (.008) 
Weekly Deviations in Estradiol .002* (.009) .0001 (.09) 
Residual .07* (.01) .07* (.009) 
   
-2 log likelihood 62.51 27.70† 
Dependent Variable: Weekly UPPS-P Positive Urgency 
 Fixed Effects 
Intercept 1.84* (.07) 1.84* (.06) 
Average Estradiol -.14* (.06) -.15* (.05) 
Weekly Deviations in Estradiol -.11* (.03) -.10* (.03) 
Avg Weekly PAI-BOR Total  .21* (.05) 
Avg PAI-BOR* Avg Estradiol  -.03 (.03) 
Avg PAI-BOR* Estradiol Deviation  -.11* (.04) 
 Random Parameters 
Intercept .17* (.04) .13* (.03) 
Weekly Deviations in Estradiol .001 (.10) .0001 (.11) 
Residual .12* (.01) .12* (.01) 
   
-2 log likelihood 201.6 186.00† 
Table Continued on Next Page 
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Dependent Variable: Weekly UPPS-P Lack of Premeditation 
 Fixed Effects 
Intercept 1.84* (.08) 1.83* (.07) 
Average Estradiol -.06 (.07) -.07 (.06) 
Weekly Deviations in Estradiol -.02 (.03) -.04 (.03) 
Avg Weekly PAI-BOR Total  .25* (.06) 
Avg PAI-BOR* Avg Estradiol  -.12* (.05) 
Avg PAI-BOR* Estradiol Deviation  -.09* (.04) 
 Random Parameters 
Intercept .28* (.07) .18* (.05) 
Weekly Deviations in Estradiol .001 (.10) .0001 (.10) 
Residual .14* (.01) .13* (.01) 
   
-2 log likelihood 220.4 208.1† 
Dependent Variable: Weekly Lack of Perseverance 
 Fixed Effects 
Intercept 1.85* (.08) 1.85* (.07) 
Average Estradiol -.04 (.07) -.03 (.07) 
Weekly Deviations in Estradiol -.15* (.06) -.16* (.04) 
Avg Weekly PAI-BOR Total  .23* (.07) 
Avg PAI-BOR* Avg Estradiol  -.04 (.08) 
Avg PAI-BOR* Estradiol Deviation  -.22* (.05) 
 Random Parameters 
Intercept .23* (.06) .18* (.04) 
Weekly Deviations in Estradiol .03 (.03) .0001 (.09) 
Residual .14* (.02) .14* (.01) 
   
-2 log likelihood 235.10 218.01† 
Dependent Variable: Weekly Sensation Seeking 
 Fixed Effects 
Intercept 2.24* (.10) 2.23* (.09) 
Average Estradiol -.05 (.10) -.04 (.09) 
Weekly Deviations in Estradiol -.07 (.06) -.06 (.06) 
Avg Weekly PAI-BOR Total  .14 (.08) 
Avg PAI-BOR* Avg Estradiol  -.14 (.10) 
Avg PAI-BOR* Estradiol Deviation  .04 (.07) 
 Random Parameters 
Intercept .36* (.09) .33* (.08) 
Weekly Deviations in Estradiol .03+ (.03) .03 (.03) 
Residual .15* (.02) .15* (.01) 
   
-2 log likelihood 262.1 257.7† 
Note. Standard errors are in parentheses.  
*p < .05.  
+p < .15. 
†Change in -2 log likelihood over the previous model is significant at p < .05. 
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In the model predicting self-control, there was a significant interaction between 
trait BPD and deviations in estradiol such that higher-than-usual levels of estradiol were 
associated with higher self-control among women higher (+1 standard deviation) in trait 
BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = .28, SE = .09, t(117) = 2.96, p = .003) but were 
not associated with self-control among women lower (-1 standard deviation) in trait BPD 
(γLOWTRAITBPD*ESTRADIOLDEVIATION = -.09, SE = .07, t(117) = -1.21, p = .23). A graph of 
this interaction can be found in Figure 13. Unexpectedly, there was also a significant 
interaction between trait BPD and average levels of estradiol such that higher average 
levels of estradiol were associated with higher levels of self-control among women 
higher in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = .19, SE = .05, t(37) = 3.34, p 
= .001), but was not associated with self-control among women lower in trait BPD 
(γLOWTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .07, t(37) = -.88, p = .38). A graph of this 
interaction can be found in Figure 14.  
In the model predicting Negative Urgency, there was a significant interaction 
between trait BPD and deviations in estradiol such that higher-than-usual levels of 
estradiol were associated with lower Negative Urgency among women higher in trait 
BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.11, SE = .04, t(117) = -2.75, p = .006) but 
were not associated with Negative Urgency among women lower in trait BPD 
(γLOWTRAITBPD*ESTRADIOLDEVIATION = .01, SE = .04, t(117) = .24, p = .80). A graph of this 
interaction can be found in Figure 15. Once again, there was also an unexpected 
interaction between trait BPD and average levels of estradiol such that higher average 
levels of estradiol were associated with lower levels of Negative Urgency among women   
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Figure 13. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly self-control.   
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Figure 14. A graph of the interaction between trait BPD symptoms and Average estradiol 
predicting weekly self-control.   
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Figure 15. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P negative urgency.   
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higher in trait BPD (γHIGHTRAITBPD*AVERAGEESTRADIOL = -.07, SE = .03, t(37) = -2.10, p 
= .04) but were not associated with levels of Negative Urgency among women lower in 
trait BPD (γLOWTRAITBPD* AVERAGEESTRADIOL = -.003, SE = .04, t(37) = -.09, p = .93). A 
graph of this interaction can be found in Figure 16.  
In the model predicting Positive Urgency, there was a significant interaction 
between trait BPD and deviations in estradiol such that higher-than-usual levels of 
estradiol were associated with lower weekly levels of Positive Urgency among women 
higher in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.20, SE = .07, t(117) = -2.90, p 
= .004) but were not associated with Positive Urgency among women lower in trait BPD 
(γLOWTRAITBPD*ESTRADIOLDEVIATION = .01, SE = .04, t(117) = .22, p = .82). A graph of the 
interaction can be found in Figure 17.  
In the model predicting Lack of Perseverance, there was a significant interaction 
between trait BPD and deviations in estradiol such that higher-than-usual levels of 
estradiol were associated with lower weekly Lack of Perseverance among women higher 
in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.39, SE = .06, t(117) = -6.45, p < .0001) 
but was not significantly associated with Lack of Perseverance among women lower in 
trait BPD (γLOWTRAITBPD*ESTRADIOLDEVIATION = .06, SE = .07, t(117) = .88, p = .38).  The 
interaction is depicted in Figure 18.  
Finally, in the model predicting Lack of Premeditation, there was a significant 
interaction between trait BPD and deviations in estradiol such that higher-than-usual 
levels of estradiol were associated with lower weekly Lack of Premeditation among 
women higher in trait BPD (γHIGHRAITBPD*ESTRADIOLDEVIATION = -.14, SE = .06, t(117) = -
1.99, p = .04) but was not significantly associated with Lack of Premeditation among  
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Figure 16. A graph of the interaction between trait BPD symptoms and average estradiol 
predicting weekly UPPS-P negative urgency.   
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Figure 17. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P positive urgency.   
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Figure 18. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P lack of perseverance.   
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women lower in trait BPD (γLOWTRAITBPD*ESTRADIOLDEVIATION = .05, SE = .05, t(117) = .96, 
p = .33). See Figure 19 for a graph of the interaction. Once again, there was a significant 
unexpected interaction between average levels of estradiol and trait BPD such that higher 
average levels of estradiol were associated with lower Lack of Premeditation among 
women with higher levels of trait BPD (γHIGHTRAITBPD*AVERAGEESTRADIOL = -.19, SE = .06, 
t(37) = -2.87, p = .006) but were not associated with Lack of Premeditation among 
women with lower levels of trait BPD (γLOWTRAITBPD* AVERAGEESTRADIOL = .05, SE = .10, 
t(37) = .49, p = .62). See Figure 20 for a graph of this interaction.  
Path B at the Weekly Level: Do changes in weekly self-control and impulsivity 
impact weekly BPD symptom expression? Next, I tested whether average levels of and 
weekly changes in self-control and impulsivity impact expression of BPD symptoms. 
Results of models regressing BPD symptoms on average levels of and deviations in self-
control and UPPS-P impulsivity on BPD symptom expression are presented in Tables 18-
23 and discussed in the following sections.  
Self-Control. In models predicting BPD symptoms from average and weekly 
deviations in self-control, models including fixed effects of deviations in self-control 
significantly improved model fit. However, models including random effects of 
deviations in self-control did not significantly improve model fit, suggesting that the 
impact of changes in self-control on BPD symptoms is similar across individuals. In each 
case, both average levels of self-control and higher-than-usual levels of self-control were 
associated with lower BPD symptom expression.  
Negative Urgency. In models predicting BPD symptoms from average and weekly 
deviations in Negative Urgency, model fit improved significantly with the inclusion of  
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Figure 19. A graph of the interaction between trait BPD symptoms and deviation in 
estradiol predicting weekly UPPS-P lack of premeditation.   
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Figure 20. A graph of the interaction between trait BPD symptoms and average estradiol 
predicting weekly UPPS-P lack of premeditation.   
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Table 18 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Weekly Self-Control and Weekly Deviations in Self-Control 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50 (.10) -.51* (.07) -.52* (.07) 
Average Self-Control  -.45* (.07) -.45* (.07) 
Deviations in Self-Control  -.30* (.06) -.30* (.06) 
 Random Parameters 
Intercept .39* (.09) .18* (.05) .18* (.05) 
Deviations in Self-Control   .001 (.01) 
Residual .08* (.01) .06* (.009) .06* (.009) 
    
-2 Restricted Log Pseudo-
likelihood 
240.55 202.85† 203.59 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60 (.15) -.62* (.11) -.62* (.11) 
Average Self-Control  -.62* (.11) -.62* (.11) 
Deviations in Self-Control  -.36* (.09) -.36* (.09) 
 Random Parameters 
Intercept .83* (.23) .43* (.13) .42* (.13) 
Deviations in Self-Control   .0001 (.03) 
Residual .16* (.02) .15* (.02) .15* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
370.17 342.56† 342.24 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30 (.11) -.31* (.09) -.31* (.09) 
Average Self-Control  -.40* (.09) -.40* (.09) 
Deviations in Self-Control  -.25* (.07) -.27* (.07) 
 Random Parameters 
Intercept .45* (.11) .29* (.07) .29* (.07) 
Deviations in Self-Control   .02 (.03) 
Residual .12* (.01) .11* (.01) .10* (.01) 
    
-2 Restricted Log Pseudo-
likelihood 
274.93 254.46† 254.59 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.42* (.09) -.42* (.09) 
Average Self-Control  -.45* (.09) -.45* (.10) 
Deviations in Self-Control  -.25* (.09) -.25* (.09) 
 Random Parameters 
Intercept .53* (.14) .32* (.09) .32* (.09) 
Deviations in Self-Control   .0001 (.04) 
Residual .16* (.02) .16* (.09) .16* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
332.16 316.38† 315.89 
Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03* (.11) -1.05* (.09)  -1.05* (.09) 
Average Self-Control  -.39* (.09) -.39* (.09) 
Deviations in Self-Control  -.41* (.14) -.41* (.14) 
 Random Parameters 
Intercept .35* (.12) .20* (.08) .20* (.08) 
Deviations in Self-Control   .0001 (.04) 
Residual .18* (.02) .17* (.02) .17* (.02) 
    
-2 Restricted Log Pseudo-
likelihood 
407.23 391.96† 391.01 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .14 (.18) .13 (.18) 
Average Self-Control  -.85* (.18) -.86* (.18) 
Deviations in Self-Control  -.40* (.11) -.45* (.11) 
 Random Parameters 
Intercept 1.80* (.54) 1.09* (.34) 1.12* (.35) 
Deviations in Self-Control   .02 (.03) 
Residual .68* (.09) .64* (.08) .62* (.08) 
    
-2 Restricted Log Pseudo-
likelihood 
481.04 462.90† 462.42 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05 (.16) 2.01* (.14) 2.00* (.14) 
Average Self-Control  -.63* (.14) -.63* (.14) 
Deviations in Self-Control  -.40* (.08) -.41* (.08) 
 Random Parameters 
Intercept 1.06* (.29) .75* (.20) .75* (.20) 
Deviations in Self-Control   .009 (.03) 
Residual 2.34* (.31) 1.91* (.25) 1.86* (.30) 
    
-2 Restricted Log Pseudo-
likelihood 
379.72 350.31† 350.41 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 19 
 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Weekly UPPS-P Negative Urgency and Weekly Deviations in UPPS-P Negative 
Urgency 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50 (.10) -.52* (.06) -.52* (.06) 
Average Negative Urgency  .49* (.06) .50* (.06) 
Deviations in Negative Urgency  .36* (.06) .40* (.08) 
 Random Parameters 
Intercept .39* (.09) .13* (.03) .13* (.03) 
Deviations in Negative Urgency   .03 (.02) 
Residual .08* (.01) .06* (.008) .05* (.007) 
    
-2 Restricted Log Pseudo-likelihood 240.55 180.48† 172.80† 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60 (.15) -.63* (.10) -.65* (.10) 
Average Negative Urgency  .64* (.10) .65* (.10) 
Deviations in Negative Urgency  .51* (.09) .58* (.12) 
 Random Parameters 
Intercept .83* (.23) .37* (.11) .40* (.12) 
Deviations in Negative Urgency   .09 (.07) 
Residual .16* (.02) .13* (.01) .12* (.01) 
    
-2 Restricted Log Pseudo-likelihood 370.17 322.53† 322.48 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30 (.11) -.32* (.07) -.32* (.07) 
Average Negative Urgency  .52* (.06) .53* (.07) 
Deviations in Negative Urgency  .31* (.06) .39* (.08) 
 Random Parameters 
Intercept .45* (.11) .16* (.04) .16* (.04) 
Deviations in Negative Urgency   .03 (.03) 
Residual .12* (.01) .10* (.01) .09* (.01) 
    
-2 Restricted Log Pseudo-likelihood 274.93 226.11† 222.81† 
Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.43* (.08) -.43* (.09) 
Average Negative Urgency  .50* (.08) .50* (.08) 
Deviations in Negative Urgency  .36* (.09) .39* (.11) 
 Random Parameters 
Intercept .53* (.14) .26* (.08) .26* (.08) 
Deviations in Negative Urgency   .03 (.07) 
Residual .16* (.02) .15* (.02) .14* (.02) 
    
-2 Restricted Log Pseudo-likelihood 332.16 302.14† 303.40 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03* (.11) -1.04* (.09) -1.04* (.09) 
Average Negative Urgency  .29* (.09) .29* (.09) 
Deviations in Negative Urgency  .20* (.10) .20* (.10) 
 Random Parameters 
Intercept .35* (.12) .26* (.10) .26* (.10) 
Deviations in Negative Urgency   .01 (.08) 
Residual .18* (.02) .18* (.02) .18* (.02) 
    
-2 Restricted Log Pseudo-likelihood 407.23 403.45† 403.59 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .10 (.17) .06* (.18) 
Average Negative Urgency  .93* (.17) .95* (.17) 
Deviations in Negative Urgency  .59* (.10) .70* (.16) 
 Random Parameters 
Intercept 1.80* (.54) 1.01* (.32) 1.11* (.35) 
Deviations in Negative Urgency   .24 (.20) 
Residual .68* (.09) .55* (.07) .48* (.16) 
    
-2 Restricted Log Pseudo-likelihood 481.04 444.98† 451 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05 (.16) 2.00* (.13) 1.99* (.13) 
Average Negative Urgency  .70* (.13) .71* (.13) 
Deviations in Negative Urgency  .47* (.07) .53* (.11) 
 Random Parameters 
Intercept 1.06* (.29) .61* (.17) .64* (.18) 
Deviations in Negative Urgency   .09+ (.06) 
Residual 2.34* (.31) 1.74* (.23) 1.53* (.21) 
    
-2 Restricted Log Pseudo-likelihood 379.72 332.24† 329.89† 
Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
+p < .15. 
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 20 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Weekly UPPS-P Positive Urgency and Weekly Deviations in UPPS-P Positive 
Urgency 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50 (.10) -.51* (.09) -.51* (.09) 
Average Positive Urgency  .29* (.09) .29* (.09) 
Deviations in Positive Urgency  .14* (.07) .15+ (.10) 
 Random Parameters 
Intercept .39* (.09) .31* (.08) .31* (.08) 
Deviations in Positive Urgency   .03 (.08) 
Residual .08* (.01) .07* (.01) .07* (.01) 
    
-2 Restricted Log Pseudo-likelihood 240.55 235† 235.19 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60 (.15) -.61* (.15) -.61* (.14) 
Average Positive Urgency  .36* (.14) .36* (.14) 
Deviations in Positive Urgency  .13 (.11) .13 (.11) 
 Random Parameters 
Intercept .83* (.23) .71* (.20) .71* (.20) 
Deviations in Positive Urgency   .0001 (.08) 
Residual .16* (.02) .16* (.02) .16* (.02) 
    
-2 Restricted Log Pseudo-likelihood 370.17 367.28† 367.28 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30 (.11) -.30* (.10) -.31* (.10) 
Average Positive Urgency  .25* (.10) .25* (.10) 
Deviations in Positive Urgency  .12 (.09) .15 (.11) 
 Random Parameters 
Intercept .45* (.11) .39* (.10) .40* (.10) 
Deviations in Positive Urgency   .11 (.13) 
Residual .12* (.01) .12* (.01) .11 (.01) 
    
-2 Restricted Log Pseudo-likelihood 274.93 271.76† 273.56 
Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.42* (.11) -.42* (.11) 
Average Positive Urgency  .31* (.11) .31* (.11) 
Deviations in Positive Urgency  .17* (.09) .17* (.09) 
 Random Parameters 
Intercept .53* (.14) .45* (.12) .45* (.13) 
Deviations in Positive Urgency   .0001 (.07) 
Residual .16* (.02) .16* (.02) .16* (.02) 
    
-2 Restricted Log Pseudo-likelihood 332.16 328.31† 328.31 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03* (.11) -1.03* (.10) -1.05* (.10) 
Average Positive Urgency  .26* (.10) .26* (.10) 
Deviations in Positive Urgency  .17 (.25) .20 (.19) 
 Random Parameters 
Intercept .35* (.12) .27* (.10) .29* (.11) 
Deviations in Positive Urgency   .25 (.29) 
Residual .18* (.02) .18* (.02) .17* (.02) 
    
-2 Restricted Log Pseudo-likelihood 407.23 405.26† 406.49 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .15 (.21) .15 (.21) 
Average Positive Urgency  .54* (.21) .54* (.21) 
Deviations in Positive Urgency  .29* (.13) .29* (.12) 
 Random Parameters 
Intercept 1.80* (.54) 1.58* (.48) 1.58* (.48) 
Deviations in Positive Urgency   .0001 (.04) 
Residual .68* (.09) .67* (.09) .67* (.10) 
    
-2 Restricted Log Pseudo-likelihood 481.04 478.24† 478.20 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05 (.16) 2.02* (.16) 2.00* (.16) 
Average Positive Urgency  .38* (.16) .39* (.16) 
Deviations in Positive Urgency  .23* (.10) .23 (.17) 
 Random Parameters 
Intercept 1.06* (.29) .99* (.22) 1.05* (.28) 
Deviations in Positive Urgency   .39 (.22) 
Residual 2.34* (.31) 2.24* (.29) 1.80* (.27) 
    
-2 Restricted Log Pseudo-likelihood 379.72 354.81† 375.27 
Note. Standard errors are in parentheses.  
*p < .05.  
+p < .15. 
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 21 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Weekly UPPS-P Lack of Premeditation and Weekly Deviations in UPPS-P Lack 
of Premeditation 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50 (.10) -.52* (.09) -.52* (.09) 
Average Lack of Premeditation  .25* (.09) .25* (.09) 
Deviations in Lack of Premeditation  .34* (.06) .35* (.07) 
 Random Parameters 
Intercept .39* (.09) .33* (.08) .34* (.08) 
Deviations in Lack of Premeditation   .01 (.03) 
Residual .08* (.01) .06* (.008) .06* (.008) 
    
-2 Restricted Log Pseudo-likelihood 240.55 216.89† 216.50 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60* (.15) -.64* (.14) -.65* (.14) 
Average Lack of Premeditation  .32* (.14) .32* (.14) 
Deviations in Lack of Premeditation  .52* (.09) .54* (.13) 
 Random Parameters 
Intercept .83* (.23) .78 (.22) .81* (.23) 
Deviations in Lack of Premeditation   .15 (.14) 
Residual .16* (.02) .13* (.01) .12* (.01) 
    
-2 Restricted Log Pseudo-likelihood 370.17 351.33† 353.86 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30 (.11) -.31* (.10) -.31* (.10) 
Average Lack of Premeditation  .21* (.10) .21* (.10) 
Deviations in Lack of Premeditation  .24* (.07) .26* (.08) 
 Random Parameters 
Intercept .45* (.11) .41* (.10) .41* (.10) 
Deviations in Lack of Premeditation   .01 (.03) 
Residual .12* (.01) .11* (.01) .11* (.01) 
    
-2 Restricted Log Pseudo-likelihood 274.93 267.26† 267.11 
Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.42* (.11) -.42* (.11) 
Average Lack of Premeditation  .22* (.11) .21* (.11) 
Deviations in Lack of Premeditation  .29* (.09) .28* (.09) 
 Random Parameters 
Intercept .53* (.14) .49* (.13) .48* (.11) 
Deviations in Lack of Premeditation    
Residual .16* (.02) .15* (.02) .15* (.01) 
    
-2 Restricted Log Pseudo-likelihood 332.16 327.50† 326.70 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03* (.11) -1.04* (.09) -1.06* (.09) 
Average Lack of Premeditation  .32* (.09) .32* (.09) 
Deviations in Lack of Premeditation  .39* (.14) .41* (.18) 
 Random Parameters 
Intercept .35* (.12) .23* (.09) .25* (.10) 
Deviations in Lack of Premeditation   .22 (.30) 
Residual .18* (.02) .18* (.02) .16* (.02) 
    
-2 Restricted Log Pseudo-likelihood 407.23 399.10† 398.67 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .14 (.22) .10 (.22) 
Average Lack of Premeditation  .42* (.21) .42 (.22) 
Deviations in Lack of Premeditation  .41* (.11) .45* (.18) 
 Random Parameters 
Intercept 1.80* (.54) 1.73* (.52) 1.83* (.55) 
Deviations in Lack of Premeditation   .30 (.26) 
Residual .68* (.09) .63* (.08) .57* (.09) 
    
-2 Restricted Log Pseudo-likelihood 481.04 476.74† 483.59 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05 (.16) 2.01* (.16) 1.98* (.17) 
Average Lack of Premeditation  .25* (.12) .24* (.12) 
Deviations in Lack of Premeditation  .43* (.08) .43* (.14) 
 Random Parameters 
Intercept 1.06* (.29) 1.08* (.29) 1.17* (.31) 
Deviations in Lack of Premeditation   .26 (.15) 
Residual 2.34* (.31) 1.94* (.26) 1.48* (.22) 
    
-2 Restricted Log Pseudo-likelihood 379.72 364.74† 364.70 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 22 
 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Weekly UPPS-P Lack of Perseverance and Weekly Deviations in UPPS-P Lack 
of Perseverance 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50 (.10) -.51* (.09) -.51* (.09) 
Average Lack of Perseverance  .28* (.09) .28* (.09) 
Deviations in Lack of Perseverance  .26* (.06) .25* (.08) 
 Random Parameters 
Intercept .39* (.09) .32* (.08) .32* (.08) 
Deviations in Lack of Perseverance   .04 (.04) 
Residual .08* (.01) .07* (.009) .06* (.009) 
    
-2 Restricted Log Pseudo-likelihood 240.55 226.66† 225.66 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60 (.15) -.63* (.13) -.64* (.14) 
Average Lack of Perseverance  .44* (.13) .45* (.14) 
Deviations in Lack of Perseverance  .43* (.09) .43* (.12) 
 Random Parameters 
Intercept .83* (.23) .69* (.19) .72* (.20) 
Deviations in Lack of Perseverance   .11 (.09) 
Residual .16* (.02) .14* (.01) .13* (.01) 
    
-2 Restricted Log Pseudo-likelihood 370.17 353.09† 354.71 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30 (.11) -.31* (.10) -.31* (.10) 
Average Lack of Perseverance  .20* (.10) .20* (.10) 
Deviations in Lack of Perseverance  .28* (.07) .28* (.07) 
 Random Parameters 
Intercept .45* (.11) .42* (.10) .42* (.10) 
Deviations in Lack of Perseverance   .0001 (.03) 
Residual .12* (.01) .11* (.01) .11* (.01) 
    
-2 Restricted Log Pseudo-likelihood 274.93 267.37† 267.30 
 
Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.42* (.11) -.42* (.11) 
Average Lack of Perseverance  .23* (.11) .23* (.11) 
Deviations in Lack of Perseverance  .21* (.10) .22* (.11) 
 Random Parameters 
Intercept .53* (.14) .49* (.13) .49* (.14) 
Deviations in Lack of Perseverance   .03 (.07) 
Residual .16* (.02) .16* (.02) .15* (.02) 
    
-2 Restricted Log Pseudo-likelihood 332.16 322.42† 330.69 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03* (.11) -1.03* (.09) -1.06* (.09) 
Average Lack of Perseverance  .32* (.09) .32* (.09) 
Deviations in Lack of Perseverance  .06 (.13) -.03 (.21) 
 Random Parameters 
Intercept .35* (.12) .24* (.09) .27* (.10) 
Deviations in Lack of Perseverance   .52 (.36) 
Residual .18* (.02) .18* (.02) .15* (.02) 
    
-2 Restricted Log Pseudo-likelihood 407.23 400.24† 403.53 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .13 (.21) .13 (.21) 
Average Lack of Perseverance  .50* (.21) .51* (.21) 
Deviations in Lack of Perseverance  .49* (.12) .46* (.14) 
 Random Parameters 
Intercept 1.80* (.54) 1.69* (.51) 1.71* (.51) 
Deviations in Lack of Perseverance   .06 (.11) 
Residual .68* (.09) .64* (.08) .62* (.08) 
    
-2 Restricted Log Pseudo-likelihood 481.04 478.44† 479.57 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05 (.16) 1.98* (.17) 1.98* (.17) 
Average Lack of Perseverance  .40* (.17) .41* (.17) 
Deviations in Lack of Perseverance  .59* (.08) .53* (.11) 
 Random Parameters 
Intercept 1.06* (.29) 1.09* (.29) 1.10* (.29) 
Deviations in Lack of Perseverance   .09 (.08) 
Residual 2.34* (.31) 1.58* (.21) 1.45* (.21) 
    
-2 Restricted Log Pseudo-likelihood 379.72 345.95† 345.14 
Note. Standard errors are in parentheses. CP = Daily Conception Probability. 
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 23 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average 
Levels of Weekly UPPS-P Sensation Seeking and Weekly Deviations in UPPS-P 
Sensation Seeking 
 
Parameter Model 1  
(null) 
Model 2  
(fixed deviation slope) 
Model 3  
(random 
deviation slope) 
Dependent Variable: PAI-BOR Total Score   
 Fixed Effects 
Intercept -.50 (.10) -.50* (.10) -.51* (.10) 
Average Sensation Seeking  .11 (.10) .11 (.10) 
Deviations in Sensation Seeking  -.03 (.06) -.03 (.08) 
 Random Parameters 
Intercept .39* (.09) .39* (.09) .39* (.09) 
Deviations in Sensation Seeking   .04 (.04) 
Residual .08* (.01) .08* (.01) .07* (.01) 
    
-2 Restricted Log Pseudo-likelihood 240.55 239.37 240.15 
Dependent Variable: PAI-BOR Affective Instability Subscale 
 Fixed Effects 
Intercept -.60 (.15) -.61* (.15) -.62* (.15) 
Average Sensation Seeking  .06 (.15) .06 (.15) 
Deviations in Sensation Seeking  -.007 (.09) -.02 (.12) 
 Random Parameters 
Intercept .83* (.23) .85* (.24) .88* (.24) 
Deviations in Sensation Seeking    .13 (.11) 
Residual .16* (.02) .16* (.02) .14* (.01) 
    
-2 Restricted Log Pseudo-likelihood 370.17 369.08 370.03 
Dependent Variable: PAI-BOR Identity Disturbance Subscale 
 Fixed Effects 
Intercept -.30 (.11) -.30* (.10) -.31* (.10) 
Average Sensation Seeking  .15 (.10) .15 (.10) 
Deviations in Sensation Seeking  -.10 (.07) -.10 (.08) 
 Random Parameters 
Intercept .45* (.11) .44* (.11) .44* (.11) 
Deviations in Sensation Seeking   .02 (.04) 
Residual .12* (.01) .12* (.01) .11* (.01) 
    
-2 Restricted Log Pseudo-likelihood 274.93 274.29 273.24 
Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.42* (.12) -.42* (.12) 
Average Sensation Seeking  .14 (.11) .14 (.12) 
Deviations in Sensation Seeking  .01 (.09) .006 (.10) 
 Random Parameters 
Intercept .53* (.14) .52* (.14) .53* (.14) 
Deviations in Sensation Seeking   .04 (.07) 
Residual .16* (.02) .16* (.02) .16 (.02) 
    
-2 Restricted Log Pseudo-likelihood 332.16 329.15 331.99 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Self-Harm Subscale 
 Fixed Effects 
Intercept -1.03* (.11) -1.03* (.11) -1.06* (.11) 
Average Sensation Seeking  .04 (.11) .04 (.11) 
Deviations in Sensation Seeking  -.01 (.14) .08 (.19) 
 Random Parameters 
Intercept .35* (.12) .36* (.12) .39* (.13) 
Deviations in Sensation Seeking   .34 (.27) 
Residual .18* (.02) .18* (.02) .16* (.02) 
    
-2 Restricted Log Pseudo-likelihood 407.23 406.88 412.39 
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .14 (.21) .12 (.22) 
Average Sensation Seeking  .47* (.21) .48* (.21) 
Deviations in Sensation Seeking  -.04 (.11) .02 (.14) 
 Random Parameters 
Intercept 1.80* (.54) 1.67* (.50) 1.72* (.52) 
Deviations in Sensation Seeking   .12 (.12) 
Residual .68* (.09) .68* (.09) .64* (.09) 
    
-2 Restricted Log Pseudo-likelihood 481.04 479.09† 480.16 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23) 
 Fixed Effects 
Intercept 2.05 (.16) 2.03* (.16) 1.99* (.17) 
Average Sensation Seeking  .25* (.12) .27* (.12) 
Deviations in Sensation Seeking  .07 (.09) .10 (.14) 
 Random Parameters 
Intercept 1.06* (.29) 1.03* (.28) 1.12* (.30) 
Deviations in Sensation Seeking   .25* (.12) 
Residual 2.34* (.31) 2.32* (.32) 1.70* (.25) 
    
-2 Restricted Log Pseudo-likelihood 379.72 371.19† 378.42 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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fixed effects of average Negative Urgency and deviations in Negative Urgency. Further, 
in the case of models predicting the PAI-BOR total score, the PAI-BOR Identity 
Disturbance subscale, and the BSL-23, model fit improved further with the addition of 
random effects of deviations in Negative Urgency, indicating that the impact of changes 
in impulsivity on BPD symptoms may differ across individuals. In each case, both higher 
average levels of Negative Urgency and higher-than-usual Negative Urgency were 
associated with increased expression of BPD symptoms.  
Positive Urgency. In models predicting BPD symptoms from average levels of 
and weekly deviations in Positive Urgency, model fit improved significantly with the 
inclusion of fixed effects of average and weekly deviations in Positive Urgency. They 
were not further improved by the addition of random effects of deviations in Positive 
Urgency, suggesting that the impact of fluctuations in Positive Urgency on BPD 
symptoms are similar across individuals. In the models predicting the PAI-BOR total 
score, the Negative Relationships subscale of the PAI-BOR, the MSI-BPD, and the BSL-
23, both average levels of Positive Urgency and deviations in Positive Urgency were 
associated with higher expression of BPD symptoms.  In the models predicting the PAI-
BOR Self-Harm subscale, the PAI-BOR Identity Disturbance subscale, and the PAI-BOR 
Affective Instability subscale, only higher average levels of Positive Urgency were 
associated with higher BPD symptom expression.      
Lack of Premeditation. In models predicting BPD symptoms from average and 
weekly deviations in Lack of Premeditation, model fit was improved significantly by the 
inclusion of fixed effects of average and weekly deviations in Lack of Premeditation, but 
was not further improved by the inclusion of the random effect of weekly deviations in 
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Lack of Premeditation, indicating that the impact of changes in lack of premeditation on 
BPD symptoms was similar across individuals. In each model, both higher average levels 
of Lack of Premeditation and higher-than-usual Lack of Premeditation were associated 
with greater BPD symptom expression.  
Lack of Perseverance. In models predicting BPD symptoms from average and 
weekly deviations in Lack of Perseverance, model fit was improved significantly by the 
inclusion of the fixed effects of average and weekly deviations in Lack of Perseverance, 
but was not further improved by the inclusion of random effects of deviations in Lack of 
Perseverance, indicating that the impact of changes in Lack of Perseverance on BPD 
symptoms were similar across individuals. In each case except the model predicting the 
PAI-BOR Self-Harm subscale, both higher average levels of Lack of Perseverance and 
higher-than-usual Lack of Perseverance were associated with greater expression of BPD 
symptoms. In the model predicting the PAI-BOR Self-Harm subscale, only average 
levels of Lack of Perseverance were associated with higher BPD symptom expression.  
Sensation Seeking. In models predicting BPD symptoms from average and weekly 
deviations in Sensation Seeking, model fit was only improved by the inclusion of fixed 
effects of average Sensation Seeking and weekly deviations in Sensation Seeking in the 
case of the MSI-BPD and the BSL-23, and was never further improved by the inclusion 
of random effects of deviations in sensation seeking, suggesting that the impact of 
changes in Sensation Seeking on BPD symptoms was similar (i.e., null) across 
individuals.  In both of those models, there was a significant effect of average Sensation 
Seeking on BPD symptoms. There were no significant effects of weekly deviations in 
Sensation Seeking on BPD symptom expression.  
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Tests of Indirect Effects. Next, I once again used the RMediation program 
(Tofighi & MacKinnon, 2011), to create a 95% confidence intervals for the indirect 
effects of the interaction of trait BPD and deviations in estradiol on weekly BPD 
symptoms through all weekly self-control and impulsivity variables that: (1) were 
significantly predicted by the interaction between Trait BPD and deviations in estradiol 
(e.g., Trait BPD X Deviations in estradiol predict self-control), and (2) significantly 
predicted BPD symptoms (e.g., deviations in self-control predict weekly scores on the 
PAI-BOR).   
Self-Control. Figures 21-24 depict mediation models with self-control as the 
mediator. The 95% confidence intervals did not include zero for the indirect effects of 
Trait BPD x Deviations in Estradiol via self-control on the PAI-BOR total scale (95% CI: 
-.01 to -.10), the Affective Instability subscale of the PAI-BOR (95% CI: -.02 to -.13), the 
Identity Disturbance subscale of the PAI-BOR (95% CI: -.01 to -.09), or the BSL-23 
(95% CI: -.03 to -.14) via weekly self-control. Furthermore, when average and weekly 
deviations in self-control were included in the model predicting BPD from the interaction 
of Trait BPD with estradiol, the interactive effects of Trait BPD X Deviations in Estradiol 
were no longer significant (Predicting the PAI-BOR total score: 
γTRAITBPD*ESTRADIOLDEVIATION = -.04, SE = .05, t(117) = -.86, p = .39; Predicting the PAI-
BOR Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .08, t(117) 
= -.79, p = .43; Predicting the PAI-BOR Identity Disturbance subscale: 
γTRAITBPD*ESTRADIOLDEVIATION = -.07, SE = .05, t(117) = -1.33, p = .18; Predicting the BSL-
23: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .07, t(117) = -.76, p = .45). These results   
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Figure 21. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly self-control.   
Weekly Self-Control 
Weekly PAI-BOR Total 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = -.30*, SE = .06 
γ = -.10*, SE = .05 
γ = .18*, SE = .06 
(γ = -.04, SE = .05) 
95% CI for Indirect Effect: -.01 to -.10  
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Figure 22. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
self-control.   
Weekly Self-Control 
Weekly PAI-BOR 
Affective Instability 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = -.36*, SE = .09 
γ = -.13*, SE = .03 
γ = .18*, SE = .06 
(γ = -.06, SE = .08) 
95% CI for Indirect Effect: -.02 to -.13  
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Figure 23. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
self-control. 
  
Weekly Self-Control 
Weekly PAI-BOR Identity 
Disturbance 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = -.27*, SE = .07 
γ = -.13*, SE = .05 
γ = .18*, SE = .06 
(γ = -.07, SE = .05) 
95% CI for Indirect Effect: -.01 to -.09  
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Figure 24. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly self-control. 
  
Weekly Self-Control 
Weekly BSL-23 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = -.41*, SE = .08 
γ = -.13*, SE = .05 
γ = .18*, SE = .06 
(γ = -.05, SE = .07) 
95% CI for Indirect Effect: -.03 to -.14  
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indicate that the interactive effect of trait BPD and deviations estradiol on BPD symptom 
expression is partially attributable to changes in self-control. 
Negative Urgency. Figures 25-28 depict mediation models with Negative Urgency. 
The 95% confidence intervals did not include zero for the indirect effects of Trait BPD x 
Deviations in Estradiol via Negative Urgency on the PAI-BOR total scale (95% CI: -.01 
to -.04), the Affective Instability subscale (95% CI: -.001 to -.06), the Identity 
Disturbance subscale (95% CI: -.01 to -.09), or the BSL-23 (95% CI: -.004 to -.06) via 
Negative Urgency.  When average and weekly deviations in Negative Urgency were 
included in the model predicting BPD from the interaction of Trait BPD with estradiol, 
the interactive effects of Trait BPD X Deviations in Estradiol were no longer significant 
(Predicting PAI-BOR total: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE = .05, t(117) = -.71, p 
= .47; Predicting Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE 
= .07, t(117) = -.42, p = .67; Predicting Identity Disturbance subscale: 
γTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .05, t(117) = -1.13, p = .26; Predicting BSL-23: 
γTRAITBPD*ESTRADIOLDEVIATION = -.02, SE = .07, t(117) = -.42, p = .67). Thereore, the 
interactive effect of trait BPD and deviations estradiol on BPD symptoms is partially 
attributable to changes in Negative Urgency. 
Positive Urgency. Figure 29 depicts the significant mediation model with Positive 
Urgency. The 95% confidence interval did not include zero for the indirect effect of Trait 
BPD x Deviation in Estradiol via Positive Urgency on BSL-23 (-.01 to -.06). When 
average and weekly deviation in Positive Urgency were included in the model predicting   
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Figure 25. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P 
Negative Urgency.   
Weekly Negative 
Urgency 
Weekly PAI-BOR Total 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .40*, SE = .08 
γ = -.10*, SE = .05 
γ = -.06*, SE = .03 
(γ = -.03, SE = .05) 
95% CI for Indirect Effect: -.01 to -.04  
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Figure 26. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
UPPS-P Negative Urgency.   
Weekly Negative 
Urgency 
Weekly PAI-BOR 
Affective Instability 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .58*, SE = .12 
γ = -.13*, SE = .03 
γ = -.06*, SE = .03 
(γ = -.03, SE = .07) 
95% CI for Indirect Effect: -.001 to -.06  
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Figure 27. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
UPPS-P Negative Urgency. 
  
Weekly Negative 
Urgency 
Weekly PAI-BOR Identity 
Disturbance 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .39*, SE = .08 
γ = -.13*, SE = .05 
γ = -.06*, SE = .03 
(γ = -.06, SE = .07) 
95% CI for Indirect Effect: -.01 to -.09  
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Figure 28. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Negative 
Urgency. 
 
  
Weekly Negative 
Urgency 
Weekly BSL-23 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .53*, SE = .11 
γ = -.13*, SE = .05 
γ = -.06*, SE = .03 
(γ = -.02, SE = .07) 
95% CI for Indirect Effect: -.004 to -.06  
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Figure 29. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Positive 
Urgency. 
  
Weekly Positive Urgency 
Weekly BSL-23 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .23*, SE = .17 
γ = -.13*, SE = .05 
γ = -.11*, SE = .04 
(γ = -.11, SE = .07) 
95% CI for Indirect Effect: -.01 to -.06  
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symptoms from the interaction of Trait BPD with estradiol, the interactive effects of Trait 
BPD X Deviations in Estradiol were no longer significant for the BSL-23 only 
(Predicting the BSL-23: γTRAITBPD*ESTRADIOLDEVIATION = -.11, SE = .07, t(117) = -1.53, p 
= .12). These results indicate that the interactive effect of trait BPD and deviations 
estradiol on expression of more extreme BPD symptoms are partially attributable to 
changes in Positive Urgency.  
Lack of Perseverance. Figures 30-33 depict mediation models with Lack of 
Perseverance as the mediator. The 95% confidence intervals did not include zero for the 
indirect effects of Trait BPD x Deviations in Estradiol via Lack of Perseverance on the 
PAI-BOR total scale (95% CI: -.04 to -.10), the Affective Instability subscale of the PAI-
BOR (95% CI: -.04 to -.16), the Identity Disturbance subscale of the PAI-BOR (95% CI: 
-.02 to -.11), or the BSL-23 (95% CI: -.07 to -.20) via Lack of Perseverance. Furthermore, 
when average and weekly deviations in Lack of Perseverance were included in the model 
predicting BPD from the interaction of Trait BPD with estradiol, the interactive effects of 
Trait BPD X Deviations in Estradiol were no longer significant (Predicting the PAI-BOR 
total score: γTRAITBPD*ESTRADIOLDEVIATION = -.03 SE = .05, t(117) = -.74, p = .45; Predicting 
the PAI-BOR Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE = .07, 
t(117) = -.50, p = .61; Predicting the PAI-BOR Identity Disturbance subscale: 
γTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .06, t(117) = -1.05, p = .29; Predicting the BSL-
23: γTRAITBPD*ESTRADIOLDEVIATION = -.01, SE = .06, t(117) = -.23, p = .82). These results 
indicate that the interactive effect of trait BPD and deviations estradiol on BPD symptom 
expression is partially attributable to changes in Lack of Perseverance. 
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Figure 30. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P Lack 
of Perseverance.   
Weekly Lack of 
Perseverance 
Weekly PAI-BOR Total 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .25*, SE = .08 
γ = -.10*, SE = .05 
γ = -.22*, SE = .05 
(γ = -.03, SE = .05) 
95% CI for Indirect Effect: -.04 to -.10  
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Figure 31. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
UPPS-P Lack of Perseverance.   
Weekly Lack of 
Perseverance 
Weekly PAI-BOR 
Affective Instability 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .43*, SE = .12 
γ = -.13*, SE = .03 
γ = -.22*, SE = .05 
(γ = -.03, SE = .07) 
95% CI for Indirect Effect: -.04 to -.13  
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Figure 32. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
UPPS-P Lack of Perseverance. 
  
Weekly Lack of 
Perseverance 
Weekly PAI-BOR Identity 
Disturbance 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .28*, SE = .07 
γ = -.13*, SE = .05 
γ = -.22*, SE = .05 
(γ = -.06, SE = .06) 
95% CI for Indirect Effect: -.02 to -.16  
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Figure 33. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Lack of 
Perseverance. 
 
  
Weekly Lack of 
Perseverance 
Weekly BSL-23 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .53*, SE = .11 
γ = -.13*, SE = .05 
γ = -.22*, SE = .05 
(γ = -.01, SE = .06) 
95% CI for Indirect Effect: -.07 to -.20  
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Lack of Premeditation. Figures 34-37 depict mediation models with Lack of 
Premeditation as the mediator.  The 95% confidence intervals did not include zero for the 
indirect effects of Trait BPD x Deviations in Estradiol via Lack of Premeditation on the 
PAI-BOR total scale (95% CI: -.004 to -.06), the Affective Instability subscale of the 
PAI-BOR (95% CI: -.001 to -.06), the Identity Disturbance subscale of the PAI-BOR 
(95% CI: -.01 to -.07), or the BSL-23 (95% CI: -.01 to -.07) via Lack of Premeditation. 
Furthermore, when average and weekly deviations in Lack of Premeditation were 
included in the model predicting BPD from the interaction of Trait BPD with estradiol, 
the interactive effects of Trait BPD X Deviations in Estradiol were no longer significant 
(Predicting the PAI-BOR total score: γTRAITBPD*ESTRADIOLDEVIATION = -.04, SE = .05, t(117) 
= -.91, p = .36; Predicting the PAI-BOR Affective Instability subscale: 
γTRAITBPD*ESTRADIOLDEVIATION = -.04, SE = .07, t(117) = -.52, p = .60; Predicting the PAI-
BOR Identity Disturbance subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.09, SE = .05, t(117) 
= -1.54, p = .12; Predicting the BSL-23: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .07, 
t(117) = -.76, p = .44). These results indicate that the interactive effect of trait BPD and 
deviations estradiol on BPD symptom expression is partially attributable to changes in 
Lack of Premeditation. 
Testing Alternative Moderators: Dismantling Trait BPD Moderation Effects Using 
FFM Personality and Childhood Maltreatment 
A final set of analyses sought to further explore the finding that “trait BPD” (as 
measured using average scores on a heterogeneous measure of BPD symptoms) 
moderates the effect of within-person changes in estradiol on BPD symptom expression. I 
wanted to determine whether extreme levels of FFM personality domain scores (in  
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Figure 34. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P Lack 
of Premeditation.   
Weekly Lack of 
Premeditation 
Weekly PAI-BOR Total 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .35*, SE = .07 
γ = -.10*, SE = .05 
γ = -.09*, SE = .04 
(γ = -.04, SE = .05) 
95% CI for Indirect Effect: -.004 to -.06  
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Figure 35. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly 
UPPS-P Lack of Premeditation.   
Weekly Lack of 
Premeditation 
Weekly PAI-BOR 
Affective Instability 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .54*, SE = .13 
γ = -.13*, SE = .03 
γ = -.09*, SE = .04 
(γ = -.04, SE = .07) 
95% CI for Indirect Effect: -.001 to -.06  
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Figure 36. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly 
UPPS-P Lack of Premeditation. 
  
Weekly Lack of 
Premeditation 
Weekly PAI-BOR Identity 
Disturbance 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .26*, SE = .08 
γ = -.13*, SE = .05 
γ = -.09*, SE = .04 
(γ = -.09, SE = .05) 
95% CI for Indirect Effect: -.01 to -.07  
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Figure 37. A depiction of the indirect effect of the interactive effect of trait BPD and 
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Lack of 
Premeditation. 
 
  
Weekly Lack of 
Premeditation 
Weekly BSL-23 
Trait BPD  
X  
Weekly Deviation in 
Estradiol 
γ = .43*, SE = .14 
γ = -.13*, SE = .05 
γ = -.09*, SE = .04 
(γ = -.05, SE = .07) 
95% CI for Indirect Effect: -.01 to -.07  
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accordance with the FFM theory of BPD) or different types of childhood maltreatment 
(in accordance with the biosocial theory of BPD) would perform similarly to “trait BPD” 
as moderators of the effects of weekly deviations in estradiol on BPD symptom 
expression.   
FFM Personality Domains as Alternative Moderators. First, I substituted each 
of the domain scores (Neuroticism, Extraversion, Openness, Agreeableness, and 
Conscientiousness) for Trait BPD (for original model, see Table 7). Results of these 
models are presented in Tables 24-28. The null models have been transposed from Table 
3 for ease of model comparison. Consistent with a FFM personality model of BPD in 
which extremely high Neuroticism is a key underlying aspect of BPD, Neuroticism 
exerted main effects and interacted significantly with estradiol variables to predict BPD 
symptom expression. In each case except the Self-Harm subscale of the PAI-BOR, higher 
levels of Neuroticism were associated with greater BPD symptoms. Additionally, there 
were significant interactions between Neuroticism and average estradiol in three models. 
Among women lower in Neuroticism, higher average levels of estradiol were associated 
with lower levels of Affective Instability (γLOWNEUROTICISM*AVGESTRADIOL = -.31, SE = .15, 
t(37) = -1.99, p = .04), Identity Disturbance (γLOWNEUROTICISM *AVGESTRADIOL = -.16, SE 
= .07, t(37) = -2.28, p = .02), and the BSL-23 (γLOWNEUROTICISM *AVGESTRADIOL = -.27, SE 
= .10, t(37) = -2.70, p = .01). Among women higher in Neuroticism, higher average 
levels of estradiol were not significantly associated with Affective Instability 
(γHIGHNEUROTICISM*AVGESTRADIOL = .08, SE = .19, t(37) = .46, p = .64) or Identity 
Disturbance (γHIGHNEUROTICISM*AVGESTRADIOL = .12, SE = .14, t(37) = .85, p = .40), but 
were associated with higher scores on the BSL-23 (γHIGHNEUROTICISM*AVGESTRADIOL = .29,  
	  
 131 
Table 24 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the 
Interaction of Neuroticism with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.51* (.09) 
Avg Estradiol  -.02 *.09) 
Weekly Deviation in Estradiol   .01 (.05) 
Neuroticism  .31* (.09) 
Neuroticism*Avg Estradiol  .06 (.08) 
Neuroticism*Estradiol Deviation  -.03 (.04) 
 Random Parameters 
Intercept .39* (.09) .29* (.08) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 239.20 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.64* (.12) 
Avg Estradiol  -.11 (.13) 
Weekly Deviation in Estradiol   -.02 (.07) 
Neuroticism  .50* (.13) 
Neuroticism*Avg Estradiol  .20* (.08) 
Neuroticism*Estradiol Deviation  -.05 (.07) 
 Random Parameters 
Intercept .83* (.23) .83* (.22) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 362.00† 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.32* (.09) 
Avg Estradiol  -.02 (.10) 
Weekly Deviation in Estradiol   .04 (.05) 
Neuroticism  .32* (.10) 
Neuroticism*Avg Estradiol  .14* (.04) 
Neuroticism*Estradiol Deviation  -.10 (.09) 
 Random Parameters 
Intercept .45* (.11) .32* (.08) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 264.30† 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.41* (.11) 
Avg Estradiol  -.04 (.11) 
Weekly Deviation in Estradiol   .006 (.06) 
Neuroticism  .38* (.11) 
Neuroticism*Avg Estradiol  -.04 (.09) 
Neuroticism*Estradiol Deviation  .08 (.06) 
 Random Parameters 
Intercept .53* (.14) .42* (.12) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 324.17† 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.04* (.11) 
Avg Estradiol  .01 (.12) 
Weekly Deviation in Estradiol   .03 (.09) 
Neuroticism  .05 (.11) 
Neuroticism*Avg Estradiol  .008 (.10) 
Neuroticism*Estradiol Deviation  -.05 (.09) 
 Random Parameters 
Intercept .35* (.12) .39* (.14) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.03) 
   
-2 Restricted Log Pseudo-likelihood 407.23 406.69 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 2.00* (.13) 
Avg Estradiol  .001 (.14) 
Weekly Deviation in Estradiol   -.12 (.07) 
Neuroticism  .60* (.14) 
Neuroticism*Avg Estradiol  .27* (.12) 
Neuroticism*Estradiol Deviation  .006 (.92) 
 Random Parameters 
Intercept 1.06* (.29) .65* (.19) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.24* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 369.59† 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .15 (.21) 
Avg Estradiol  -.07 (.22) 
Weekly Deviation in Estradiol   -.11 (.09) 
Neuroticism  .61* (.22) 
Neuroticism*Avg Estradiol  .05 (.18) 
Neuroticism*Estradiol Deviation  .06 (.08) 
 Random Parameters 
Intercept 1.80* (.54) 1.58* (.50) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .69* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 480.08 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 25 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the 
Interaction of Extraversion with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.53* (.11) 
Avg Estradiol  -.07 (.11) 
Weekly Deviation in Estradiol   .02 (.05) 
Extraversion  -.06 (.11) 
Extraversion*Avg Estradiol  -.01 (.10) 
Extraversion*Estradiol Deviation  .05 (.04) 
 Random Parameters 
Intercept .39* (.09) .40* (.10) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08 (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 238.77 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.70* (.16) 
Avg Estradiol  -.17 (.17) 
Weekly Deviation in Estradiol   -.01 (.07) 
Extraversion  -.19 (.16) 
Extraversion*Avg Estradiol  -.15 (.16) 
Extraversion*Estradiol Deviation  .07 (.06) 
 Random Parameters 
Intercept .83* (.23) .84* (.24) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 368.72 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.34* (.11) 
Avg Estradiol  -.07 (.12) 
Weekly Deviation in Estradiol   .01 (.05) 
Extraversion  .003 (.12) 
Extraversion*Avg Estradiol  -.01 (.11) 
Extraversion*Estradiol Deviation  .04 (.05) 
 Random Parameters 
Intercept .45* (.11) .46* (.12) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 273.75 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.45* (.13) 
Avg Estradiol  -.07 (.13) 
Weekly Deviation in Estradiol   .05 (.06) 
Extraversion  -.06 (.13) 
Extraversion*Avg Estradiol  -.01 (.13) 
Extraversion*Estradiol Deviation  .04 (.06) 
 Random Parameters 
Intercept .53* (.14) .55* (.15) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 331.99 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.00* (.11) 
Avg Estradiol  -.04 (.12) 
Weekly Deviation in Estradiol   .05 (.10) 
Extraversion  -.11 (.11) 
Extraversion*Avg Estradiol  .10 (.11) 
Extraversion*Estradiol Deviation  .07 (.08) 
 Random Parameters 
Intercept .35* (.12) .37* (.13) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 331.11 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.96* (.18) 
Avg Estradiol  -.04 (.19) 
Weekly Deviation in Estradiol   -.10 (.06) 
Extraversion  -.10 (.19) 
Extraversion*Avg Estradiol  -.10 (.18) 
Extraversion*Estradiol Deviation  .05 (.06) 
 Random Parameters 
Intercept 1.06* (.29) 1.15* (.32) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.26* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 377.15 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .11 (.25) 
Avg Estradiol  -.08 (.27) 
Weekly Deviation in Estradiol   -.11 (.08) 
Extraversion  .03 (.25) 
Extraversion*Avg Estradiol  -.01 (.24) 
Extraversion*Estradiol Deviation  -.07 (.07) 
 Random Parameters 
Intercept 1.80* (.54) 2.02* (.63) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .69* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 480.26 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 26 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of 
Openness to Experience with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.52* (.09) 
Avg Estradiol  -.01 (.09) 
Weekly Deviation in Estradiol   -.001 (.04) 
Openness  .21* (.09) 
Openness*Avg Estradiol  -.23* (.10) 
Openness*Estradiol Deviation  .04 (.04) 
 Random Parameters 
Intercept .39* (.09) .32* (.08) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 236.98† 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.64* (.14) 
Avg Estradiol  -.07 (.14) 
Weekly Deviation in Estradiol   -.05 (.06) 
Openness  .28 (.16) 
Openness*Avg Estradiol  -.42* (.16) 
Openness*Estradiol Deviation  .03 (.06) 
 Random Parameters 
Intercept .83* (.23) .70* (.20) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 362.07† 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.33* (.10) 
Avg Estradiol  -.03 (.11) 
Weekly Deviation in Estradiol   -.01 (.05) 
Openness  .17 (.11) 
Openness*Avg Estradiol  -.21* (.11) 
Openness*Estradiol Deviation  .02 (.04) 
 Random Parameters 
Intercept .45* (.11) .40* (.10) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 272.63† 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.44* (.11) 
Avg Estradiol  -.01 (.12) 
Weekly Deviation in Estradiol   .03 (.06) 
Openness  .17 (.12) 
Openness*Avg Estradiol  -.20 (.13) 
Openness*Estradiol Deviation  .03 (.04) 
 Random Parameters 
Intercept .53* (.14) .49* (.14) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 330.48 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.04* (.11) 
Avg Estradiol  .06 (.12) 
Weekly Deviation in Estradiol   .01 (.09) 
Openness  .18 (.12) 
Openness*Avg Estradiol  -.19 (.12) 
Openness*Estradiol Deviation  .13 (.08) 
 Random Parameters 
Intercept .35* (.12) .38 * (.13) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 405.97 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 2.00* (.16) 
Avg Estradiol  .06 (.16) 
Weekly Deviation in Estradiol   -.12 (.06) 
Openness  .29 (.16) 
Openness*Avg Estradiol  -.53* (.18) 
Openness*Estradiol Deviation  .03 (.05) 
 Random Parameters 
Intercept 1.06* (.29) .90* (.25) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.27* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 375.44† 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .12 (.21) 
Avg Estradiol  .03 (.22) 
Weekly Deviation in Estradiol   -.09 (.07) 
Openness  .60* (.22) 
Openness*Avg Estradiol  -.53* (.23) 
Openness*Estradiol Deviation  .06 (.06) 
 Random Parameters 
Intercept 1.80* (.54) 1.49* (.47) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .70* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 473.55† 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 27 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the 
Interaction of Agreeableness with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.54* (.09) 
Avg Estradiol  -.05 (.09) 
Weekly Deviation in Estradiol   .02 (.05) 
Agreeableness  -.16 (.10) 
Agreeableness*Avg Estradiol  -.15 (.10) 
Agreeableness*Estradiol Deviation  .04 (.04) 
 Random Parameters 
Intercept .39* (.09) .33* (.08) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 238.22 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.66* (.14) 
Avg Estradiol  -.16 (.14) 
Weekly Deviation in Estradiol   -.02 (.07) 
Agreeableness  -.27 (.14) 
Agreeableness*Avg Estradiol  -.22 (.15) 
Agreeableness*Estradiol Deviation  .06 (.06) 
 Random Parameters 
Intercept .83* (.23) .72* (.21) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 368.41 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.34* (.10) 
Avg Estradiol  -.08 (.10) 
Weekly Deviation in Estradiol   .01 (.05) 
Agreeableness  -.16 (.11) 
Agreeableness*Avg Estradiol  -.12 (.11) 
Agreeableness*Estradiol Deviation  .02 (.04) 
 Random Parameters 
Intercept .45* (.11) .41* (.10) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 273.36 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.45* (.10) 
Avg Estradiol  -.06 (.10) 
Weekly Deviation in Estradiol   .03 (.07) 
Agreeableness  -.30* (.11) 
Agreeableness*Avg Estradiol  -.16 (.11) 
Agreeableness*Estradiol Deviation  -.001 (.05) 
 Random Parameters 
Intercept .53* (.14) .39* (.11) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 332.05 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.05* (.11) 
Avg Estradiol  .04 (.12) 
Weekly Deviation in Estradiol   .05 (.09) 
Agreeableness  .12 (.12) 
Agreeableness*Avg Estradiol  -.13 (.12) 
Agreeableness*Estradiol Deviation  .13 (.08) 
 Random Parameters 
Intercept .35* (.12) .41* (.14) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 406.07 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.98* (.16) 
Avg Estradiol  -.04 (.16) 
Weekly Deviation in Estradiol   -.12 (.06) 
Agreeableness  -.27 (.16) 
Agreeableness*Avg Estradiol  -.35 (.18) 
Agreeableness*Estradiol Deviation  -.01 (.05) 
 Random Parameters 
Intercept 1.06* (.29) .92* (.26) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.26* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 378.34 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .11 (.22) 
Avg Estradiol  -.10 (.22) 
Weekly Deviation in Estradiol   -.09 (.08) 
Agreeableness  -.29 (.22) 
Agreeableness*Avg Estradiol  -.33 (.23) 
Agreeableness*Estradiol Deviation  -.01 (.07) 
 Random Parameters 
Intercept 1.80* (.54) 1.70* (.54) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .70* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 480.81 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 28 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the 
Interaction of Conscientiousness with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.53* (.10) 
Avg Estradiol  -.05 (.10) 
Weekly Deviation in Estradiol   .01 (.10) 
Conscientiousness  -.13 (.10) 
Conscientiousness*Avg Estradiol  .02 (.10) 
Conscientiousness*Estradiol Deviation  -.02 (.04) 
 Random Parameters 
Intercept .39* (.09) .38* (.10) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 238.71 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.65* (.15) 
Avg Estradiol  -.14 (.15) 
Weekly Deviation in Estradiol   -.05 (.06) 
Conscientiousness  -.18 (.15) 
Conscientiousness*Avg Estradiol  .05 (.16) 
Conscientiousness*Estradiol Deviation  -.01 (.05) 
 Random Parameters 
Intercept .83* (.23) .83* (.24) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 368.84 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -33* (.11) 
Avg Estradiol  -.07 (.11) 
Weekly Deviation in Estradiol   -.01 (.05) 
Conscientiousness  -.11 (.11) 
Conscientiousness*Avg Estradiol  .01 (.11) 
Conscientiousness*Estradiol Deviation  .01 (.04) 
 Random Parameters 
Intercept .45* (.11) .44* (.11) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 272.18 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.45* (.12) 
Avg Estradiol  -.04 (.12) 
Weekly Deviation in Estradiol   .03 (.06) 
Conscientiousness  -.13 (.12) 
Conscientiousness*Avg Estradiol  -.01 (.12) 
Conscientiousness*Estradiol Deviation  -.05 (.05) 
 Random Parameters 
Intercept .53* (.14) .53* (.15) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 330.85 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.04* (.11) 
Avg Estradiol  .02 (.11) 
Weekly Deviation in Estradiol   .01 (.09) 
Conscientiousness  -.13 (.11) 
Conscientiousness*Avg Estradiol  .08 (.11) 
Conscientiousness*Estradiol Deviation  -.10 (.08) 
 Random Parameters 
Intercept .35* (.12) .37* (.13) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 405.01 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.98* (.33) 
Avg Estradiol  2.27* (.30) 
Weekly Deviation in Estradiol   -.11 (.07) 
Conscientiousness  -.09 (.18) 
Conscientiousness*Avg Estradiol  .08 (.18) 
Conscientiousness*Estradiol Deviation  .02 (.04) 
 Random Parameters 
Intercept 1.06* (.29) 1.15* (.33) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.27* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 378.77 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .08 (.24) 
Avg Estradiol  -.12 (.24) 
Weekly Deviation in Estradiol   -.08 (.07) 
Conscientiousness  -.07 (.24) 
Conscientiousness*Avg Estradiol  .18 (.24) 
Conscientiousness*Estradiol Deviation  -.03 (.05) 
 Random Parameters 
Intercept 1.80* (.54) 1.98* (.62) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .69* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 480.64 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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SE = .10, t(37) = 2.90, p = .006). See Figures 38-40 for depictions of these interactions. 
There were no significant interactions of Neuroticism with deviations in estradiol.  
Also consistent with dimensional models of BPD in which high Openness to 
Experience (specifically, high scores on the facets of Openness to Actions and Openness 
to Feelings) are associated with higher levels of BPD, there were significant interactions 
of Openness to Experience with average levels of estradiol to predicting weekly PAI-
BOR total score, PAI-BOR Affective Instability, PAI-BOR Identity Disturbance, the 
BSL-23, and the MSI-BPD. In the model predicting the PAI-BOR Total score, among 
women lower in Openness, higher average levels of estradiol were associated with higher 
scores (γLOWOPENNESS *AVGESTRADIOL = .22, SE = .10, t(37) = 2.20, p = .03); among women 
higher in Openness, higher average levels of estradiol were associated with lower scores 
(γHIGHOPENNESS *AVGESTRADIOL = -.25, SE = .12, t(37) = -1.98, p = .05). See Figure 41 for a 
graph of this interaction. In model predicting the Affective Instability subscale, among 
women lower in Openness, higher average levels of estradiol were associated with higher 
scores (γLOWOPENNESS *AVGESTRADIOL = .35, SE = .14, t(37) = 2.50, p = .01); among women 
higher in Openness, higher average levels of estradiol were associated with lower scores 
(γHIGHOPENNESS *AVGESTRADIOL = -.50, SE = .20, t(37) = -2.50, p = .01). See Figure 42 for a 
graph of the interaction. In the model predicting Identity Disturbance, among women 
lower in Openness, higher average levels of estradiol were not significantly associated 
with higher scores  (γLOWOPENNESS *AVGESTRADIOL = .17, SE = .18, t(37) = .33, p = .33); 
among women higher in Openness, higher average levels of estradiol were associated 
with lower scores (γHIGHOPENNESS *AVGESTRADIOL = -.25, SE = .11, t(37) = -2.10, p = .04). 
This interaction is depicted in Figure 43. In the model predicting the BSL-23, among 
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Figure 38. A graph of the interaction between Neuroticism and average estradiol 
predicting weekly PAI-BOR Affective Instability subscale score.   
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Figure 39. A graph of the interaction between Neuroticism and average estradiol 
predicting weekly PAI-BOR Identity Disturbance subscale score.   
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Figure 40. A graph of the interaction between Neuroticism and average estradiol 
predicting weekly BSL-23 score.   
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Figure 41. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR total score.   
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Figure 42. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR Affective Instability subscale score.   
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Figure 43. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR Identity Disturbance subscale score.   
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women lower in Openness, higher average levels of estradiol were associated with higher 
scores (γLOWOPENNESS *AVGESTRADIOL = .59, SE = .27, t(37) = 2.21, p = .03); among women 
higher in Openness, higher average levels of estradiol were associated with lower scores 
(γHIGHOPENNESS *AVGESTRADIOL = -.47, SE = .22, t(37) = -2.14, p = .03). See Figure 44 for a 
graph of this interaction. Finally, in the model predicting number of symptoms endorsed 
on the MSI-BPD, among women lower in Openness, higher average levels of estradiol 
were associated with a higher number of symptoms endorsed on the MSI-BPD 
(γLOWOPENNESS *AVGESTRADIOL = .51, SE = .24, t(37) = 2.12, p = .04); among women higher 
in Openness, higher average levels of estradiol were associated with fewer symptoms 
endorsed on the MSI-BPD (γHIGHOPENNESS *AVGESTRADIOL = -.50, SE = .21, t(37) = -2.42, p 
= .02). See Figure 45 for a graph of this interaction. There were no interactions of 
Openness to Experience with weekly deviations in estradiol predicting BPD symptom 
expression.  
In general, there were not significant main effects of or interactions of estradiol 
variables with Agreeableness or Conscientiousness, the other two FFM variables 
hypothesized to be abnormal in BPD. There was one exception: higher levels of 
Agreeableness were associated with lower scores on the PAI-BOR Negative 
Relationships subscale.   
Types of Childhood Maltreatment as Alternative Moderators. Next, I substituted 
each scale of the CTQ for the Trait BPD variable (again, for original model, see Table 7). 
Results of models testing interactions of estradiol variables with the subscales of the CTQ 
are presented in Tables 29-33. Consistent with the biosocial theory, which posits that 
invalidation of a child’s desires and emotions is associated with risk for BPD, both the   
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Figure 44. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly PAI-BOR Affective Instability subscale score.   
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Figure 45. A graph of the interaction between Openness to Experience and average 
estradiol predicting weekly number of items endorsed on the MSI-BPD.   
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Table 29 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of 
the Emotional Abuse scale of the CTQ with Average Estradiol and Weekly Deviations in 
Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.53* (.10) 
Avg Estradiol  -.14 (.10) 
Weekly Deviation in Estradiol   .01 (.04) 
Emotional Abuse  .30* (.13) 
Emotional Abuse*Avg Estradiol  -.05 (.12) 
Emotional Abuse*Estradiol Deviation  -.01 (.05) 
 Random Parameters 
Intercept .39* (.09) .33* (.08) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 237.91 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.66* (.15) 
Avg Estradiol  -.28 (.15) 
Weekly Deviation in Estradiol   .04 (.06) 
Emotional Abuse  .44* (.19) 
Emotional Abuse*Avg Estradiol  -.07 (.18) 
Emotional Abuse*Estradiol Deviation  .01 (.07) 
 Random Parameters 
Intercept .83* (.23) .69* (.20) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 368.08 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.33* (.11) 
Avg Estradiol  -.15 (.11) 
Weekly Deviation in Estradiol   .01 (.05) 
Emotional Abuse  .28* (.13) 
Emotional Abuse*Avg Estradiol  .01 (.13) 
Emotional Abuse*Estradiol Deviation  -.06 (.05) 
 Random Parameters 
Intercept .45* (.11) .39* (.10) 
Weekly Deviation in Estradiol   
Residual .12* (.01) -.15 (.11) 
   
-2 Restricted Log Pseudo-likelihood 274.93 272.34 
Table Continued on Next Page  
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.46* (.12) 
Avg Estradiol  -.15 (.12) 
Weekly Deviation in Estradiol   .03 (.06) 
Emotional Abuse  .30* (.14) 
Emotional Abuse*Avg Estradiol  -.01 (.15) 
Emotional Abuse*Estradiol Deviation  -.01 (.06) 
 Random Parameters 
Intercept .53* (.14) .47* (.13) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 331.30 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.01* (.12) 
Avg Estradiol  .01 (.12) 
Weekly Deviation in Estradiol   .01 (.09) 
Emotional Abuse  .14 (.16) 
Emotional Abuse*Avg Estradiol  -.10 (.15) 
Emotional Abuse*Estradiol Deviation  .03 (.11) 
 Random Parameters 
Intercept .35* (.12) .41* (.14) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 406.69 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.99* (.17) 
Avg Estradiol  -.18 (.17) 
Weekly Deviation in Estradiol   -.12 (.06) 
Emotional Abuse  .54* (.21) 
Emotional Abuse*Avg Estradiol  -.07 (.20) 
Emotional Abuse*Estradiol Deviation  -.01 (.05) 
 Random Parameters 
Intercept 1.06* (.29) .91* (.27) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.27* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 369.74† 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .08 (.24) 
Avg Estradiol  -.26 (.24) 
Weekly Deviation in Estradiol   -.06 (.07) 
Emotional Abuse  .51 (.30) 
Emotional Abuse*Avg Estradiol  -.02 (.29) 
Emotional Abuse*Estradiol Deviation  -.07 (.08) 
 Random Parameters 
Intercept 1.80* (.54) 1.81* (.57) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .70* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 478.96 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 30 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of 
the Emotional Neglect scale of the CTQ with Average Estradiol and Weekly Deviations in 
Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.54* (.09) 
Avg Estradiol  -.07 (.09) 
Weekly Deviation in Estradiol   .01 (.04) 
Emotional Neglect  .25* (.09) 
Emotional Neglect*Avg Estradiol  -.02 (.09) 
Emotional Neglect*Estradiol Deviation  -.02 (.03) 
 Random Parameters 
Intercept .39* (.09) .33* (.09) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 237.74 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.67* (.14) 
Avg Estradiol  -.19 (.14) 
Weekly Deviation in Estradiol   -.03 (.07) 
Emotional Neglect  .38* (.13) 
Emotional Neglect*Avg Estradiol  -.01 (.13) 
Emotional Neglect*Estradiol Deviation  -.01 (.05) 
 Random Parameters 
Intercept .83* (.23) .68* (.20) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 369.20 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.33* (.10) 
Avg Estradiol  -.08 (.10) 
Weekly Deviation in Estradiol   .01 (.05) 
Emotional Neglect  .26* (.10) 
Emotional Neglect*Avg Estradiol  -.001 (.09) 
Emotional Neglect*Estradiol Deviation  -.05 (.04) 
 Random Parameters 
Intercept .45* (.11) .40* (.10) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 274.03 
Table Continued on Next Page  
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.47* (.12) 
Avg Estradiol  -.08 (.12) 
Weekly Deviation in Estradiol   .02 (.06) 
Emotional Neglect  .24* (.11) 
Emotional Neglect*Avg Estradiol  .01 (.11) 
Emotional Neglect*Estradiol Deviation  .001 (.05) 
 Random Parameters 
Intercept .53* (.14) .49* (.14) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 330.01 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.03* (.11) 
Avg Estradiol  .03 (.12) 
Weekly Deviation in Estradiol   .01 (.09) 
Emotional Neglect  .12 (.11) 
Emotional Neglect*Avg Estradiol  -.11 (.10) 
Emotional Neglect*Estradiol Deviation  -.003 (.08) 
 Random Parameters 
Intercept .35* (.12) .40* (.14) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 407.13 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.98* (.26) 
Avg Estradiol  -.08 (.16) 
Weekly Deviation in Estradiol   -.13* (.06) 
Emotional Neglect  .49* (.15) 
Emotional Neglect*Avg Estradiol  .03 (.14) 
Emotional Neglect*Estradiol Deviation  .01 (.04) 
 Random Parameters 
Intercept 1.06* (.29) .87* (.26) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.27* (.31) 
   
-2 Restricted Log Pseudo-likelihood 379.72 369.90† 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .09 (.22) 
Avg Estradiol  -.13 (.23) 
Weekly Deviation in Estradiol   -.08 (.08) 
Emotional Neglect  .52* (.21) 
Emotional Neglect*Avg Estradiol  -.05 (.20) 
Emotional Neglect*Estradiol Deviation  -.003 (.05) 
 Random Parameters 
Intercept 1.80* (.54) 1.71* (.55) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .71* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 478.93 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 31 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of 
the Physical Abuse scale of the CTQ with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.52* (.11) 
Avg Estradiol  -.14 (.12) 
Weekly Deviation in Estradiol   -.001 (.04) 
Physical Abuse  .26 (.24) 
Physical Abuse*Avg Estradiol  -.08 (.21) 
Physical Abuse*Estradiol Deviation  .01 (.05) 
 Random Parameters 
Intercept .39* (.09) .38* (.10) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 238.75 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.62* (.16) 
Avg Estradiol  -.32 (.17) 
Weekly Deviation in Estradiol   -.04 (.06) 
Physical Abuse  .51 (.34) 
Physical Abuse*Avg Estradiol  -.23 (.31) 
Physical Abuse*Estradiol Deviation  .01 (.08) 
 Random Parameters 
Intercept .83* (.23) .77* (.23) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 370.04 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.36* (.12) 
Avg Estradiol  -.10 (.12) 
Weekly Deviation in Estradiol   .01 (.05) 
Physical Abuse  .08 (.26) 
Physical Abuse*Avg Estradiol  .11 (.23) 
Physical Abuse*Estradiol Deviation  -.01 (.06) 
 Random Parameters 
Intercept .45* (.11) .43 (11) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 273.48 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.45* (.14) 
Avg Estradiol  -.13 (.14) 
Weekly Deviation in Estradiol   .02 (.06) 
Physical Abuse  .22 (.29) 
Physical Abuse*Avg Estradiol  -.05 (.26) 
Physical Abuse*Estradiol Deviation  .04 (.07) 
 Random Parameters 
Intercept .53* (.14) .53* (.15) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 331.24 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -.97* (.13) 
Avg Estradiol  -.04 (.13) 
Weekly Deviation in Estradiol   .01 (.09) 
Physical Abuse  .30 (.27) 
Physical Abuse*Avg Estradiol  -.27 (.24) 
Physical Abuse*Estradiol Deviation  -.01 (.13) 
 Random Parameters 
Intercept .35* (.12) .40* (.14) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 405.73 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.97* (.19) 
Avg Estradiol  -.18 (.19) 
Weekly Deviation in Estradiol   -.14 (.06) 
Physical Abuse  .41 (.40) 
Physical Abuse*Avg Estradiol  -.01 (.35) 
Physical Abuse*Estradiol Deviation  .04 (.06) 
 Random Parameters 
Intercept 1.06* (.29) 1.03* (.30) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.26* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 376.69 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .17 (.26) 
Avg Estradiol  -.32 (.27) 
Weekly Deviation in Estradiol   -.07 (.07) 
Physical Abuse  .77 (.54) 
Physical Abuse*Avg Estradiol  -.39 (.48) 
Physical Abuse*Estradiol Deviation  -.02 (.09) 
 Random Parameters 
Intercept 1.80* (.54) 1.89* (.60) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .71* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 479.47 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 32 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of 
the Physical Neglect scale of the CTQ with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.54* (.10) 
Avg Estradiol  -.10 (.10) 
Weekly Deviation in Estradiol   .01 (.04) 
Physical Neglect  .19 (.13) 
Physical Neglect*Avg Estradiol  .001 (.13) 
Physical Neglect*Estradiol Deviation  -.04 (.04) 
 Random Parameters 
Intercept .39* (.09) .37* (.09) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 237.25 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.67* (.15) 
Avg Estradiol  -.24 (.15) 
Weekly Deviation in Estradiol   -.02 (.07) 
Physical Neglect  .34 (.19) 
Physical Neglect*Avg Estradiol  -.05 (.19) 
Physical Neglect*Estradiol Deviation  -.06 (.06) 
 Random Parameters 
Intercept .83* (.23) .75* (.22) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 370.10 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.34* (.11) 
Avg Estradiol  -.10 (.11) 
Weekly Deviation in Estradiol   .01 (.05) 
Physical Neglect  .17 (.14) 
Physical Neglect*Avg Estradiol  .07 (.14) 
Physical Neglect*Estradiol Deviation  -.09 (.05) 
 Random Parameters 
Intercept .45* (.11) .42* (.11) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .12* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 272.54 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.47* (.12) 
Avg Estradiol  -.10 (.12) 
Weekly Deviation in Estradiol   .02 (.06) 
Physical Neglect  .20 (.16) 
Physical Neglect*Avg Estradiol  -.01 (.16) 
Physical Neglect*Estradiol Deviation  .03 (.05) 
 Random Parameters 
Intercept .53* (.14) .52* (.15) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 331.18 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.04* (.12) 
Avg Estradiol  .01 (.12) 
Weekly Deviation in Estradiol   .01 (.09) 
Physical Neglect  .04 (.16) 
Physical Neglect*Avg Estradiol  -.01 (.16) 
Physical Neglect*Estradiol Deviation  -.001 (.10) 
 Random Parameters 
Intercept .35* (.12) .42* (.15) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 406.48 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.97* (.17) 
Avg Estradiol  -.12 (.17) 
Weekly Deviation in Estradiol   -.12 (.07) 
Physical Neglect  .37 (.22) 
Physical Neglect*Avg Estradiol  .03 (.22) 
Physical Neglect*Estradiol Deviation  -.01 (.04) 
 Random Parameters 
Intercept 1.06* (.29) 1.01* (.17) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.26* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 377.11 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .09 (.23) 
Avg Estradiol  -.19 (.24) 
Weekly Deviation in Estradiol   -.08 (.08) 
Physical Neglect  .45 (.31) 
Physical Neglect*Avg Estradiol  -.10 (.31) 
Physical Neglect*Estradiol Deviation  .002 (.06) 
 Random Parameters 
Intercept 1.80* (.54) 1.87* (.60) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .71* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 480.60 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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Table 33 
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of 
the Sexual Abuse scale of the CTQ with Average Estradiol and Weekly Deviations in Estradiol 
 
Parameter Model 1 
(null) 
Model 4 
(with moderator) 
Dependent Variable: PAI-BOR Total Score  
 Fixed Effects 
Intercept -.50* (.10) -.55* (.10) 
Avg Estradiol  -.09(.10) 
Weekly Deviation in Estradiol   -.01 (.04) 
Sexual Abuse  .09 (.10) 
Sexual Abuse*Avg Estradiol  .12 (.08) 
Sexual Abuse*Estradiol Deviation  -.15* (.06) 
 Random Parameters 
Intercept .39* (.09) .37* (.10) 
Weekly Deviation in Estradiol   
Residual .08* (.01) .08* (.01) 
   
-2 Restricted Log Pseudo-likelihood 240.55 234.20† 
Dependent Variable: PAI-BOR Affective Instability Subscale  
 Fixed Effects 
Intercept -.60* (.15) -.69* (.15) 
Avg Estradiol  -.21 (.15) 
Weekly Deviation in Estradiol   -.07 (.06) 
Sexual Abuse  .16 (.15) 
Sexual Abuse*Avg Estradiol  .12 (.12) 
Sexual Abuse*Estradiol Deviation  -.21* (.09) 
 Random Parameters 
Intercept .83* (.23) .83* (.23 
Weekly Deviation in Estradiol   
Residual .16* (.02) .16* (.02) 
   
-2 Restricted Log Pseudo-likelihood 370.17 360.97† 
Dependent Variable: PAI-BOR Identity Disturbance Subscale  
 Fixed Effects 
Intercept -.30* (.11) -.34* (.10) 
Avg Estradiol  -.10 (.11) 
Weekly Deviation in Estradiol   -.02 (.05) 
Sexual Abuse  .11 (.10) 
Sexual Abuse*Avg Estradiol  .16 (.09) 
Sexual Abuse*Estradiol Deviation  -.24* (.07) 
 Random Parameters 
Intercept .45* (.11) .41* (.11) 
Weekly Deviation in Estradiol   
Residual .12* (.01) .11* (.01) 
   
-2 Restricted Log Pseudo-likelihood 274.93 267.30† 
Table Continued on Next Page 
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Dependent Variable: PAI-BOR Negative Relationships Subscale 
 Fixed Effects 
Intercept -.41* (.12) -.47* (.12) 
Avg Estradiol  -.09 (.12) 
Weekly Deviation in Estradiol   .02 (.06) 
Sexual Abuse  .13 (.12) 
Sexual Abuse*Avg Estradiol  .10 (.10) 
Sexual Abuse*Estradiol Deviation  -.01 (.09) 
 Random Parameters 
Intercept .53* (.14) .52* (.15) 
Weekly Deviation in Estradiol   
Residual .16* (.02) .17* (.02) 
   
-2 Restricted Log Pseudo-likelihood 332.16 327.22† 
Dependent Variable: PAI-BOR Self-Harm Subscale  
 Fixed Effects 
Intercept -1.03* (.11) -1.06* (.11) 
Avg Estradiol  .04 (.11) 
Weekly Deviation in Estradiol   -.004 (.10) 
Sexual Abuse  -.21 (.15) 
Sexual Abuse*Avg Estradiol  .25* (.10) 
Sexual Abuse*Estradiol Deviation  -.09 (.17) 
 Random Parameters 
Intercept .35* (.12) .35* (.12) 
Weekly Deviation in Estradiol   
Residual .18* (.02) .18* (.02) 
   
-2 Restricted Log Pseudo-likelihood 407.23 404.35† 
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)  
 Fixed Effects 
Intercept 2.05* (.16) 1.96* (.17) 
Avg Estradiol  -.10 (.17) 
Weekly Deviation in Estradiol   -.14 (.06) 
Sexual Abuse  .14 (.17) 
Sexual Abuse*Avg Estradiol  .29* (.14) 
Sexual Abuse*Estradiol Deviation  -.15* (.07) 
 Random Parameters 
Intercept 1.06* (.29) .65* (.19) 
Weekly Deviation in Estradiol   
Residual 2.34* (.31) 2.24* (.30) 
   
-2 Restricted Log Pseudo-likelihood 379.72 369.64† 
Table Continued on Next Page 
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Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD) 
 Fixed Effects 
Intercept .17 (.22) .07 (.23) 
Avg Estradiol  -.15 (.23) 
Weekly Deviation in Estradiol   -.10 (.07) 
Sexual Abuse  .03 (.23) 
Sexual Abuse*Avg Estradiol  .33 (.20) 
Sexual Abuse*Estradiol Deviation  -.13 (.12) 
 Random Parameters 
Intercept 1.80* (.54) 1.81* (.59) 
Weekly Deviation in Estradiol   
Residual .68* (.09) .71* (.09) 
   
-2 Restricted Log Pseudo-likelihood 481.04 478.51† 
Note. Standard errors are in parentheses.  
*p < .05.  
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05. 
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emotional abuse and emotional neglect subscales of the CTQ predicted higher BPD 
scores in all cases except in the prediction of the Self-Harm subscale.  However, these 
subscales did not interact significantly with estradiol variables to predict BPD symptoms.  
The Sexual Abuse subscale, however, significantly interacted with estradiol variables to 
predict BPD symptom expression.  
There were significant interactions between Sexual Abuse and higher average 
levels of estradiol predicting both the PAI-BOR Self-Harm subscale and the BSL-23, 
following a similar pattern as the interactions of Neuroticism and average estradiol in the 
previous section. In the model predicting the PAI-BOR Self-Harm subscale, among 
women reporting higher levels of Sexual Abuse, higher average levels of estradiol were 
associated with higher Self-Harm (γHIGHSEXABUSE*AVGESTRADIOL = .30, SE = .09, t(37) = 
3.33, p = .001), whereas among women reporting lower levels of Sexual Abuse, higher 
average levels of estradiol were associated with lower Self-Harm 
(γLOWSEXABUSE*AVGESTRADIOL = -.21, SE = .04, t(37) = -5.25, p < .0001). See Figure 46 for 
a graph of this interaction. In the model predicting the BSL-23, among women reporting 
higher levels of Sexual Abuse, higher levels of average estradiol were associated with 
higher scores (γHIGHSEXABUSE*AVGESTRADIOL = .21, SE = .08, t(37) = 2.62, p = .01), whereas 
among women reporting lower levels of Sexual Abuse, higher levels of estradiol were 
associated with lower scores (γLOWSEXABUSE*AVGESTRADIOL = -.40, SE = .14, t(37) = -2.85, 
p = .007).  See Figure 47 for a graph of this interaction.  
There were also significant interactions between levels of Sexual Abuse and 
weekly deviations in estradiol predicting the PAI-BOR total scale, the PAI-BOR 
Affective Instability subscale, the PAI-BOR Identity Disturbance subscale, and the BSL-  
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Figure 46. A graph of the interaction between self-reported levels of childhood sexual 
abuse and average estradiol predicting weekly PAI-BOR Self-Harm subscale score.   
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Figure 47. A graph of the interaction between self-reported levels of childhood sexual 
abuse and average estradiol predicting weekly BSL-23 score.    
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23, though they indicated that the impact of higher-than-usual estradiol was opposite 
from high average levels estradiol. In the model predicting the PAI-BOR total scale, 
among women reporting higher levels of Sexual Abuse, higher-than-usual levels of 
estradiol were associated with lower BPD symptom expression 
(γHIGHSEXABUSE*ESTRADIOLDEVIATION = -.17, SE = .09, t(37) = -1.95, p = .05) whereas among 
women reporting lower levels of Sexual Abuse, higher-than-usual levels of estradiol were 
associated with higher BPD symptom expression (γLOWSEXABUSE* ESTRADIOLDEVIATION = .13, 
SE = .02, t(37) = 6.50, p < .0001). A graph of this interaction can be found in Figure 48. 
In the model predicting the PAI-BOR Affective Instability subscale, among women 
reporting higher levels of Sexual Abuse, higher-than-usual levels of estradiol were 
associated with lower levels of Affective Instability (γHIGHSEXABUSE*ESTRADIOLDEVIATION = -
.28, SE = .12, t(37) = -2.21, p = .02), whereas among women reporting lower levels of 
Sexual Abuse, higher-than-usual levels of estradiol were not associated with lower 
Affective Instability (γLOWSEXABUSE*ESTRADIOLDEVIATION = .14, SE = .10, t(37) = 1.32, p 
= .19). See Figure 49 for a graph of this interaction. In the model predicting the PAI-
BOR Identity Disturbance scale, among women reporting higher levels of Sexual Abuse, 
higher-than-usual levels of estradiol were associated with lower Identity Disturbance 
(γHIGHSEXABUSE*ESTRADIOLDEVIATION = -.26, SE = .09, t(37) = -2.82, p = .005), whereas 
among women reporting lower levels of Sexual Abuse, higher-than-usual levels of 
estradiol were associated with higher Identity Disturbance 
(γLOWSEXABUSE*ESTRADIOLDEVIATION = .21, SE = .08, t(37) = 2.66, p = .008). See Figure 50 
for a graph of this interaction. In the model predicting the BSL-23, among women 
reporting higher levels of Sexual Abuse, higher-than-usual levels of estradiol were   
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Figure 48. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly PAI-BOR total score.    
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Figure 49. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly PAI-BOR Affective Instability 
subscale score.    
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Figure 50. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly PAI-BOR Identity Disturbance 
subscale score.    
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associated with lower levels of BPD symptoms (γHIGHSEXABUSE*ESTRADIOLDEVIATION = -.30, 
SE = .11, t(37) = -2.84, p = .005), whereas among women reporting lower levels of 
Sexual Abuse, higher-than-usual levels of estradiol were not associated with BPD 
symptom expression (γLOWSEXABUSE*ESTRADIOLDEVIATION = .01, SE = .09, t(37) = .16, p 
= .87). A graph of this interaction can be found in Figure 51.  
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Figure 51. A graph of the interaction between self-reported levels of childhood sexual 
abuse and deviation in estradiol predicting weekly BSL-23 score.   
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Chapter Four: Discussion 
 
Despite recent advancements in the understanding and treatment of individuals 
with Borderline Personality Disorder, very little work has addressed the physiological 
underpinnings of day-to-day and week-to-week variability in BPD symptom expression.  
Given the higher rates of diagnosis and impairment in women diagnosed with BPD 
(Grant et al., 2008), it has been suggested that the monthly reproductive cycle—and 
particularly changes in estradiol, a hormone that peaks naturally at ovulation—may play 
a role in modulating symptoms.  The present study builds upon previous evidence that 
ovulation-related increases in estradiol are associated with greater emotional and 
behavioral symptoms of BPD, especially among women high in trait levels of BPD 
symptoms. The purpose of this project was to test a new cyclical vulnerability theory of 
BPD, which posits that women at risk for BPD experience exaggerated reductions in felt 
social acceptance at ovulation and consequent increases in BPD symptom expression at 
that time.  
The cyclical vulnerability theory and its associated hypotheses were generally 
unsupported by the data.  In fact, results of hypothesis tests actually support the opposite 
the pattern of ovulatory effects on BPD symptoms, in which individuals with high trait 
levels of affective and behavioral dysregulation report slightly lower levels of BPD 
symptoms when fertility and estradiol are higher, whereas women with low trait levels of 
these problems report slight increases in BPD symptoms when fertility and estradiol are 
higher. However, this pattern was not entirely consistent, and requires further exploration 
in subsequent studies. The results of specific hypothesis tests carried out for the present 
project are reviewed and discussed below, followed by discussions of potential 
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alternative theoretical explanations for these effects, how these effects compare to 
previously-established findings, and the ways in which the present study can be used to 
improve future work in this area.  
Do Ovulation or Increases in Estradiol Predict Greater BPD Symptoms? 
Hypothesis 1 predicted that all women would experience increases in symptoms 
of BPD at ovulation and when estradiol was relatively higher for them. Contrary to this 
prediction, there were no significant effects of conception probability on BPD symptoms 
at the daily level. At the weekly level, there was only one significant effect of within-
person changes in estradiol, and it was in the opposite of the predicted direction; when 
women had higher-than-usual estradiol—likely at visits that were relatively closer to 
ovulation—they had lower scores on the Borderline Symptom Checklist (BSL-23), a 
measure of BPD symptoms based on the DSM-IV criteria for BPD.  Zero-order 
correlations and significance tests suggested that the BSL-23 was more significantly 
related to a measure of actual diagnosis of BPD than the PAI-BOR or the MSI-BPD.  In 
the present study, then, it appears that more extreme, clinically-relevant symptoms were 
more likely to lessen under conditions of higher-than-usual levels of estradiol. 
Hypothesis 2 predicted that the effects of daily fertility and weekly fluctuations in 
estradiol would be moderated by trait levels of BPD such that women with higher levels 
of trait BPD would show exaggerated increases in BPD symptoms at higher levels of 
conception probability and higher-than-usual estradiol. Contrary to this prediction, there 
was no evidence for exaggerated symptom expression at higher fertility or higher-than-
usual estradiol among women higher in trait BPD.  Rather, there was some evidence for 
the opposite pattern. Women with low trait levels of BPD reported higher BPD symptoms 
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at higher levels of fertility and at higher-than-usual levels of estradiol, including higher 
scores on the daily and weekly total scales of the PAI-BOR. Women with high trait levels 
of BPD, on the other hand, reported symptom reduction at higher levels of fertility and 
higher-than-usual estradiol: lower scores on the weekly PAI-BOR total scale, the 
Affective Instability subscale, the Identity Disturbance subscale, and the BSL-23.  
It would appear that, rather than becoming vulnerable at ovulation and during 
periods of increased estradiol, women higher in trait BPD actually experience periods of 
reduced symptoms and enhanced well-being. This also indicates, however, that women 
high in trait BPD may experience higher symptom expression at lower levels of fertility 
and estradiol—a different sort of cyclical vulnerability.  Though the computation of 
effect sizes in multilevel Poisson regression is not straightforward, it is possible to 
discuss the practical implications of the estimates presented here in a couple of more 
practical ways. First, estimates in Poisson regression may be exponentiated to determine 
the percent change in the dependent variable that would be achieved with a one-unit 
increase in the predictor.  In the present study, the average unstandardized estimate for 
the effect of deviations in estradiol on weekly BPD symptoms among women with high 
levels of trait BPD symptoms was -.15, which means that a one unit (i.e., 100%) increase 
above an individual’s mean level of estradiol was associated with a 13.9% reduction in 
BPD symptoms among women high in trait BPD symptoms. Second, results can also be 
more clearly understood by discussing them in terms of change on the response scale. For 
example, an estimate of -.15 corresponds to a change in symptoms that is only about one-
tenth the distance between “Sometimes True” and “False, Not True at All” on the 
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response scale for the PAI-BOR. So, although there does appear to be a cyclical effect on 
symptoms, the effects found here are relatively small.  
Although clearly post-hoc, an evolutionary psychological interpretation of the 
present findings should be considered. Evolutionary psychologists have established that 
ovulation can have a profound effect on numerous psychological and behavioral 
processes of relevance to BPD symptoms.  The effects found here appear to lend further 
support to the notion that affective and behavioral symptoms do change, however 
modestly, at the higher levels of fertility and higher-than-usual levels of estradiol that 
generally accompany ovulation. As mentioned earlier, higher fertility has been associated 
with increased implicit motivation to seek out social contact, and may be associated with 
an increased tendency toward agreeableness at that time so as to improve the chances of 
finding a mate (Schultheiss, Dargel, & Rhode, 2003). However, effects here seem to 
point toward a normalizing effect of ovulation on emotions and behavior, with women 
with high trait BPD and women with low trait BPD reporting slightly more “normal” 
(more average) levels of symptoms at ovulation and higher-than-usual estradiol. It is 
possible that these opposite effects indicate that higher fertility represents a cue for 
women to appear more emotionally and behaviorally stable (in the case of high-BPD 
women) or to appear more emotionally and behaviorally provocative and risk-taking (in 
the case of low-BPD women).  Women who are better able to up- or down-regulate 
abnormally high or low levels of BPD-related traits at ovulation may appear healthier, 
more balanced, and hence more attractive to potential mates.  
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Do Ovulation or Increases in Estradiol Predict Lower Felt Acceptance? 
Hypothesis 3a predicted that changes in felt acceptance would mediate the effect 
of fertility and higher-than-usual estradiol on BPD symptoms. Contrary to prediction, 
rather than feeling exaggerated decreases in felt acceptance at higher levels of fertility 
and higher-than-usual estradiol, women with higher levels of trait BPD showed increases 
in felt acceptance under these conditions. On the other hand, women with lower trait BPD 
symptoms reported feeling less social acceptance at ovulation, a finding that is consistent 
with previous work in this area demonstrating that normal women show decreases in self-
esteem (Hill & Durante, 2009)—a construct intimately connected to feelings of social 
acceptance (Leary et al., 1998)—at ovulation. Overall, these findings suggest that, unlike 
normal women, women high in trait BPD may actually experience a boost in feelings of 
social acceptance at higher-than-usual levels of estradiol. Further, there was evidence that 
these differing effects of estradiol deviations on felt acceptance mediated the interactive 
effects of trait BPD and estradiol deviations on BPD features.  That is, there is some 
evidence that women with higher levels of trait BPD evidenced fewer BPD symptoms at 
higher levels of estradiol because that higher estradiol was associated with feeling more 
socially accepted, which, in turn, was associated with lower BPD symptoms. It should 
also be noted that the effects of daily and weekly deviations in felt acceptance were, in 
every case, significant above and beyond mean levels of felt acceptance, highlighting the 
importance of within-person changes in feelings of belongingness and social wellbeing—
especially for individuals with BPD.    
It is possible that this effect can also be explained from an evolutionary 
perspective. These divergent effects of changes in estradiol on felt acceptance may be a 	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further example of a “normalizing” ovulatory effect that confers a reproductive benefit on 
both low-BPD and high-BPD women. In theory, it should be most reproductively 
beneficial to experience whatever social emotions at ovulation encourage socializing and 
mating. Individuals with BPD experience the world as an unsafe place in which people, 
including potential mates, cannot be trusted and in which social rejection is inevitable 
(Baer, Peters, Eisenlohr-Moul, Geiger, & Sauer, 2012). In order to increase social 
motivation at ovulation among these women, adjustments to the usual ovulatory pattern 
(of decreased felt acceptance and increased social motivation) may be necessary. 
Although normal women may, in some sense, require feelings of lower social acceptance 
at ovulation in order to be motivated to seek out greater social contact and potential mates, 
women with high trait BPD may require feelings of higher social acceptance at ovulation 
in order to feel safe enough to engage in the same social, mate-seeking behaviors.  
Alternative, Proximal Mediators: Are Changes in Self-Control or Impulsivity 
Responsible for Cycle Effects? 
Hypotheses 3b and 3c predicted that, among women higher in trait BPD, higher-
than-usual levels of estradiol would be associated with decreased self-control and 
increased impulsivity, and that these changes would mediate the impact of changes in 
estradiol on BPD symptom expression. This hypothesis was also unsupported, and once 
again, significant effects were observed in the opposite of the predicted direction. Among 
women higher in trait BPD, higher-than-usual estradiol was associated with better self-
control, lower Positive and Negative Urgency, lower Lack of Perseverance, and lower 
Lack of Premeditation. Among women low in trait BPD symptoms, none of these 
associations were significant. Insofar as poor self-control and elevated levels of these 
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types of impulsivity are consistent with BPD (de Ridder, Lensvelt-Mulders, Finkenauer, 
Stok, & Baumeister, 2012; Tragesser & Robinson, 2009), these findings are entirely 
consistent with the results presented above.  
Further, both average levels of and relative changes in self-control and 
impulsivity significantly predicted BPD symptoms in expected directions in the full 
sample. This finding provides further validation of the presence and importance of self-
control and impulsivity effects on BPD symptom expression, especially at the within-
person level. Although average levels of self-control and impulsivity were associated 
with BPD symptoms, day-to-day fluctuations in these processes often had an equal or 
greater impact on daily symptoms. Further, meditational hypotheses confirmed that each 
of these variables at least partially mediated the interactive effect of Trait BPD and 
deviations in estradiol on BPD symptom expression.   
Partially consistent with the existing evidence suggesting that Negative Urgency, 
Positive Urgency, and Lack of Premeditation are associated with BPD features (Tragesser 
& Robinson, 2009), the strongest and most consistent indirect effects were found for 
Negative Urgency, Lack of Premeditation, and Lack of Perseverance. Therefore, in the 
present study, ovulatory reductions in the tendency to respond to negative emotion with 
impulsive action, the tendency to act without thinking though the consequences of one’s 
actions, and the tendency to have difficulty persisting in the face of difficulty were 
primarily responsible for estradiol-related changes in BPD symptom expression. It is 
possible that shifts in estradiol underlie changes in aspects of impulsivity or the capacity 
to regulate them, and such changes may account for the impact of the cycle on BPD 
symptoms.  
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Investigating Alternative Moderators of Cyclical and Hormonal Effects: Roles of FFM 
Personality and Childhood Maltreatment 
Because BPD is a heterogeneous disorder, it may be questionable to rely on trait 
levels of BPD as a moderator of ovulatory or hormonal effects.  It would be more 
preferable to identify moderators that capture central underlying traits or risk factors for 
BPD.  Therefore, using two theoretical models of BPD (Five Factor Models of BPD and 
Linehan’s biosocial theory) as my guide, I tested additional models in which five factor 
model domain scores and types of childhood maltreatment were substituted for Trait BPD 
in moderation models. These models provided some new insights into the reasons for 
differential effects of changes in estradiol on BPD symptom expression among women 
high and low in trait BPD symptoms. 
Neuroticism, Estradiol, and BPD Symptoms. From the FFM perspective on 
personality disorders, the central characteristic of BPD is a high level of all aspects of 
Neuroticism (Widiger & Mullins-Sweatt, 2009).  Therefore, I expected that Neuroticism 
would function as a moderator in similar ways to trait BPD. However, there were no 
significant interactions between Neuroticism and deviations in estradiol, suggesting that 
the moderating effect of trait BPD on deviations in estradiol is not due to extreme levels 
of Neuroticism, as might be expected.  It is possible that some other, more specific 
characteristic of all or some of those with higher trait BPD—such as reactivity to 
sensations (Rosenthal, Ahn, & Geiger, 2011), rejection sensitivity (Ayduk et al., 2008), 
or a chronically elevated physiological stress response (e.g., Jogems-Kosterman, de 
Knijff, Kusters, & van Hoof, 2007)—is responsible.  
Rather than modulating the effect of estradiol fluctuations, Neuroticism 
significantly altered the association between trait (or average) levels of estradiol and 
	  
 188 
BPD symptoms.  Among women low in Neuroticism, higher average levels of estradiol 
buffered against BPD symptoms, predicting lower levels of affective instability, identity 
disturbance, and more extreme symptoms of BPD as measured on the BSL-23. Among 
women high in Neuroticism, however, higher average levels of estradiol were associated 
with higher levels of more extreme symptoms on the BSL-23. Therefore, it appears that 
Neuroticism may serve as a risk factor for negative reactions to chronically elevated 
estradiol, and low Neuroticism may allow women to benefit—at least in psychological 
terms—from chronically elevated estradiol. Notably, these between-person effects were 
generally about twice as large as the within-person effects found in the interactions 
between trait BPD and deviations in estradiol discussed earlier.  
Openness to Experience, Estradiol, and BPD Symptoms. The FFM personality 
perspective also provides evidence that certain aspects of Openness to Experience—
specifically, a tendency to be open to emotions and to actions—are high among 
individuals diagnosed with BPD. Like Neuroticism, Openness to Experience did not 
interact with deviations in estradiol to predict BPD symptoms, but did moderate the 
impact of trait levels of estradiol on BPD symptoms. Among women with higher 
Openness to Experience, higher trait levels of estradiol were associated with lower scores 
on the PAI-BOR total, the Affective Instability subscale, the Identity Disturbance 
subscale, the BSL-23, and the MSI-BPD.  Among women low in Openness to Experience, 
there were smaller but significant effects of higher trait levels of estradiol predicting 
higher scores on each of these scales. When one inspects the graphs in Figures 20-24, it 
appears that high Openness to Experience actually serves as a risk factor for BPD 
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symptoms at low trait levels of estradiol—note that this in in contrast to Neuroticism, 
which served as a risk factor at high levels of average estradiol.  
Therefore, chronically low estradiol was associated with more symptoms among 
women with higher levels of Openness to Experience, though further work will be needed 
to elucidate the mechanisms of this effect.  In one small cross-sectional study that tested 
all participants during menses, lower levels of estradiol were associated with higher self-
reported risk taking (Balada, Torrubia, & Arqué, 1993).  If this association is replicable, 
it is possible that higher Openness to Experience—and especially openness to actions—
serves to disinhibit this tendency toward risk taking among women low in average 
estradiol. In any case, higher Openness to Experience has been established apart from 
Neuroticism as a fundamental FFM personality abnormality in BPD, and may therefore 
confer risk for BPD through much different pathways than Neuroticism.  
Other FFM Personality Variables, Estradiol, and BPD Symptoms. Other aspects 
of FFM personality thought to be abnormal in BPD—including Agreeableness and 
Conscientiousness—did not interact with estradiol variables to predict symptoms in the 
present study.  However, consistent with the FFM conceptualization, both Agreeableness 
and Conscientiousness showed negative zero-order correlations with average levels of 
BPD symptoms. 
Sexual Abuse, Estradiol, and BPD Symptoms. Only one subscale of the 
Childhood Trauma Questionnaire, Sexual Abuse, moderated any effects of estradiol on 
BPD symptoms. The pattern in which Sexual Abuse moderated average levels of 
estradiol was similar to Neuroticism. Among women who reported greater experiences of 
having been sexually violated as a child, higher average levels of estradiol were 
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associated with higher scores on the PAI-BOR Self-Harm subscale as well as higher 
scores on the BSL-23. Each of these measures represents relatively extreme BPD 
symptoms, indicating that Sexual Abuse may prime women in some way to experience 
greater negative behavioral (i.e., externalizing) effects of chronically-elevated estradiol. It 
has been suggested (e.g., Figueroa & Silk, 1997) and demonstrated (Jogems-Kosterman, 
de Knijff, Kusters, & van Hoof, 2007) that sexual abuse and other childhood 
maltreatment is responsible for a chronically-activated physiological stress response (e.g., 
chronically elevated cortisol) in BPD.  Such physiological changes secondary to 
childhood maltreatment may play a role in modulating the effects of average estradiol on 
BPD symptoms, and future studies should include measures of a chronic physiological 
stress activation. Crucially, these results are consistent with Linehan’s discussion of the 
biosocial model of BPD; Linehan (1993) asserts that childhood Sexual Abuse, insofar as 
it blatantly ignores the wishes of the child, can be conceptualized as the most extreme 
form of the childhood invalidating environment theorized to play a central role in the 
development of BPD.  
Several smaller interactions were found between greater reports of childhood 
sexual abuse and deviations in estradiol, though these within-person effects followed the 
opposite pattern.  Among women reporting higher levels of childhood sexual abuse, 
higher-than-usual estradiol was associated with reductions in Affective Instability, 
Identity Disturbance, and the BSL-23, whereas women reporting low or no childhood 
sexual abuse had increases in symptoms at higher levels of estradiol. These effects are 
consistent with the interactive effects of trait BPD and deviations in estradiol, and may at 
least partially explain the moderating impact of trait BPD.  
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Having experienced sexual abuse in childhood may cause women to be more 
vigilant and use greater caution at times when high fertility primes sexuality.  Such 
greater caution may, in some cases, translate into less BPD-related interpersonal and 
behavioral symptoms.  However, these effects were smaller than the effects of average 
estradiol, indicating that the interaction of childhood sexual abuse and average levels of 
estradiol may have greater consequence for BPD symptom expression. These findings 
once again highlight that between-person effects (effects of average estradiol) and within-
person effects (effects of estradiol deviations) may be quite different.  
Contextualizing the Present Findings in the Extant Literature on the Cycle and BPD 
In previous studies, ovulation-related variability and changes in estradiol were 
associated with both higher levels of and increases in BPD symptom expression (DeSoto 
et al., 2003). In the present study, I found evidence for such effects only inconsistently 
among those low in trait levels of BPD. There may be several reasons for these 
inconsistent findings.  
First, unlike the DeSoto et al. (2003) study, the present was not designed to track 
women across specific points in the ovulatory cycle. Rather, it was designed to 
investigate the unique impact of naturally-occurring changes in estradiol on the 
expression of BPD symptoms across one ovulatory cycle.  Only one of the DeSoto et al. 
(2003) studies examined the association of naturally-occurring variability in endogenous 
estradiol with BPD symptom expression, but it focused on between-person associations 
of such overall variability with trait levels of symptoms rather than within-person effects 
of week-to-week changes in estradiol. However, post-hoc correlations in the present 
study between an individual’s overall variability in estradiol and measures of BPD 
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revealed no significant associations (all r’s less than .05, all p’s > .45). Therefore, not 
only were there no within-person effects consistent with those reported by DeSoto et al. 
(2003); the data from the present study also failed to replicate their primary reported 
effect.  
Second, the present study focused on endogenous (naturally-occurring) rather 
than exogenous (synthetic) estrogen, whereas two of the three studies reported in DeSoto 
et al. (2003) reported a negative impact of hormonal contraceptives containing synthetic 
estrogen. This may be due to the fact that hormonal birth control and other exogenous 
forms of estrogen do differ in some ways from endogenous estradiol in their biochemical 
activity. Chronically elevated levels of estrogen due to taking hormonal contraceptives 
may have negative effects in some women similar to those found above, at least among 
women sensitive to higher levels of estrogen (see Kiesner, 2011).   
There are a variety of physiological pathways through which chronically-elevated 
synthetic estrogen could exert negative effects in select women; however, one 
particularly plausible pathway is via elevated levels of C-reactive protein (CRP), a 
marker of inflammation, among women taking sustained doses of synthetic estrogens in 
the form of hormonal birth control (van Rooijen et al., 2006) and hormone replacement 
therapy (Eilertsen, Sandvik, Steinsvik, & Sandset, 2008). Several studies have provided 
evidence of a causal link between elevated levels of C-Reactive Protein to later 
depression and other symptoms of affective dysregulation (Gimeno et al., 2009; 
Matthews et al., 2010; Howren, Lamkin, & Suls, 2009). Given the centrality of poor 
affect regulation in BPD, it is possible that even mild increases in levels of inflammation 
mediate the negative affective consequences of chronically elevated synthetic estrogen 
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found in some women. While normal women may not experience negative effects of 
artificially elevated synthetic hormone, women with higher trait levels of BPD may 
experience negative effects such as those found by DeSoto et al. (2003) due to a 
chronically-activated stress response system that is unable to effectively downregulate 
inflammation via vagal inhibition (Thayer, 2009) or some other physiological pathway 
that is compromised during chronic stress.  
Using Biosocial and Evolutionary Theories to Understand the Effects of the Cycle on 
BPD Symptoms 
Though the original “estradiol peak” cyclical vulnerability model was not 
supported, an inverse “estradiol trough” cyclical vulnerability model was supported. 
Women higher in trait BPD reported greater symptoms when estradiol was lower-than-
usual for them; these effects were mediated by a reduction in felt acceptance, and, more 
proximally, by changes in self-control and impulsivity. In an attempt to better understand 
the role of trait BPD in this model, alternative moderators were tested. Only Sexual 
Abuse mirrored the moderating role of trait BPD. Sexual Abuse, a social risk factor, 
interacted with cyclical changes to predict BPD symptom expression: among those 
reporting high levels of Sexual Abuse, lower-than-usual levels of estradiol (such as those 
found at menses or the premenstrual week) were associated with higher BPD symptom 
expression. This finding provides support for the idea that Linehan’s (1993) biosocial 
model may operate not only at a trait level, but at a state level, as well.  
There are several potential physiological mechanisms through which state 
physiological predisposition to emotion dysregulation may occur at lower-than-usual 
levels of estradiol.  First, recent evidence indicates that natural fluctuations (higher-than-
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usual levels) of estradiol are associated with improvements in working memory (Segal, 
2012), which may play a role in the ability to modulate negative emotion, feelings of 
rejection, or related urges (Schmeichel, Volokhov, & Demaree, 2008), premeditate the 
consequences of behavior (Bechara & Martin, 2004), or persist on goal-relevant tasks 
(McVay & Kane, 2009). This interpretation may be particularly relevant to the mediation 
of cyclical vulnerability effects by self-control and impulsivity. Second, despite evidence 
that long-term administration of exogenous estrogen elevates CRP (a marker of 
inflammation; see above), there is evidence that fluctuations in endogenous estrogen 
follow the opposite pattern, with higher-than-usual levels of estradiol predicting 
reductions in CRP (Blum et al., 2005). As noted previously, such inflammatory markers 
prospectively predict depressive symptoms, which may explain greater symptoms at 
lower-than-usual estradiol (Gimeno et al., 2009; Matthews et al., 2010; Howren, Lamkin, 
& Suls, 2009). However, it has yet to be established whether these quicker day-to-day 
and week-to-week changes in inflammation map onto changes in psychological 
symptoms.  
Finally, within-person effects of estradiol may actually be due to the parallel 
variation of estradiol and oxytocin across the cycle. Oxytocin, a hormone involved in 
social cognition, affiliative behavior, and attachment, is estradiol-dependent throughout 
the cycle, and peaks naturally the day after ovulation (i.e., the day after luteinizing 
hormone surge; Shukovski, Healy, & Findlay, 1989).  Furthermore, there is some 
evidence that trait oxytocin levels are abnormally low among women with BPD and 
women with a history of childhood maltreatment or trauma (Bertsch, Schmidinger, 
Neumann, & Herpertz, 2013), and that administration of oxytocin attenuates emotional 
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reactivity in BPD (Simeon et al., 2011; although cf. Bartz et al., 2011). It is possible, then, 
that the cyclical effect of estradiol on BPD symptoms may exist only due to oxytocin’s 
potentially ameliorative effects on BPD symptoms.  
From an evolutionary perspective, it would be reasonable to expect that such 
physiological changes that confer cyclical vulnerability to BPD symptoms among at-risk 
women would occur at points in the cycle when signaling reproductive fitness to potential 
mates and selecting a reproductively fit mate was less important.  During the periods of 
low estradiol associated with the premenstrual and menstrual weeks, fertility is also low, 
so it may be less important for women at risk for BPD symptoms to (1) present 
themselves as normal and psychologically healthy and (2) have optimized cognitive 
capacity so as to inhibit impulses to mate with less-than-ideal mates and to seek out ideal 
mates.  During periods of high fertility, however, increased estradiol may modulate the 
ability of at-risk women to accurately perceive social acceptance, to respond in helpful 
ways to emotion, think through behavior, and to persist in goal-related action. In addition 
to improving the experience of at-risk women, these positive ovulatory changes may 
serve to signal reproductive fitness to potential mates and to increase a woman’s ability 
to carefully select a mate that is higher in reproductive fitness.  
Using FFM and Biosocial Theories of BPD to Understand the Effects of Average 
Levels of Estradiol on BPD Symptoms 
Unlike the effects of estradiol fluctuations, the effects of a woman’s average 
levels of estradiol were moderated by all factors associated with risk for higher BPD 
symptoms, and the effects followed a pattern that was different from the within-person 
effects.  Between women, higher average levels of estradiol was associated with greater 
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risk among those who reported risk factors for BPD such as Neuroticism or childhood 
sexual abuse, and low average estradiol was associated with greater risk among those 
high in Openness to Experience.  
In the modified biosocial model presented and supported above, trait risk 
variables such as trait BPD or Sexual Abuse interact with state physiological variables to 
predict fluctuations in symptoms.  However, in Linehan’s (1993) classic biosocial model 
of BPD, childhood maltreatment such as Sexual Abuse interacts with trait physiological 
variables (those conferring risk for emotional dysregulation) to predict trait BPD 
symptoms.  The findings that average levels of estradiol interacts with such risk factors as 
trait BPD, Sexual Abuse, and even FFM Neuroticism and Openness are probably best 
understood using Linehan’s classic, trait-level biosocial framework in which 
psychosocial and personality factors interact with physiological dysregulation to produce 
trait BPD symptoms. In the case of three out of four of these risk-related moderators, 
higher scores on a measure of risk (trait BPD, Sexual Abuse, or Neuroticism) interacted 
synergistically with higher average estradiol to predict higher trait BPD symptoms.  
In order to provide further illustration of the association between average levels of 
estradiol and BPD symptoms at any given assessment, two additional figures are 
provided.  Figure 52 is a descriptive scatterplot of the (nonsignificant) association 
between average levels of estradiol and weekly BPD scores in the full sample. Figure 53 
is a descriptive scatterplot of the association between average levels of estradiol and 
weekly BPD scores graphed according to the individual’s self-reported trait BPD 
symptoms (as measured by the original trait version of the PAI-BOR) at recruitment. 
Upon inspection of the these figures, it seems clear that women in this sample with high 
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levels of trait BPD symptoms show a stronger, positive association between average 
levels of estradiol and BPD symptoms on any given week than women with low levels of 
trait BPD symptoms.  Indeed, among women with moderate-to-low trait BPD symptoms, 
it would appear that the association between average levels of estradiol and weekly BPD 
symptoms is either nonsignificant or negative. While descriptive only, this apparent 
pattern should motivate additional research on the role of average levels of estradiol in 
BPD.  
In what way might high levels of average estradiol represent a trait physiological 
risk factor for emotion dysregulation consistent with the biosocial model? There are 
several possibilities. First, in the present study, higher trait levels of estradiol were 
strongly associated with lower FFM Extraversion—particularly low warmth and low 
positive emotions (r’s ranging from -.30 to -.36). Although low Extraversion is not 
hypothesized to be central to BPD in the FFM dimensional model of BPD, low positive 
emotion and low warmth are nevertheless consistent with the dysregulated emotion and 
low Agreeableness found in BPD.  Assuming these associations are replicable, high 
average levels of estradiol may serve as a physiological risk factor for low warmth and 
positive emotion that interacts with other BPD risk factors to predict trait BPD symptoms.   
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Figure 52. Descriptive scatterplot of the (nonsignificant) association between an 
individual’s average levels of estradiol across four weeks and their weekly PAI-BOR 
scores in the full sample.   
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Figure 53. Descriptive scatterplot of the association between an individual’s average 
levels of estradiol across four weeks and weekly PAI-BOR scores graphed by quartiles of 
average PAI-BOR total score.   
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Other studies have found higher trait levels of estradiol among women high in 
alexithymia (a condition related to emotional awareness and expression) vs. controls 
(Ushiroyama, Ueki, Orino, & Ikeda, 1994), and higher trait levels of estradiol were 
associated with greater self-reported loneliness among a group of adolescent girls 
(Fujisawa, Nishitani, Obara, & Shinohara, 2012).  These findings provide further 
evidence that average estradiol may be associated with other psychosocial risk factors for 
BPD-related symptoms (i.e., low Extraversion, high loneliness or alexithymia) that, in 
turn, interact with trait BPD, Neuroticism, or Sexual Abuse to predict higher trait 
symptoms. Notably, these effects are consistent with the evidence that chronic 
administration of exogenous estrogen in the context of hormonal contraceptives confer 
risk for BPD among women high in trait BPD (De Soto et al., 2003).  The physiological 
mechanisms of these effects have not been studied; however, they may be similar to the 
physiological mechanisms through which chronic exogenous estrogen administration 
increases BPD symptom risk.  
In the case of high Openness to Experience (which, from the FFM perspective, 
serves as a risk factor for BPD), it was low levels of average estradiol that were 
associated with higher BPD symptoms.  Due to the divergent effects from other risk-
related moderators, one can only assume that high levels of Openness to Experience exert 
moderating effects on BPD symptoms through different physiological pathways than trait 
BPD, Neuroticism, or Sexual Abuse.  As mentioned previously, there is one study 
suggesting that risk taking is higher among women with low trait levels of estradiol 
(Balada, Torrubia, & Arqué, 1993).  It is possible that high Openness to Experience—and 
especially Openness to Actions, which is known to be high in BPD—serve to unmask 
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higher levels of risk-taking behavior among women low in estradiol.  However, this is but 
one of many potential explanations for this finding, and a clear understanding of these 
results awaits further research.  
Limitations and General Recommendations for Future Work in this Area 
The project presented here is not without flaws, and the insights gained here may 
be used to refine the methodology of future projects on this topic. Perhaps most 
importantly, it is likely that the non-clinical sample used here created a floor effect in 
which the range of daily and weekly BPD symptoms was restricted (i.e., to the lower 
range). Although the sample was selected to create a flat distribution of BPD symptoms, 
the distributions for trait BPD were still relatively positively skewed, and only four of the 
individuals in the study met SCID-II criteria for BPD. Future studies will include a larger 
number of women overall, with a greater number of women meeting diagnostic criteria 
for BPD.  
Another limitation concerns the definition and measurement of the ovulatory 
cycle. In the present study, the focus was relatively limited to ovulatory and estradiol 
effects. In the future, it would be appropriate to examine other hormones (e.g., 
progesterone) that can provide more information about hormonal changes in symptoms 
occurring at other points in the cycle (e.g., the luteal phase). Although the reliability of 
luteal-phase effects on mood-related issues (i.e., Premenstrual Syndrome or PMS) has 
recently been seriously questioned (Romans et al., 2012), it is possible that such effects 
are more robust among individuals with BPD, and that non-ovulatory cycle effects are 
important for understanding cycle-related variability in BPD symptom expression.  A 
related point, mentioned previously, is that higher-than-usual levels of estradiol in the 
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current study may covary with some third hormonal variable (e.g., luteinizing hormone or 
oxytocin) that exerts more powerful ovulatory effects on BPD symptoms. In future 
studies, alternative ways of defining and measuring the cycle should be explored.  
It is also possible that low statistical power played a role in the failure to identify 
significant small interactive effects at the weekly level. Therefore, the failure of some 
small effects presented in the current study to reach significance should not necessarily 
be interpreted as evidence for nonsignificance; larger sample sizes may be necessary to 
detect small interactive effects of trait variables with deviations in estradiol on BPD 
symptoms. On the other hand, several small interactive effects were detected, suggesting 
that these effects are reasonably robust and that low statistical power may not be 
responsible for the failure of some small interactive effects to reach significance.   
Finally, the present study could have benefitted from the inclusion of more 
concrete measures of basic underlying traits and processes. The study failed to include 
measures of some core trait constructs that may have served as clearer, more powerful 
moderators of the effects of estradiol. Chronic physiological stress activation such as that 
found in post-traumatic stress, sensitivity to rejection or sensations, or some other risk 
variable that is associated with trait BPD may be truly responsible for the interactive 
effects seen here.  Future studies should seek to pinpoint and measure such key constructs. 
The study also relied on daily and weekly self-report measures of BPD symptoms using 
heterogeneous symptom inventories; in the future, studies may be strengthened by the 
inclusion of more concrete measures of behavior, such as substance use, aggression, or 
observer reports of interpersonal functioning.  
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Clinical Implications and Directions for Future Clinical Research 
The small effect sizes found here may indicate that cyclical vulnerability does not 
exert clinically meaningful effects on BPD.  However, future studies should explore the 
possibility that the synergistic effects of the cycle with other daily and weekly variables 
may be more significant in the lives of women who suffer from diagnosable levels of 
BPD.  Small cycle-related changes symptoms may become more significant in the face of 
the more serious stressors that often plague the lives of women with BPD.  In the context 
of ongoing BPD-related stressors such as unemployment, physical disability, substance 
use or abuse, or even simply ongoing interpersonal stress, small cyclical changes in 
emotional or behavioral vulnerability (i.e., at low levels of estradiol and fertility) may 
have larger, more serious implications. Further, trait levels of estradiol may also interact 
with either acute or chronic stressors in the lives of women with BPD to predict 
symptoms. As mentioned previously, the present study used a sample of generally 
healthy undergraduate women, and though they were sampled to achieve higher sample 
levels of BPD than would be found in the general population, only four of the participants 
met SCID-II criteria for BPD. Therefore, it is crucial that future studies examine whether 
the effects found here generalize to clinical populations. 
The most appropriate next step in this line of research would be another, larger 
prospective study aimed at replicating and extending the present findings to women with 
a diagnosis of BPD.  Ideally, such a study would recruit groups of women clinically 
diagnosed with BPD, clinically diagnosed with an Axis I disorder such as Major 
Depressive Disorder, and women with no diagnosis. Inclusion of the Axis I group would 
allow for a determination of whether increases in fertility and estradiol benefit women 
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with risk for psychopathology in general or only women with a pattern of symptoms 
consistent with BPD. This study should also include progesterone, oxytocin, and other 
ways of measuring the cycle, and should aim to determine whether it is truly low fertility 
and estradiol that are the key cycle variables responsible for the effects observed here. A 
study that included more information about the individual’s trait and weekly hormonal 
levels as well as a sample that provides a less restricted range of symptoms may prove 
elucidating. 
If the effects observed here were found to be clinically significant in a larger 
study, the eventual goal of this program of research would be to conduct a randomized 
controlled trial of an adjunctive intervention (i.e., an addition to a broader empirically-
supported treatment such as Dialectical Behavior Therapy) for women with BPD.  Such 
an intervention would be carried out in the context of individual therapy.  Daily symptom 
tracking sheets, which are already a standard part of Dialectical Behavior Therapy, would 
be modified to include information about cycle day and menses. After the individual had 
tracked emotional and behavioral symptoms across two cycles, the therapist would 
aggregate the data and determine whether a cycle or phase-related pattern had emerged. If 
so, the therapist would explain the results of this assessment to the client, and would 
encourage the client to focus the use of skills such as those learned in DBT on the 
problematic times of the month.  Several different types of skills may be relevant to 
compensating for symptom vulnerability at certain times of the month, including the 
ability to exercise nonjudgmental present-centered awareness of physical symptoms or 
emotional lability (i.e., DBT mindfulness skills), the ability to label, understand, and 
respond effectively to emotions as they arise (i.e., DBT emotion regulation skills), the 
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ability to tolerate distress without acting on impulses (i.e., DBT distress tolerance skills), 
and the ability to interact with others in useful ways even in the presence of strong 
emotion (i.e., DBT interpersonal effectiveness skills). Such a study would seek to 
determine whether focusing the use of skills on times of the month that are generally 
problematic for the client might boost the effectiveness of the intervention.  
Conclusions 
The present study provides some interesting preliminary evidence about the role 
of fertility and estradiol in predicting BPD symptom expression.  A great deal of 
additional work is needed to clarify the role of the cycle and related hormones in BPD 
symptom expression, to tease apart between-person and within-person effects of 
hormones, to clarify the key BPD-related traits responsible for moderated cycle effects, 
and to better understand the physiological and psychological mechanisms through which 
the cycle exerts its influence. If clear mechanisms of naturalistic change across the cycle 
can be established, medical, psychiatric, and psychotherapeutic attempts to improve 
functioning in BPD can become more timely, focused, and effective, reducing the 
considerable burden of this debilitating disorder.   
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